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large animal studies, and (iii) investigate the timing of EV presentation on cardiac repair. First, three MSC
culture systems (tissue culture plastic, microcarriers in a spinner flask, and perfusion bioreactor) were
explored towards scaling up EV production to generate large doses. MSC-EVs were characterized for size,
distribution, yield, morphology, content and in vitro potential, which motivated microcarriers to create
large doses for pre-clinical studies. The therapeutic potential of MSC-EVs delivered from injectable
hydrogels was then investigated in a porcine MI model, which indicated improvements in infarct area with
EV delivery. Secondly, extended delivery of EVs through an interpenetrating network (IPN) hydrogel was
studied with metabolic labeling to understand the timing, release, and biodistribution of MSC-EVs. The
therapeutic potential of extended MSC-EV delivery was studied in a rat model of MI, with the IPN delivery
of EVs improving outcomes of vascularization over controls. Finally, a radiopaque hydrogel system was
developed to evaluate hydrogel localization after injection via a SPECT/CT imaging system towards
clinical translation. Overall, this thesis highlights the importance of cell culture conditions for scale-up of
MSC-EVs for cardiac repair and the use of injectable hydrogels as a therapeutic delivery vehicle towards
translation of these therapeutics for clinical use.
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ABSTRACT

INJECTABLE HYDROGELS TO DELIVER EXTRACELLULAR VESICLES FOR
TREATMENT AFTER MYOCARDIAL INFARCTION

Selen Uman
Jason Burdick

There is a tremendous clinical need to develop new therapies to limit the
progression to heart failure after myocardial infarction (MI). Recent studies have
suggested that extracellular vesicles (EVs) derived from mesenchymal stromal cells
(MSCs) can mediate cardioprotection and preserve function post-MI due to their key roles
in paracrine signaling with angiogenic, proliferative, anti-inflammatory, and anti-apoptotic
effects via transfer of proteins and miRNAs. Despite this interest, there are still challenges
related to EV scale-up, sustained delivery, and analysis in clinically-relevant animal
models that need to be addressed prior to their translation.
With these considerations in mind, the overall goals of this dissertation were to (i)
develop injectable hydrogels, which allow localization and sustained release, for minimally
invasive delivery of EVs to the heart, (ii) scale-up production of MSC-EVs to generate
doses required for preclinical large animal studies, and (iii) investigate the timing of EV
presentation on cardiac repair.
First, three MSC culture systems (tissue culture plastic, microcarriers in a spinner
flask, and perfusion bioreactor) were explored towards scaling up EV production to
generate large doses. MSC-EVs were characterized for size, distribution, yield,
v

morphology, content and in vitro potential, which motivated microcarriers to create large
doses for pre-clinical studies. The therapeutic potential of MSC-EVs delivered from
injectable hydrogels was then investigated in a porcine MI model, which indicated
improvements in infarct area with EV delivery. Secondly, extended delivery of EVs through
an interpenetrating network (IPN)

hydrogel was studied with metabolic labeling to

understand the timing, release, and biodistribution of MSC-EVs. The therapeutic potential
of extended MSC-EV delivery was studied in a rat model of MI, with the IPN delivery of
EVs improving outcomes of vascularization over controls. Finally, a radiopaque hydrogel
system was developed to evaluate hydrogel localization after injection via a SPECT/CT
imaging system towards clinical translation. Overall, this thesis highlights the importance
of cell culture conditions for scale-up of MSC-EVs for cardiac repair and the use of
injectable hydrogels as a therapeutic delivery vehicle towards translation of these
therapeutics for clinical use.
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CHAPTER 1
INTRODUCTION

1.1 SIGNIFICANCE
Myocardial infarction (MI) is a leading cause of morbidity and mortality in the United
States (US) and approximately every 40 seconds an American will have an MI.1 Major
advances in reperfusion therapies have greatly improved acute mortality rates after MI;
however, a cascade of pathological remodeling may still be initiated and result in cardiac
hypertrophy, chamber dilation, and eventually left ventricular (LV) dysfunction and heart
failure (HF).2,3 Although percutaneous coronary intervention (PCI) has drastically reduced
the incidence of HF due to acute MI in the past three decades,4 mortality rates remain high
in patients without coronary reperfusion or when reperfusion is delayed.5 Importantly,
epidemiological studies have reported that the rate of HF after MI is between 10-40%.6
Approximately 4.6 million Americans are diagnosed with HF, with ~400,000
patients receiving a new diagnosis of HF annually and more than 43,000 individuals dying
of HF in the US each year.1 Due to decreases in mortality after MI, the prevalence of HF
is projected to increase and affect more than 8 million individuals by 2030, increasing the
overall cost and burden of HF.1 While the total cost of HF was estimated to be $30.7 billion
in 2012, projections indicate that by 2030 the total cost of HF will rise by 127% to 69.8
billion, amounting to $244 for every US adult.1
Improvements in mortality rates after HF onset have been attributed primarily to
evidence-based approaches to treat HF risk factors and the implementation of treatment
with renin-angiotensin system antagonists, beta-blockers, coronary revascularization,
implantable cardioverter-defibrillators and cardiac resynchronization therapies.7 As most
1

deaths after MI occur in patients who develop HF, future survival gains can be attained
through improved treatment strategies among MI patients at risk for HF to attenuate the
adverse consequences of MI.8

1.2 LEFT VENTRICULAR REMODELING AFTER MI
LV remodeling plays a key role in the pathogenesis of post-infarction ventricular
dysfunction and is mediated by active processes of cardiomyocyte loss after infarction,
inflammation, and fibrosis.8 The acute alterations of myocardial tissue and resultant
increase in loading conditions trigger a cascade of biochemical signaling processes
including dilatation, hypertrophy, and the formation of a collagen scar.9 This remodeling
process can continue for weeks or months and its severity is determined by the size,
location, and transmurality of the infarct, the extent of myocardial stunning, the patency of
the infarct-related artery, and local tropic factors.10,11 Inflammation plays a key role in this
remodeling process, as MI results in the migration of neutrophils followed by monocytes
and macrophages into the infarct zone, resulting in remodeling of cardiomyocytes and the
extracellular matrix.11
The early phase of remodeling (within 72 hours) involves the acute loss of
cardiomyocytes through apoptosis and necrosis, followed by the expansion of the infarct
zone, which may result in wall thinning and early ventricular wall rupture or aneurysm
formation. Infarct expansion occurs as a result of increased matrix metalloproteinases
(MMPs) during this early phase that degrade collagen within the myocardial extracellular
matrix and soften the tissue 3,12 (Figure 1.1). Decreased wall thickness leads to increased
wall stress, stimulating the sympathetic nervous system and triggering the renin2

angiotensin-aldosterone (RAAS) system.13 This compensatory mechanism with
augmented shortening and increased heart rate results in temporary circulatory
compensation, but triggers global changes in the LV architecture.11

.

Figure 1.1. Cardiac Remodeling After MI. The various acute and chronic stages of cardiac
remodeling after MI starting with apoptosis, inflammation followed by granulation tissue formation
and ventricular remodeling. Adapted from Martin et al.10

Next stages of remodeling involves the LV globally and is associated with timedependent dilatation, the distortion of ventricular shape, and mural hypertrophy (Figure
1.1).14 The early neutrophil response is replaced by recruited as well as resident
monocytes and macrophages that secrete pro-inflammatory mediators (e.g., tumor
necrosis factor (TNFa) and interleukin-1b (IL-1b)) and pro-fibrotic growth factors
(transforming growth factor b (TGFb), fibroblast growth factor (FGF), platelet derived
growth factor (PDGF)).15 The triggered compensatory neurohormonal activation which
includes increased angiotensin II, norepinephrine, endothelin-1, and TGF-b production
3

increases myocyte hypertrophy and stimulates collagen production by myofibroblasts,
contributing to a vicious cycle of deterioration.11 Cardiac fibrosis is characterized by
increased collagen concentration in the interstitial space,16 and although some degree of
fibrosis may be protective against further LV dilatation, excess fibrosis changes the
mechanical properties of the myocardium, resulting in both systolic and diastolic
dysfunction15 (Figure 1.2).

Figure 1.2. Vicious cycle of pathological remodeling. Simplified schematic depicting the vicious
cycle of cardiac remodeling. Decreased tissue perfusion results in a decrease in nitric oxide (N)
release from vascular endothelial cell nitric oxide synthase (NOS, diminishing a cardioprotective
mechanism. Epinephrine released by the adrenal gland results in Gs-coupled cardiac beta
adrenergic receptors that acutely increase contractility by adenylyl cyclase/protein kinase A
signaling but chronically leading to cardiomyocyte toxicity. Renal hypoperfusion stimulates
erythropoietin (EPO) but also renin activating the renin-angitensin-aldosterone pathway, resulting
in hypertrophy. Central nervous system activates sympathetic nerves that release norepinephrine
into the myocardium activating beta and alpha-1 adrenergic receptors. Ang II: angiotensin II, AR:
adrenergic receptor, AT1R: angiotensin type I receptor, eNOS: endothelial nitric oxide synthase,
EPI: epinephrine, GRK2: G-2 protein receptor kinase 2, EPI: epinephrine, EPO: erythropoietin, LV:
left ventricular, MR: mineralocorticoid receptor, NE: norepinephrine, NO: nitric oxide, PKA: protein
kinase A, PKC: protein kinase C, ROS: reactive oxygen species. Adapted from Dorn et al.12
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It is important to provide metrics with which to measure heart function after MI,
including with therapeutic intervention. LV ejection fraction (LVEF) is the central measure
of LV systolic function, defined by the fraction of chamber volume ejected in systole (stroke
volume) in relation to the volume of the blood in the LV at the end of diastole (end-diastolic
volume). 17 LVEF takes into account the Frank-Starling relationship and therefore is more
useful than stroke volume as a marker of LV function, and it is mainly affected by preload,
afterload, and contractility.18 LVEF plays a very important role in assessing the systolic
function of the heart and has a prognostic value in predicting outcomes in patients with
HF, after MI, and after revascularization.17 While useful, it does not fully explain whether
a low LVEF is due to low stroke volume or increased LV diastolic volume. The addition of
absolute volumes provide more detailed information on the heart function as end-systolic
volume (ESV) is mainly affected by afterload and contractility, and end-diastolic volume
(EDV) is affected by preload and contractility.18,19 LV enlargement and reduced EF are
negative prognostic factors in patients with HF.20
A new set of parameters have recently become available for the assessment of LV
function. Increasingly, indices of myocardial deformation such as strain and strain rate
have been proposed as additional indicators as markers of contractility.21 This dissertation
will frequently refer to LVEF, ESV, and EDV as functional outcome measures as
determined by different modalities such as echocardiography21, pressure-volume loops,
cardiac magnetic resonance imaging (CMR)22, computed tomography (CT), and SPECT23
and will also turn to global strain measurements when possible.

1.3 CURRENT THERAPIES FOR CARDIAC REPAIR
5

Initial medical therapy for acute ST-elevation MI (STEMI) includes supplemental
oxygen24, sublingual nitroglycerin and morphine for enhanced coronary blood flow and
reduction of ischemic pain25, high-intensity statin therapy (atorvastatin 80 mg daily or
rosuvastatin 20 or 40 mg daily) to lower low density lipoprotein-cholesterol (LDL) levels26,
antithrombotic therapy (dual antiplatelet therapy with aspirin, and a platelet P2Y12
receptor blocker (ticagrelor, prasugrel or clopidrogel))27, in addition to appropriate
anticoagulation therapy. The implementation of mechanical (e.g., stents) and/or
pharmacological reperfusion therapy plays a key role in limiting the primary infarction and
salvaging myocardial tissue;28 therefore, immediate angiography and revascularization is
critical to reduce mortality.
If high quality PCI is available, multiple randomized trials have shown enhanced
survival and lower rates of intracranial hemorrhage and recurrent MI when compared to
fibrinolysis with door-to-balloon times less than 90 minutes.28 Coronary artery bypass graft
surgery (CABG) is infrequently performed in patients with STEMI; however, it may be
considered after unsuccessful or complicated PCI, due to mechanical complications of
acute MI. In patients with high-grade left main or three-vessel coronary disease with
clinical or hemodynamic instability, CABG is often preferred to PCI as the primary
reperfusion strategy.29 The decision is often complex and individualized and management
involves a team of cardiothoracic surgeons and interventional cardiologists on a
multidisciplinary team. The current clinical treatment strategies for patients with MI
complicated by HF are briefly summarized here (Table 1.1).

6

Table 1.1: Current treatments for MI complicated by HF (adapted from Bahit et al.6)
Treatment

Key Points

Key Trials

Beta-blockers

Early use (within 24h) should be avoided for MI patients
with HF or high-risk for cardiogenic shock

CAPRICORN

ACE inhibitors should be administered within first 24h for
HF patients of EF<40%. Significant survival benefit in the
first day of treatment.

SAVE

ACE-inhibitors

COMMIT-CCS 2

AIRE
TRACE

ARBs (as alternative
to ACE inhibitors)

ARBs are indicated for patients intolerant to ACE inhibitors.

OPTIMAL

Aldosterone
antagonists

Early initiation of eplerenone (<7 days) for patients with EF
<40% had reduction in mortality.

EPHESUS

Early
revascularization

Early revascularization is the only therapy proven to
reduce mortality in MI patients presenting with cardiogenic
shock

SHOCK

Mechanical
circulatory support

Routine use of intra-aortic balloon pump is not indicated to
reduce infarct size or manage cardiogenic shock

IABP SHOCK II

VALIANT

ALBATROSS

IMPRESS

Angiotensin-converting enzyme (ACE) inhibitors have been shown to limit
remodeling and reduce morbidity and mortality in patients with HF with systolic LV
dysfunction in post-infarction setting.30 Interestingly, it has been shown that the reversal
of the pathological remodeling exerted by ACE inhibitors is related to their mechanism of
action beyond inhibition of Ang-II formation.31 This has been largely linked to their
blockage of the breakdown of bradykinin, prolonging vasodilatory and antitrophic effects.31
In contrast to ACE inhibitors, RAS blockage with angiotensin receptor blockers (ARBs) is
achieved through inhibition of angiotension II type 1 (AT1) receptor blockade.

32

While

combination therapy with ACE inhibitors and ARBs have been cited frequently in the
literature33, the decision for combination therapy is complex and affected by comorbidities.

7

More recently, combination of an ARB and neprilysin inhibitor was shown to be superior
to ACE inhibition alone in patients with chronic HF.34
In addition to reducing morbidity and mortality in HF due to LV systolic dysfunction,
beta-blockade has been shown to both improve EF and reverse remodeling in patients
already treated with ACE inhibitors.35 The EPHESUS (Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Survival) study also established the benefits of an
aldosterone antagonist added to optimal medical therapy with earlier initiation associated
with better outcomes.36
These therapies clinically used and shown to be effective in reducing mortality and
morbidity in HF have also been shown to limit LV remodeling in some patients. LV
remodeling is considered a primary target for treatment and a reliable surrogate for longterm outcomes.6 In addition to primary prevention strategies for MI, there’s a window of
opportunity for new therapeutic strategies that focus on limiting remodeling via cellular and
molecular tissue repair pathways, including hypertrophy, fibrosis, and capillary
microcirculation and that promote cardiac regeneration via enabling cardiomyocyte
proliferation, immunomodulation, and cell migration.

1.4 NOVEL STRATEGIES TO LIMIT VENTRICULAR REMODELING POST-MI
Approaches to cardiac repair have been a tremendous focus area of research in
the past decades. These strategies not only attempt to interrupt the vicious cycle of
progressive LV remodeling, but also aim to regenerate the necrotic myocardium and
restore LV function. Early pharmacological strategies have focused on the different stages
of cardiac remodeling and included targeting reactive oxygen species, calcium overload,
8

endothelial preservation, and neutrophil inhibition; yet, their assessment in clinical trials
have been met with limited success.37
More recent efforts in cardiac repair have focused on harnessing the regenerative
potential of stem and progenitor cells. Due to the heart’s inability to regenerate lost muscle
mass in the infarct, multiple groups have turned to regenerating new muscle by cellular
implantation. Bone marrow derived cells (mesenchymal stromal cells (MSCs) and
endothelial progenitor cells (EPCs)) as well as cardiosphere-derived cells or cardiac
progenitor cells (CPCs) have been used in initial clinical trials aimed at cardiac repair via
either intracoronary infusion or intramyocardial delivery (Table 1.2).10 While some of these
trials have demonstrated modest improvements, low levels of cell retention and
engraftment within the myocardium and limited evidence for transdifferentiation have been
observed.38 These observations led to the hypothesis that delivered cells may have a
paracrine effect on the surrounding tissue, rather than directly integrating into the
regenerated muscle tissue.39 Paracrine factors, such as growth factors, cytokines, and
extracellular

vesicles

(EVs)

can

mediate

cardiac

repair

by

regulation

of

neovascularization, fibrosis, inflammation, cardiac myocyte survival, contractility,
bioenergetics, and endogenous repair.40 Consistent with these mechanisms, studies have
demonstrated that the administration of conditioned medium derived from stem cells
recapitulates the beneficial effects of cell-based therapies.41,42
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Table 1.2: Summary of cell therapy based clinical trials for heart disease. Delivery route
includes intracoronary (IC), intramyocardial (IM), transendocardial (TE), endoventricular
(EV).
Clinical Trial

Year

Cell source

Patient
Population

Delivery
Route

Timing

Efficacy
Endpoint

Trial
Number

MYSTAR

2007

BMMononuclear
Cells

ACUTE MI

IC or IM

21-42
days
after MI

Increase
in EF

NCT003
84982

REPAIR-AMI

2007

BMprogenitor
cells

ACUTE MI

IC

3-6 days
after reperfusion

Increase
in EF

NCT002
79175

BALANCE

2009

BMmononuclear
cells

ACUTE MI

IC

5-9 days
after MI

Improved
EF

NCT020
33278

POSEIDON

2012

Allogeneic
and
autologous
BM-MSC

ICM

TE

30 days
post-PCI

Increased
EF;
decreased
infarct
size;
increased
quality of
life

NCT010
87996

Autologous
ASC

Acute
STEMI

IC

Hours
post- PCI

Increased
EF;

NCT004
42806

APOLLO

2012

EF<50%

decreased
infarct size
C-CURE

CADUCEUS

PROMETHEUS

PRECISE

2013

2013

2014

2014

Autologous
BM-MSC

EF

At least 2
months
after
ischemic
event

Increased
EF;

IC

1.5-3
months
after MI

Reduced
infarct size

NCT008
93360

IM

70-1565
days
after last
MI

Increased
EF;

NCT005
87990

Unclear

No
reduction
in
scar
size;
no

15-40%

Cardiosphere
-derived
autologous
stem cells

EF

Autologous
BM-MSC

ICM/

Autologous
ASC

EV

25-45%

CABG

LVEF <45%
with
evidence of
reversible

10

TE

NCT008
10238

increased
6-min walk
distance

decreased
infarct size
NCT004
26868

perfusion
defect
TRIDENT

2017

Allogeneic
BM-MSC

EF<50%

increase in
EF
TE

Unclear

Reduced
infarct
size;
increased
EF with

NCT020
13674

100 million
cell dose
CHART-1

2017

Autologous
BM-MSC

EF<35%

IM

Median
45
months
post HF
diagnosis

No
changes in
EF
or
infarct size

NCT017
68702

ATHENA

2017

Autologous
ASC

EF<45%

IM

At least
>60 days
post-MI

No
changes in
EF
or
infarct size

NCT015
56022

MyStromalCell

2017

Autologous
ASC

EF>40%

IM

Unclear

Improved
quality of
life

NCT014
49032

Investigating the specific paracrine factors exerted by stem cells, Kamihata et al.
demonstrated that bone-marrow mononuclear cells mediated angiogenesis via increased
expression of FGF, vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), IL1b, and TNF-a.

43

Various other studies demonstrated that MSCs can also switch

macrophages from a pro-inflammatory M1 phenotype to an anti-inflammatory M2
phenotype both in vivo44 and in vitro45,46 via secreted factors including IGF-147 and IL-10.48
In addition to angiogenesis and immunomodulation, cardiomyocyte proliferation has been
shown to be mediated through MSC paracrine effects.40 In vitro studies implicated FGF2,
PDGF,

and

neuregulin-1

in

cardiomyocyte

proliferation

through

connexin-43

phosphorylation,49 Akt activation50 and DNA synthesis through ErbB4,51 respectively.
More recently, it has been shown that the paracrine functions of MSCs and other
cell types are potentially mediated by EVs.52 Many studies have pointed toward EVs as
11

important mediators of cardioprotection with angiogenic,53,54 proliferative,55 antiinflammatory,

56

and anti-apoptotic57 effects via transfer of bioactive cargos such as

proteins, lipids, and miRNAs. The potential role of EVs in cardiac repair and challenges
associated will be discussed in the next section.

1.5. EV-BASED THERAPEUTICS FOR CARDIAC REPAIR
EVs are heterogeneous membrane-bound vesicle released by all cell types that
contain cell-derived cargos such as DNA, RNA, proteins, and lipids.58 EVs play a big role
in many cellular processes, including intracellular communication, recycling of membrane
proteins, immunomodulation, senescence, angiogenesis, cellular proliferation and
differentiation via transfer of nucleic acids and proteins and activation of cell surface
receptors. 58
Cells release several types of vesicles with different physiological properties,
contents, and functions and these vesicles are differentiated based on their size range
and biogenesis, including exosomes (30-150 nm), microvesicles (100-350 nm), and
apoptotic bodies (500-100 nm).58 Apoptotic bodies are generated by vesiculation of an
entire cell undergoing apoptosis, while microvesicles are generated by outward budding
of the plasma membrane58 and exosomes are generated in endosomal structures called
multivesicular bodies (MVBs) (Figure 1.3). Exosome membranes are enriched in lipids
such as cholesterol, ceramide, and sphingolipids that are involved in the budding process
of MVBs.59 Once released, exosomes may be subsequently internalized by other cells via
membrane fusion, endocytosis, or cell-type specific phagocytosis.60 Despite initial studies
highlighting the therapeutic potential of small EVs or exosomes specifically over other
12

vesicles, there is increasing evidence that there is a continuum of vesicle types with
overlapping properties secreted from cells and present in body fluids.61 Since EVs are a
heterogenous group of vesicles and specific subpopulations are still being actively
investigated, as per International Society of Extracellular Vesicles (ISEV) guidelines, this
thesis will refer to small extracellular vesicles or exosomes as EVs.

Figure 1.3: Biogenesis of extracellular vesicles. EVs are presumed to be a homogeneous
population of vesicles of endocytic origin that are formed by the inward budding of the multivesicular
body (MVB) membrane. Microvesicles, however, represent a relatively heterogeneous population
of vesicles that are formed by the outward budding and fission of the cell membrane, which could
be controlled by membrane lipid microdomains and regulatory proteins. Reproduced from
Andoloussi et al.58
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The rapid advances in the study of EVs have demonstrated a range of biological
functions and physiological roles that EVs play, which has generated great interest for
regenerative medicine and tissue repair applications. There is a wide variety of therapeutic
applications in pre-clinical and clinical stages in many disease states ranging from
cancer,62 retinal disease,63 traumatic brain injury,64 acute kidney injury,65 graft-versus-host
disease66 to lung injury,67 osteoarthritis,68 ischemic stroke,69 and MI,70 using EVs derived
from various cell sources including dendritic cells,71 macrophages,72 induced pluripotent
stem cells (iPSCs),73 and MSCs.74
Among different cell sources for EV generation, MSCs have emerged as a
promising cell source due to their scalability and therapeutic potential.75 MSCs are
described as multipotent non-hematopoietic adult stem cells that express surface markers
such as CD90, CD105, and CD73 without the expression of CD14, CD34 and CD45.76
They were originally isolated from the bone marrow but since then have been isolated
from other adult tissues such as adipose tissues, placenta, and amniotic fluid.77 MSCs
have various important features including differentiation potential, and colony forming and
self-renewal abilities.78 They can be differentiated into mesenchymal lineages such as
osteoblasts, chondrocytes, and adipocytes, as well as non-mesenchymal lineages such
as hepatocytes and neuronal cell types.79 It was originally thought that MSCs exerted their
therapeutic effects by migrating to the sites of damage and differentiating into desired cell
types for tissue regeneration;77 however, more recent studies have demonstrated that
MSCs exert most of their effects through the aforementioned paracrine functions that
include the production and release of a wide range of growth factors, chemokines,
cytokines, lipids, miRNAs, and regulatory proteins, including through the release of EVs
that contain these some or all of these factors.39 Since EVs have been implicated as key
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modulators of intracellular communication for a variety of pathological and physiological
processes (Figure 1.4), they have attracted a lot of attention as a way to harness the
therapeutic benefits of MSCs as an “off-the-shelf” cell-free therapy.

Figure 1.4: EVs as therapeutic agents. EVs are thought to have regenerative properties due to
cell-receptor interactions such as antigen presentation, immunomodulation and tissue repair via
angiogenesis and anti-apoptosis. Reproduced from Andoloussi et al.58

Due to their liposome-like structures that reflects the bilayer phospholipid
membrane of their parental cells, EVs are more stable when compared to other foreign
particles.80 In addition, MSC-EVs have low immunogenicity, long half-lifves, and are
readily taken up by cells.81 This way, MSC-EVs can bypass many of the challenges
associated

with

cell

injections,

such

as

low

cell

viability/engraftment,

high

manufacturing/storage costs, and batch to batch variability.82 The role of MSC-EVs in
many aspects of cell-to-cell communication are still being investigated; however, they
have been implicated in many essential processes in regenerative medicine including but
not limited to cell viability/proliferation,83 angiogenesis,84 extracellular matrix interactions,85
and immunomodulation,86 (Figure 1.5) and they have shown promise in a variety of
disease models in pre-clinical studies and clinical studies. Currently there are more than
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20 clinical trials listed in ClinicalTrial.gov investigating the therapeutic potential of MSCEVs in a variety of disease states (Table 1.3). However, none of these clinical trials have
been completed and challenges remain for the clinical application of MSC-EVs.

Figure 1.5. MSC-EV Mechanism of Action. MSC-EVs and their cargo, which have
multiple roles in mediating tissue repair. Adapted from Brennan et al.125

Table 1.3: Clinical trials using MSC-EVs as therapies.
Year

MSC-Origin

Title

Reference

2014

Cord blood

Effect of Microvesicles and Exosomes Therapy on β-cell
Mass in Type I Diabetes Mellitus (T1DM)

NCT02138331

2018

Human
umbilical cord

MSC-Exos Promote Healing of Macular holes MHs

NCT03437759

2019

Bone marrow

A Safety Study of IV Stem Cell-derived Extracellular

NCT03857841

Vesicles (UNEX-42) in Preterm Neonates at High Risk for
Bronchopulmonary Dysplasia
2020

Bone marrow

MSC EVs in Dystrophic Epidermolysis Bullosa

16

NCT04173650

2020

Adipose tissue

Effects of ASC Secretome on Human Osteochondral

NCT04223622

Explants (ASC-OA)
2020

Bone marrow

A Tolerance Clinical Study on Aerosol Inhalation of

NCT04313647

MSC-EXO in Healthy Volunteers
2020

Adipose tissue

A Pilot Clinical Study on Inhalation of MSC-EXO

NCT04276987

Treating Severe Novel Coronavirus Pneumonia
2020

Adipose
Tissue

Evaluation of Safety and Efficiency of Method of

NCT04491240

Exosome Inhalation in SARS-CoV-2 Associated
PneumoniaSARS-Cov2 pneumonia

2020

Human
umbilical cord

Effect of UMSCs Derived Exosomes on Dry Eye in Patients
With cGVHD

NCT04213248

2020

Adipose tissue

Evaluation of Adipose Derived Stem Cells Exo in
Treatment of Periodontitis

NCT04270006

2020

Wharton’s jelly

Therapeutic Potential of Stem Cell Conditioned Medium on
Chronic Ulcer Wounds

NCT04134676

2020

Bone marrow

MSC-EXO for Multiple Organ Dysfunction Syndrome After
Surgical Repair of Acute Type A Aortic Dissection

NCT04356300

2020

Adipose tissue

A Clinical Study of MSC-EXO Nebulizer for the Treatment
of Pulmonary Infection

NCT04544215

2020

Adipose tissue

Safety and Efficacy Evaluation of Allogenic Adipose MSCExos in Patients with Alzheimer’s Disease

NCT04388982

Despite the therapeutic success of MSC-EVs in pre-clinical studies, there are
critical challenges in the translation of MSC-EVs from bench to bedside. These challenges
include the large-scale production and isolation of clinical-grade xeno-free MSC-EVs with
minimal batch to batch variability, developing methods for the rapid and accurate
characterization of EVs, the accurate characterization of EV cargo, understanding the
biodistribution and targeting of MSC-EVs to target tissues, characterizing the
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pharmacokinetics of EV delivery, and developing a safety profile to determine the optimal
clinical dosage.87 The manufacture of large amounts of MSC-EVs with high purity is
difficult and highly dependent on seeding cell number, media volume, isolation method,
and time.
Additionally, the characterization of EVs across studies is a challenge. Even
though ISEV has identified minimal requirements for the characterization of EVs, including
nanoparticle tracking analysis (NTA), confirmation of phospholipid bilayer membrane via
transmission electron microscopy (TEM), confirmation of EV surface markers such as
CD63, and quantification of protein content via Bradford assay, as well as thorough the
description of cell-source and isolation methods, many studies in the literature do not
adhere to all of these criteria 88, making it difficult to assess efficacy and to compare across
studies. Therefore, optimization of culture conditions and thorough characterization of EV
cargo will be critical for translation of MSC-EVs from bench to bedside.

1.6 INJECTABLE HYDROGELS FOR MI
One class of biomaterials of great interest in treating cardiac tissues are hydrogels
(i.e., water-swollen polymer networks).89 The use of hydrogels to deliver cell-derived
therapeutics such as EVs is promising because hydrogels can be designed to be
injectable through minimally-invasive methods (e.g., catheter technologies), reducing risks
for patients and lowering hospital costs when compared to open-heart procedures with the
ability to administered at the time of hospitalization. For injectability, the hydrogel or the
hydrogel precursor must flow through the syringe or catheter, and quickly gel at the
injection site for material retention. This is generally achieved either by using shear18

thinning and rapidly self-healing hydrogels or in situ cross-linking hydrogels.89 For both
preclinical and clinical trials, hydrogels can be delivered via five different methods:
intracoronary, intramyocardial, transendocardial, intrapericardial, or as a cardiac patch
(Figure 1.6).90

Figure 1.6. Hydrogel delivery methods. Hydrogels can be delivered via transendocardial,
intracoronary, intramyocardial or intrapericardial injections or via a cardiac patch. Adapted from
Filgueira et al.90

Due to their ability to increase the thickness of the left ventricular wall, thereby
reducing wall stress and preserving cardiac function, intramyocardial delivery of injectable
hydrogels have been promising for limiting pathological remodeling post-MI.91–94 Based on
LaPlace’s law (T = (P*R)/t), tension in the myocardial wall (T) is directly proportional to
intraventricular pressure (P) and radius of curvature (R) and inversely proportional to wall
thickness (t). Therefore, increasing wall thickness through the injection of bulking agents
such as hydrogels can decrease wall stress. Based on modified LaPlace’s law, finite
element models have demonstrated that multiple hydrogel injections into the infarct can
19

reduce myofiber stresses. 95,96 Furthermore, hydrogels with increased stiffness were found
to be more effective in ameliorating left ventricular remodeling and preserving function
(Figure 1.7) .97

Figure 1.7. Effects of hydrogel injection on wall stress. Left ventricular end-diastolic myofiber
stress distribution after hydrogel injection. Adapted from Wang et al.98

A completed clinical trial (NCT01226563, PRESERVATION 1) investigated the
intracoronary injection of alginate hydrogels (IK-5001). The alginate hydrogel precursor is
assumed to permeate the infarcted tissue, and crosslink into a hydrogel within the calciumrich environment of the myocardium, forming a bioabsorbable scaffold. While this
application faces the risk of embolism, the results indicate safety of this approach, but with
limited efficacy in the over 300 enrolled patients, likely due to an unclear crosslinking
efficacy where the hydrogel is needed.99
20

Intramyocardial injections may be beneficial due to their improved retention in the
target tissue in addition to acting as a prosthetic scaffold that can reduce wall stress and
preventing pathological remodeling of the heart. Intramyocardial injections of alginatehydrogel implants have been shown to be superior to standard medical therapy for
patients with advanced chronic heart failure in AUGMENT-HF trial (NCT01311791).100
As an alternative to intramyocardial hydrogel injections, several approaches have
been reported in pre-clinical studies that apply hydrogels to the outer surface of the heart
(epicardium) for local delivery of encapsulated therapeutics. Recently, an epicardially
placed gelatin-based reservoir was placed on the infarcted heart and connected to a
subcutaneous port, enabling multiple minimally invasive replenishments directly to the
target site without causing toxicity associated with high systemic dose.101 While allowing
minimally invasive replenishment of therapeutics, it is important to note that the placement
of this reservoir currently requires an open thoracotomy similar other cardiac patches
designed in pre-clinical studies.102
All three approaches come with inherent challenges towards delivering
biomaterials to the heart. Since an open thoracotomy is invasive in nature and has
potential for complications, a minimally invasive and percutaneous approach would be
more attractive for suitable patients. Thus, the ability to deliver a hydrogel to the
myocardium through a percutaneous route, such as through a catheter, may enable
improved translation of hydrogel therapies for the heart, as it confers several advantages
including lower procedural risk and suitability for repeat applications when compared to
thoracotomy. A Phase I clinical trial (NCT02305602) investigated the catheter delivery of
a decellularized extracellular matrix (ECM) gel (Ventrix) and showed safety in delivery.103
Generally, catheter delivery of hydrogels is challenging, as the limitations of commercially
available catheters have placed demanding design restraints on hydrogels being
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developed. Similarly, a specially designed catheter has been used in a proof-of-concept
study demonstrating the ability to deliver in situ crosslinking hydrogels into the pericardial
space.104
Challenges remain for hydrogel therapies to promote cardiac repair after MI and
prevent HF. Recent large animal studies and their reported parameters are summarized
here (Table 1.4), demonstrating large discrepancies in animal models, timing and volume
of injection, the types of materials and their mechanical properties, as well as outcome
measures. Additionally, it is important to note that while some of these studies used
hydrogels as mechanical bulking agents, others have encapsulated therapeutic agents
allowing hydrogels to acts as delivery vehicles, making it difficult to compare results.

Table 1.4: Large animal studies for hydrogel only and hydrogel+therapy treatment for MI.

Material

Species

MI model

Injection
Time

Injection
Volume

Time
Observed

Cardiac
Function

R
ef

Thiol modified
HA (PRP)

Yorkshire
pigs

Permanent
ligation of
proximal LCx

60 mins
after

30 x 200
ul

8 weeks

Improved
EF

105

Permanent
ligation of OM1
and OM2

Immediate

9 x 100
ul

2 weeks

Improved
EF

106

Yorkshire
pigs 25 kg

Permanent
ligation of OM1
and OM2

Immediate

9 x 100
ul

4 weeks

Improved
EF

107

Yorkshire
pigs

Permanent
ligation of LCx
and OM

30 min
after

20 x 300
ul

12 weeks

No
improved
EF

108

Permanent
ligation of LAD
and DB

30 min
after

20 x 300
ul

8 weeks

No
improved
EF

109

65-70 kg
HeMA-HA
(TIMP3)

Yorkshire
pigs
25 kg

HA HYD/ALD
(TIMP3)
HeMA-HA

40-50 kg
HeMA-HA

Dorset
sheep 3540 kg
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MeHA

Dorset
sheep 3540 kg

Permanent
ligation of LAD
and DB

30 min
after

20 x 300
ul

8 weeks

No
improved
EF

110

HA

Dorset
sheep 45
kg

Permanent
ligation of the
OM branches

30 min
after

16 x 300
ul

8 weeks

Improved
EF, ESV

97

Calcium
Hydroxyapatite
microspheres

Sheep 3540 kg

Permanent
ligation of LAD
and DB

Within 3h

20 x 130
ul

8 weeks

Improved
EF, ESV,
EDV
greater
infarct
blood
flow

111

Calcium
Hydroxyapatite
microspheres

Yorkshire
pigs

Permanent
ligation of Lcx or
its branches

30 min
after

20 x 150
ul

4 weeks

Improved
EF, ESV,
EDV

112

(CD-thiol/AdMe-HA)

37.2±1.2
kg
Calcium
Hydroxyapatite
microspheres

Yorkshire
pigs 25 kg

Permanent
ligation of OM1
and OM2

Immediate

1.3 or 2.6
mL

3 weeks

Improved
EF

113

Fibrin/Alginate

Yorkshire
pigs 25 kg

Permanent of
OM1 and OM2

7 days
after

25 x 100
ul

3 weeks

No
improved
EF

114

Ventrigel
(ECM)

Yucatan
minipigs

Percutaneous
coil embolism
infarct of LAD

2 weeks
after

15 x 250
ul

3 months

Improved
EF, EDV,
ESV

103

Yucatan
minipigs
28-40 kg

Percutaneous
coil embolism
infarct of LAD

2 weeks
after

1-2 h

Not
reported

115

Particulate
ECM

Jersey
calves,
65-95 kg

Polystyrene
latex
microspheres
embolization of
LAD and/or LCx

30 days
after

9-11 mL

60-90
days

Improved
EDP,
ESV,
EDV;
n=2 for
each
group

116

Algisyl-LVR

Canine

Polystyrene
latex
microspheres
embolization of
LAD and/or LCx

2 weeks
after

7
injections
, total
1.8-2.1
mL

17 weeks

Improved
EF, ESV,
EDV

117

Goat 70
kg

75 min
occlusion of
proximal LCx

4 weeks
after

10 x 200
ul

4 weeks

Not
reported

118

45-50 kg
Ventrigel
(ECM)

(Alginate)

UPy PEG

Myostar
15 x 250
ul
Myostar

23

Permanent
occlusion of
LAD

Immediate

40 x 50
ul

12 weeks

Improved
EDP

119

Yorkshire
pigs, 2030 kg

Permanent
ligation of LAD

10
minutes
after
(sutured)

3.5 cm
round
patch

7 days

Not
reported

120

Dalland
Landrace,
68±4 kg

75 min
occlusion of
proximal LCx

4 weeks
after

10 x 0.2
mL

4 weeks

EF
improved
in GF
and
Gel+GF

121

Poly(NIPAAmco-HEMA-coMAPLA)

Yorkshire
pigs, 2030 kg

Permanent
ligation of LAD

2 weeks
after

20 x 200
ul

8 weeks

EF
improved

122

PLGA
microparticles

Gottingen
minipigs,
60-80 kg

120 minute
occlusion of
LAD distal to
second diagonal

7 days
after

30 x 300
ul
injection

12 weeks

FS
improved

123

Lanyu
minipigs

Permanent
occlusion of
LAD

10
minutes
after

40 x 50
ul

2 months

EF
improved

124

Yorkshire
pigs

90 minute
occlusion of
LAD

4 weeks

30 x 100
ul

4 weeks

EF
improved

125

PDGF binding
peptide

Minipigs

Porcine ECM
(Conditioned
Media)
UPy hydrogel
(IGF1 and
HGF)

(FGF1 and
NRG1)
HA
(bonemarrow
mononuclear
cells)
Gelatin sheet
(hCDCs +
FGF)

5 months
old

NOGA

1.7. EV DELIVERY WITH HYDROGELS
While MSC-EVs have shown great promise for therapeutic strategies in
regenerative medicine, many of these therapeutics face challenges including short halflives and rapid clearance from injection site.126 Common methods of EV administration for
therapeutic applications include intravenous, intraperitoneal, subcutaneous injections, or
direct injections to the delivery site. While systemic injections provide ease, they suffer
from rapid systemic clearance and therefore insufficient doses at the target site. Therefore,
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many groups prefer local injection of EVs at the site of injury.127 However, this method
presents its own set of problems such as clearance from the injection site, in some cases
requiring repeated injections.126 In addition to their ability to bulk thinning infarct tissue
after MI, hydrogels play a unique role in overcoming many pharmacokinetic and
pharmacodynamics concerns during therapeutic delivery due to the localization and
sustained release of cargo. Injectable hydrogels, therefore, have recently been
investigated in preclinical studies for their ability to increase the retention and stability of
EVs at the delivery site. Encapsulating EVs in biomaterials extends their bioavailability,
permits sustained delivery, and maintains stability of the EV cargo, thereby potentially
increasing the potency of EV-based therapeutics. 128
Earlier studies using biomaterials functionalized with EVs have demonstrated the
ability of biomaterials to increase EV stability. Human placenta MSC-derived EVs were
delivered with an injectable chitosan hydrogel in a mouse model of hindlimb ischemia, and
the chitosan hydrogel was shown to increase the stability of proteins and miRNAs in EVs,
as well as increase their retention in vivo.129 In another mouse hindlimb ischemia model,
human umbilical cord MSC-derived EVs were delivered in an injectable silk fibroin
hydrogel, which resulted in increased perfusion after 4 weeks.130
More recently, Liu et al. encapsulated iPSC-derived cardiomyocyte EVs in a
collagen-based hydrogel patch sutured to the myocardium in an open-thoracotomy
procedure and demonstrated that the sustained release of EVs promoted LVEF recovery,
reduced infarct size, and decreased cardiomyocyte apoptosis in a rat model of MI.131 Other
studies have also shown improvements in LVEF and reduction in infarct size in a rat model
of MI using amphiphilic peptide130,132- and alginate133-based hydrogels to deliver human
and rat MSC-EVs, respectively. Similarly, our group has previously investigated EPCderived EVs and showed improved functional outcomes and increased vessel density in
25

a rat permanent LAD-ligation model using an injectable hyaluronic acid based hydrogel.
134,135

In both rat and pig MI models, a cardiac patch from decellularized myocardial

extracellular matrix was fabricated from porcine myocardium as an off-the-shelf product
to deliver cardiac stromal cell-derived conditioned medium and was shown to decrease
infarct size and promote angiogenesis,120 demonstrating the power of biomaterial delivery
platforms to enhance the therapeutic efficacy of EV-based therapeutics.

1.8 CONCLUSIONS
MI complicated by HF exerts a tremendous burden on the American healthcare
system and current available therapies largely fail to prevent or reverse the pathological
remodeling of the heart. While clinical trials for cell therapies have widely failed to replicate
the improvements in cardiac function and remodeling observed in preclinical studies, cellderived therapeutics such as EVs have recently emerged as a powerful tool to harness
the therapeutic potential of MSCs without the disadvantages of cell based therapeutics.
Although injectable hydrogels alone are useful for myocardial bulking, their ability to act
as delivery vehicles and overcome the low retention rates of bolus injections of EVs can
optimize their therapeutic potential. This thesis describes the development of injectable
hydrogel systems to deliver MSC-derived EV therapeutics for improved retention and
preserved cardiac function.

1.9 REFERENCES
1.

Aparicio, H. J. et al. Heart Disease and Stroke Statistics-2021 Update A Report
26

from
the
American
Heart
doi:10.1161/CIR.0000000000000950

Association.

Circulation

(2021).

2.

McMurray, J. J. V. Clinical practice. Systolic heart failure. N. Engl. J. Med. (2010).
doi:10.1056/NEJMcp0909392

3.

Holmes, J. W., Borg, T. K. & Covell, J. W. Structure and Mechanics of Healing
Myocardial Infarcts. http://dx.doi.org/10.1146/annurev.bioeng.7.060804.100453 7,
223–253 (2005).

4.

Chacko, L. et al. Effects of Percutaneous Coronary Intervention on Death and
Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A
Meta-Analysis of Randomized Controlled Trials. Circ. Cardiovasc. Qual. Outcomes
13, (2020).

5.

Park, J. et al. Prognostic Implications of Door-to-Balloon Time and Onset-to-Door
Time on Mortality in Patients With ST-Segment–Elevation Myocardial Infarction
Treated With Primary Percutaneous Coronary Intervention. J. Am. Heart Assoc. 8,
(2019).

6.

Bahit, M. C., Kochar, A. & Granger, C. B. Post-Myocardial Infarction Heart Failure.
JACC Hear. Fail. 6, 179–186 (2018).

7.

Cahill, T. J. & Kharbanda, R. K. Heart failure after myocardial infarction in the era
of primary percutaneous coronary intervention: Mechanisms, incidence and
identification of patients at risk. World J. Cardiol. 9, 407 (2017).

8.

Cahill, T. J., Choudhury, R. P. & Riley, P. R. Heart regeneration and repair after
myocardial infarction: Translational opportunities for novel therapeutics. Nat. Rev.
Drug Discov. 16, 699–717 (2017).

9.

Enomoto, Y. et al. Early ventricular restraint after myocardial infarction: Extent of
the wrap determines the outcome of remodeling. Ann. Thorac. Surg. (2005).
doi:10.1016/j.athoracsur.2004.05.072

10.

Martin, K., Huang, C. & Caplice, N. M. Regenerative Approaches to PostMyocardial Infarction Heart Failure. Curr. Pharm. Des. 20, 1930–1940 (2014).

11.

St. John Sutton, M. G. & Sharpe, N. Left ventricular remodeling after myocardial
infarction: Pathophysiology and therapy. Circulation 101, 2981–2988 (2000).

12.

Dorn, G. W. Novel Pharmacotherapies to abrogate postinfarction ventricular
modeling. Nat. Rev. Cardiol. 6, 283–291 (2009).

13.

Werner, C. M. & Böhm, M. The therapeutic role of RAS blockade in chronic heart
failure. Ther. Adv. Cardiovasc. Dis. 2, 167–177 (2008).

14.

Zornoff, L. A. M., Paiva, S. A. R., Duarte, D. R. & Spadaro, J. Ventricular remodeling
after myocardial infarction: concepts and clinical implications. Arq. Bras. Cardiol.
92, 152–159 (2009).

15.

Kong, P., Christia, P. & Frangogiannis, N. G. The pathogenesis of cardiac fibrosis.
Cell. Mol. Life Sci. 2013 714 71, 549–574 (2013).

16.

Brower, G. L. et al. The relationship between myocardial extracellular matrix
remodeling and ventricular function §. doi:10.1016/j.ejcts.2006.07.006

17.

Kosaraju, A., Goyal, A., Grigorova, Y. & Makaryus, A. N. Left Ventricular Ejection
27

Fraction. StatPearls (2017).
18.

Marwick, T. H. Ejection Fraction Pros and Cons: JACC State-of-the-Art Review. J.
Am. Coll. Cardiol. 72, 2360–2379 (2018).

19.

Januzzi, J. L. Requiem for a Heavyweight Ejection Fraction as a Prognostic Marker.
JACC Hear. Fail. 7, (2019).

20.

Hajouli, S. & Ludhwani, D. Heart Failure And Ejection Fraction. StatPearls (2021).

21.

Potter, E. & Marwick, T. H. Assessment of Left Ventricular Function by
Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to
Ejection Fraction. JACC Cardiovasc. Imaging 11, 260–274 (2018).

22.

Schulz-Menger, J. et al. Standardized image interpretation and post processing in
cardiovascular magnetic resonance: Society for Cardiovascular Magnetic
Resonance (SCMR) Board of Trustees Task Force on Standardized Post
Processing. J. Cardiovasc. Magn. Reson. 15, 1–19 (2013).

23.

Faber, T. L. et al. Geometric approximations can be used with various image
measurements to estimate ED and ES volumes or EF Left Ventricular Function and
Perfusion from Gated SPECT Perfusion Images: An Integrated Method.
JouRNi@wOF Nucl. Med. â€¢ 40, (1999).

24.

Hofmann, R. et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. N.
Engl. J. Med. 377, 1240–1249 (2017).

25.

Garadah, T. et al. Impact of intravenous nitroglycerin on pulsed Doppler indexes of
left ventricular filling in acute anterior myocardial infarction. Am. Heart J. 136, 812–
817 (1998).

26.

Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute
coronary syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).

27.

Mauri, L. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting
stents. N. Engl. J. Med. 371, 2155–2166 (2014).

28.

Keeley, E. C., Boura, J. A. & Grines, C. L. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction: a quantitative review of 23
randomised trials. Lancet (London, England) 361, 13–20 (2003).

29.

Toma, M. et al. Non-culprit coronary artery percutaneous coronary intervention
during acute ST-segment elevation myocardial infarction: insights from the APEXAMI trial. Eur. Heart J. 31, 1701–1707 (2010).

30.

Franzosi, M. G. Indications for ACE inhibitors in the early treatment of acute
myocardial infarction: systematic overview of individual data from 100,000 patients
in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.
Circulation 97, 2202–2212 (1998).

31.

Linz, W., Wiemer, G., Gohlke, P., Unger, T. & Schölkens, B. A. Contribution of
kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Pharmacol. Rev. 47, (1995).

32.

Heran, B. S., Musini, V. M., Bassett, K., Taylor, R. S. & Wright, J. M. Angiotensin
receptor blockers for heart failure. Cochrane Database Syst. Rev. 2012, (2012).

33.

Kuenzli, A. et al. Meta-Analysis of Combined Therapy with Angiotensin Receptor
28

Antagonists versus ACE Inhibitors Alone in Patients with Heart Failure. PLoS One
5, e9946 (2010).
34.

McMurray, J. J. V. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart
Failure. N. Engl. J. Med. 371, 993–1004 (2014).

35.

Dargie, H. J. Effect of carvedilol on outcome after myocardial infarction in patients
with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet
(London, England) 357, 1385–1390 (2001).

36.

Adamopoulos, C. et al. Timing of eplerenone initiation and outcomes in patients
with heart failure after acute myocardial infarction complicated by left ventricular
systolic dysfunction: insights from the EPHESUS trial†. Eur. J. Heart Fail. 11, 1099–
1105 (2009).

37.

Dirksen, M. T., Laarman, G. J., Simoons, M. L. & Duncker, D. J. G. M. Reperfusion
injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies.
Cardiovasc. Res. 74, 343–355 (2007).

38.

Reinecke, H. & Murry, C. E. Taking the Death Toll After Cardiomyocyte Grafting: A
Reminder of the Importance of Quantitative Biology. J Mol Cell Cardiol 34, 251–253
(2002).

39.

Maltais, S., Tremblay, J. P., Perrault, L. P. & Ly, H. Q. The Paracrine Effect: Pivotal
Mechanism in Cell-Based Cardiac Repair. doi:10.1007/s12265-010-9198-2

40.

Hodgkinson, C. P., Bareja, A., Gomez, J. A. & Dzau, V. J. Emerging Concepts in
Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology. Circ.
Res. 118, 95 (2016).

41.

Gnecchi, M. et al. Paracrine action accounts for marked protection of ischemic heart
by Akt-modified mesenchymal stem cells. Nat. Med. 11, 367–368 (2005).

42.

Doyle, B. et al. Progenitor cell therapy in a porcine acute myocardial infarction
model induces cardiac hypertrophy, mediated by paracrine secretion of
cardiotrophic factors including TGFbeta1. Stem Cells Dev. 17, 941–951 (2008).

43.

Kamihata, H. et al. Implantation of Bone Marrow Mononuclear Cells Into Ischemic
Myocardium Enhances Collateral Perfusion and Regional Function via Side Supply
of Angioblasts, Angiogenic Ligands, and Cytokines. Circulation 104, 1046–1052
(2001).

44.

Zhang, Q. Z. et al. Human Gingiva-Derived Mesenchymal Stem Cells Elicit
Polarization of M2 Macrophages and Enhance Cutaneous Wound Healing. Stem
Cells 28, 1856 (2010).

45.

Kim, J. & Hematti, P. Mesenchymal stem cell-educated macrophages: a novel type
of alternatively activated macrophages. Exp. Hematol. 37, 1445–1453 (2009).

46.

Dayan, V. et al. Mesenchymal stromal cells mediate a switch to alternatively
activated monocytes/macrophages after acute myocardial infarction. Basic Res.
Cardiol. 106, 1299–1310 (2011).

47.

Guo, J. et al. Insulin-Like Growth Factor 1 Treatment of MSCs Attenuates
Inflammation and Cardiac Dysfunction Following MI. Inflammation 37, 2156–2163
(2014).

48.

Burchfield, J. S. & Dimmeler, S. Role of paracrine factors in stem and progenitor
29

cell mediated cardiac repair and tissue fibrosis. Fibrogenes. Tissue Repair 1, 1–11
(2008).
49.

Kardami, E. et al. PKC-dependent phosphorylation may regulate the ability of
connexin43 to inhibit DNA synthesis. Cell Commun. Adhes. 10, 293–297 (2003).

50.

Hinrichsen, R., Haunsø, S. & Busk, P. K. Different regulation of p27 and Akt during
cardiomyocyte proliferation and hypertrophy. Growth Factors 25, 132–140 (2007).

51.

Zhao, Y. Y. et al. Neuregulins promote survival and growth of cardiac myocytes.
Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular
myocytes. J. Biol. Chem. 273, 10261–10269 (1998).

52.

Massa, M. et al. Clinical applications of mesenchymal stem/stromal cell derived
extracellular vesicles: Therapeutic potential of an acellular product. Diagnostics 10,
1–17 (2020).

53.

Gangadaran, P. et al. Extracellular vesicles from mesenchymal stem cells activates
VEGF receptors and accelerates recovery of hindlimb ischemia. J. Control. Release
264, 112–126 (2017).

54.

Luther, K. M. et al. Exosomal miR-21a-5p mediates cardioprotection by
mesenchymal stem cells. J. Mol. Cell. Cardiol. 119, 125–137 (2018).

55.

Wang, N. et al. Mesenchymal stem cells-derived extracellular vesicles, via miR210, improve infarcted cardiac function by promotion of angiogenesis. Biochim.
Biophys. Acta - Mol. Basis Dis. 1863, 2085–2092 (2017).

56.

Teng, X. et al. Mesenchymal stem cell-derived exosomes improve the
microenvironment of infarcted myocardium contributing to angiogenesis and antiinflammation. Cell. Physiol. Biochem. 37, 2415–2424 (2015).

57.

Arslan, F. et al. Mesenchymal stem cell-derived exosomes increase ATP levels,
decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial
viability and prevent adverse remodeling after myocardial ischemia/reperfusion
injury. Stem Cell Res. 10, 301–312 (2013).

58.

El Andaloussi, S., Mäger, I., Breakefield, X. O. & Wood, M. J. A. Extracellular
vesicles: Biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov.
12, 347–357 (2013).

59.

Skotland, T., Sandvig, K. & Llorente, A. Lipids in exosomes: Current knowledge and
the way forward. Prog. Lipid Res. 66, 30–41 (2017).

60.

Mulcahy, L. A., Pink, R. C. & Carter, D. R. F. Routes and mechanisms of
extracellular vesicle uptake. J. Extracell. Vesicles 3, (2014).

61.

van der Pol, E., Böing, A. N., Harrison, P., Sturk, A. & Nieuwland, R. Classification,
functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev. 64, 676–
705 (2012).

62.

Vader, P., Breakefield, X. O. & Wood, M. J. A. Extracellular vesicles: emerging
targets for cancer therapy. Trends Mol. Med. 20, 385–393 (2014).

63.

Mead, B. & Tomarev, S. Extracellular vesicle therapy for retinal diseases. Prog.
Retin. Eye Res. 79, 100849 (2020).

64.

Mondello, S. et al. Extracellular vesicles: pathogenetic, diagnostic and therapeutic
30

value in traumatic brain injury. https://doi.org/10.1080/14789450.2018.1464914 15,
451–461 (2018).
65.

Li, J. K. et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential
Therapeutic Strategy for Acute Kidney Injury. Front. Immunol. 12, 2124 (2021).

66.

Gupta, M. et al. Preclinical Studies of MSC-Derived Extracellular Vesicles to Treat
or Prevent Graft Versus Host Disease: a Systematic Review of the Literature. Stem
Cell Rev. Reports 17, 332–340 (2021).

67.

Lanyu, Z. & Feilong, H. Emerging role of extracellular vesicles in lung injury and
inflammation. Biomed. Pharmacother. 113, 108748 (2019).

68.

Wu, X. et al. Extracellular vesicles: Potential role in osteoarthritis regenerative
medicine. J. Orthop. Transl. 21, 73–80 (2020).

69.

Doeppner, T. R., Bähr, M., Hermann, D. M. & Giebel, B. Concise Review:
Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke.
Stem Cells Transl. Med. 6, 2044–2052 (2017).

70.

Fu, S. et al. Extracellular vesicles in cardiovascular diseases. Cell Death Discov.
2020 61 6, 1–9 (2020).

71.

Kowal, J. & Tkach, M. Dendritic cell extracellular vesicles. Int. Rev. Cell Mol. Biol.
349, 213–249 (2019).

72.

Wang, Y. et al. Macrophage-derived extracellular vesicles: diverse mediators of
pathology and therapeutics in multiple diseases. doi:10.1038/s41419-020-03127-z

73.

Adamiak, M. et al. Induced Pluripotent Stem Cell (iPSC)-derived extracellular
vesicles are safer and more effective for cardiac repair than iPSCs. Circ. Res. 122,
296–309 (2018).

74.

Zhang, B., Tian, X., Hao, J. & Xu, G. Mesenchymal Stem Cell-Derived Extracellular
Vesicles in Tissue Regeneration. 29, 1–14 (2020).

75.

Katsuda, T., Kosaka, N., Takeshita, F. & Ochiya, T. The therapeutic potential of
mesenchymal stem cell-derived extracellular vesicles. Proteomics 13, 1637–1653
(2013).

76.

Keshtkar, S., Azarpira, N. & Ghahremani, M. H. Mesenchymal stem cell-derived
extracellular vesicles: Novel frontiers in regenerative medicine. Stem Cell Res.
Ther. 9, 1–9 (2018).

77.

Hass, R., Kasper, C., Böhm, S. & Jacobs, R. Different populations and sources of
human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissuederived MSC. Cell Commun. Signal. 9, 1–14 (2011).

78.

Ullah, I., Subbarao, R. B. & Rho, G. J. Human mesenchymal stem cells - current
trends and future prospective. Biosci. Rep. 35, 191 (2015).

79.

Berebichez-Fridman, R. & Montero-Olvera, P. R. Sources and Clinical Applications
of Mesenchymal Stem Cells: State-of-the-art review. Sultan Qaboos Univ. Med. J.
18, e264 (2018).

80.

de Jong, O. G., van Balkom, B. W. M., Schiffelers, R. M., Bouten, C. V. C. &
Verhaar, M. C. Extracellular vesicles: Potential roles in regenerative medicine.
Front. Immunol. 5, 608 (2014).
31

81.

Teng, F. & Fussenegger, M. Shedding Light on Extracellular Vesicle Biogenesis
and Bioengineering. Adv. Sci. 8, 2003505 (2021).

82.

Tieu, A. et al. An Analysis of Mesenchymal Stem Cell-Derived Extracellular Vesicles
for Preclinical Use. ACS Nano (2020). doi:10.1021/acsnano.0c01363

83.

Xuan, W., Khan, M. & Ashraf, M. Extracellular Vesicles From Notch Activated
Cardiac Mesenchymal Stem Cells Promote Myocyte Proliferation and
Neovasculogenesis. Front. Cell Dev. Biol. 8, 11 (2020).

84.

Bian, S. et al. Extracellular vesicles derived from human bone marrow
mesenchymal stem cells promote angiogenesis in a rat myocardial infarction
model. J. Mol. Med. (2014). doi:10.1007/s00109-013-1110-5

85.

Rilla, K. et al. Extracellular vesicles are integral and functional components of the
extracellular matrix. Matrix Biol. 75–76, 201–219 (2019).

86.

Kim, H. et al. Comprehensive Molecular Profiles of Functionally Effective MSCDerived Extracellular Vesicles in Immunomodulation. Mol. Ther. 28, 1628–1644
(2020).

87.

Gowen, A., Shahjin, F., Chand, S., Odegaard, K. E. & Yelamanchili, S. V.
Mesenchymal Stem Cell-Derived Extracellular Vesicles: Challenges in Clinical
Applications. Front. Cell Dev. Biol. 8, 1–8 (2020).

88.

Poupardin, R., Wolf, M. & Strunk, D. Adherence to minimal experimental
requirements for defining extracellular vesicles and their functions. Adv. Drug Deliv.
Rev. 176, 113872 (2021).

89.

Uman, S., Dhand, A. & Burdick, J. A. Recent advances in shear-thinning and selfhealing hydrogels for biomedical applications. J. Appl. Polym. Sci. 137, 1–20
(2020).

90.

Filgueira, C. S. et al. Technologies for intrapericardial delivery of therapeutics and
cells. Adv. Drug Deliv. Rev. (2019). doi:10.1016/j.addr.2019.02.006

91.

Dobner, S., Bezuidenhout, D., Govender, P., Zilla, P. & Davies, N. A Synthetic Nondegradable Polyethylene Glycol Hydrogel Retards Adverse Post-infarct Left
Ventricular Remodeling. J. Card. Fail. 15, 629–636 (2009).

92.

Plotkin, M. et al. The effect of matrix stiffness of injectable hydrogels on the
preservation of cardiac function after a heart attack. Biomaterials 35, 1429–1438
(2014).

93.

Sabbah, H. N. et al. Augmentation of Left Ventricular Wall Thickness With Alginate
Hydrogel Implants Improves Left Ventricular Function and Prevents Progressive
Remodeling in Dogs With Chronic Heart Failure. JACC Hear. Fail. 1, 252–258
(2013).

94.

Ifkovits, J. L. et al. Injectable hydrogel properties influence infarct expansion and
extent of postinfarction left ventricular remodeling in an ovine model. Proc. Natl.
Acad. Sci. U. S. A. 107, 11507–11512 (2010).

95.

Wang, H. et al. Effects of hydrogel injection on borderzone contractility postmyocardial infarction. Biomech. Model. Mechanobiol. 17, 1533–1542 (2018).

96.

Wang, H. et al. Computational sensitivity investigation of hydrogel injection
characteristics for myocardial support. J. Biomech. 64, 231–235 (2017).
32

97.

Rodell, C. B. et al. Injectable Shear-Thinning Hydrogels for Minimally Invasive
Delivery to Infarcted Myocardium to Limit Left Ventricular Remodeling. Circ.
Cardiovasc. Interv. (2016). doi:10.1161/CIRCINTERVENTIONS.116.004058

98.

Wang, H. et al. Effects of hydrogel injection on borderzone contractility postmyocardial infarction. Biomech. Model. Mechanobiol. (2018). doi:10.1007/s10237018-1039-2

99.

Frey, N. et al. Intracoronary Delivery of Injectable Bioabsorbable Scaffold (IK-5001)
to Treat Left Ventricular Remodeling After ST-Elevation Myocardial Infarction: A
First-in-Man Study. Circ. Cardiovasc. Interv. 7, 806–812 (2014).

100. Anker, S. D. et al. A prospective comparison of alginate-hydrogel with standard
medical therapy to determine impact on functional capacity and clinical outcomes
in patients with advanced heart failure (AUGMENT-HF trial). Eur. Heart J. (2015).
doi:10.1093/eurheartj/ehv259
101. Whyte, W. et al. Sustained release of targeted cardiac therapy with a replenishable
implanted epicardial reservoir /692/4019/2773 /639/301/54/152 /14/5 /14/35 /14/63
/59/5 /96/106 /96/100 /96/34 article. Nat. Biomed. Eng. (2018). doi:10.1038/s41551018-0247-5
102. Montgomery, M. et al. Flexible shape-memory scaffold for minimally invasive
delivery of functional tissues. Nat. Mater. 16, 1038–1046 (2017).
103. Seif-Naraghi, S. B. et al. Safety and efficacy of an injectable extracellular matrix
hydrogel for treating myocardial infarction (Science Translational Medicine (2013)
5 (173ra25)). Sci. Transl. Med. 6, (2014).
104. Garcia, J. R. et al. A Minimally Invasive, Translational Method to Deliver Hydrogels
to the Heart Through the Pericardial Space. JACC Basic to Transl. Sci. (2017).
doi:10.1016/j.jacbts.2017.06.003
105. Vu, T. D. et al. An autologous platelet-rich plasma hydrogel compound restores left
ventricular structure, function and ameliorates adverse remodeling in a minimally
invasive large animal myocardial restoration model: A translational approach. Vu
and Pal "Myocardial Repai. Biomaterials 45, 27–35 (2015).
106. Eckhouse, S. R. et al. Local hydrogel release of recombinant TIMP-3 attenuates
adverse left ventricular remodeling after experimental myocardial infarction. Sci.
Transl. Med. (2014). doi:10.1126/scitranslmed.3007244
107. Purcell, B. P. et al. Injectable and bioresponsive hydrogels for on-demand matrix
metalloproteinase inhibition. Nat. Mater. 13, 653–61 (2014).
108. Dorsey, S. M. et al. MRI evaluation of injectable hyaluronic acid-based hydrogel
therapy to limit ventricular remodeling after myocardial infarction. Biomaterials 69,
65–75 (2015).
109. Tous, E. et al. Influence of injectable hyaluronic acid hydrogel degradation behavior
on infarction-induced ventricular remodeling. Biomacromolecules 12, 4127–4135
(2011).
110. Ifkovits, J. L. et al. Injectable hydrogel properties influence infarct expansion and
extent of postinfarction left ventricular remodeling in an ovine model. Proc. Natl.
Acad. Sci. (2010). doi:10.1073/pnas.1004097107
33

111. Morita, M. et al. Modification of infarct material properties limits adverse ventricular
remodeling. Ann. Thorac. Surg. 92, 617–624 (2011).
112. McGarvey, J. R. et al. Injectable microsphere gel progressively improves global
ventricular function, regional contractile strain, and mitral regurgitation after
myocardial infarction. Ann. Thorac. Surg. 99, 597–603 (2015).
113. McGarvey, J. R. et al. Targeted injection of a biocomposite material alters
macrophage and fibroblast phenotype and function following myocardial infarction:
Relation to left ventricular remodeling. J. Pharmacol. Exp. Ther. 350, 701–709
(2014).
114. Mukherjee, R. et al. Targeted Myocardial Microinjections of a Biocomposite Material
Reduces Infarct Expansion in Pigs. Ann. Thorac. Surg. 86, 1268–1276 (2008).
115. Singelyn, J. M. et al. Catheter-deliverable hydrogel derived from decellularized
ventricular extracellular matrix increases endogenous cardiomyocytes and
preserves cardiac function post-myocardial infarction. J. Am. Coll. Cardiol. 59, 751–
763 (2012).
116. Soucy, K. G. et al. Feasibility Study of Particulate Extracellular Matrix (P-ECM) and
Left Ventricular Assist Device (HVAD) Therapy in Chronic Ischemic Heart Failure
Bovine Model. ASAIO J. 61, 161–169 (2015).
117. Sabbah, H. N. et al. Augmentation of left ventricular wall thickness with alginate
hydrogel implants improves left ventricular function and prevents progressive
remodeling in dogs with chronic heart failure. JACC Hear. Fail. 1, 252–258 (2013).
118. Bastings, M. M. C. et al. A fast pH-switchable and self-healing supramolecular
hydrogel carrier for guided, local catheter injection in the infarcted myocardium.
Adv. Healthc. Mater. 3, 70–78 (2014).
119. Lin, Y. D. et al. Injection of peptide nanogels preserves postinfarct diastolic function
and prolongs efficacy of cell therapy in pigs. Tissue Eng. - Part A 21, 1662–1671
(2015).
120. Huang, K. et al. An off-the-shelf artificial cardiac patch improves cardiac repair after
myocardial infarction in rats and pigs. Sci. Transl. Med. 12, (2020).
121. Koudstaal, S. et al. Sustained delivery of insulin-like growth factor-1/hepatocyte
growth factor stimulates endogenous cardiac repair in the chronic infarcted pig
heart. J. Cardiovasc. Transl. Res. 7, 232–241 (2014).
122. Matsumura, Y. et al. Intramyocardial injection of a fully synthetic hydrogel
attenuates left ventricular remodeling post myocardial infarction. Biomaterials 217,
119289 (2019).
123. Garbayo, E. et al. Catheter-based intramyocardial injection of FGF1 or NRG1loaded MPs improves cardiac function in a preclinical model of ischemiareperfusion. Sci. Rep. 6, 1–12 (2016).
124. Chen, C. H., Chang, M. Y., Wang, S. S. & Hsieh, P. C. H. Injection of autologous
bone marrow cells in hyaluronan hydrogel improves cardiac performance after
infarction in pigs. Am. J. Physiol. - Hear. Circ. Physiol. 306, 1078–1086 (2014).
125. Takehara, N. et al. Controlled Delivery of Basic Fibroblast Growth Factor Promotes
Human Cardiosphere-Derived Cell Engraftment to Enhance Cardiac Repair for
34

Chronic Myocardial Infarction. J. Am. Coll. Cardiol. 52, 1858–1865 (2008).
126. Brennan, M., Layrolle, P. & Mooney, D. J. Biomaterials Functionalized with MSC
Secreted Extracellular Vesicles and Soluble Factors for Tissue Regeneration. Adv.
Funct. Mater. 30, 1909125 (2020).
127. Ibrahim, A. G. E. et al. Augmenting canonical Wnt signalling in therapeutically inert
cells converts them into therapeutically potent exosome factories. Nat. Biomed.
Eng. 3, 695–705 (2019).
128. Brennan, M., Layrolle, P. & Mooney, D. J. Biomaterials Functionalized with MSC
Secreted Extracellular Vesicles and Soluble Factors for Tissue Regeneration. Adv.
Funct. Mater. 1909125, 1–21 (2020).
129. Zhang, K. et al. Enhanced Therapeutic Effects of Mesenchymal Stem Cell-Derived
Exosomes with an Injectable Hydrogel for Hindlimb Ischemia Treatment. ACS Appl.
Mater. Interfaces 10, 30081–30091 (2018).
130. Han, C. et al. Human umbilical cord mesenchymal stem cell derived exosomes
encapsulated in functional peptide hydrogels promote cardiac repair. Biomater. Sci.
7, 2920–2933 (2019).
131. Liu, B. et al. Cardiac recovery via extended cell-free delivery of extracellular
vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells.
Nat. Biomed. Eng. 2, 293–303 (2018).
132. Han, Y. L. et al. Directed self-assembly of microscale hydrogels by electrostatic
interaction. Biofabrication 5, (2013).
133. Lv, K. et al. Incorporation of small extracellular vesicles in sodium alginate hydrogel
as a novel therapeutic strategy for myocardial infarction. Theranostics 9, 7403–
7416 (2019).
134. Chung, J. J. et al. Delayed delivery of endothelial progenitor cell-derived
extracellular vesicles via shear thinning gel improves postinfarct hemodynamics. J.
Thorac. Cardiovasc. Surg. 159, 1825-1835.e2 (2020).
135. Chen, C. W. et al. Sustained release of endothelial progenitor cell-derived
extracellular vesicles from shear-thinning hydrogels improves angiogenesis and
promotes function after myocardial infarction. Cardiovasc. Res. 114, 1029–1040
(2018).

35

CHAPTER 2
RESEARCH OVERVIEW

2.1 SPECIFIC AIMS
Acute myocardial infarction (MI) complicated by heart failure (HF) is a growing
cause of morbidity and mortality in the United States.1 Recent studies have suggested
that extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) can
mediate cardioprotection post-MI due to their key roles in paracrine signaling with
angiogenic,2,3 proliferative,4 anti-inflammatory, 5 and anti-apoptotic6 effects via transfer of
cytoprotective proteins and miRNAs. While MSC-EVs have shown promise in small animal
models,7–10 large animal studies are required to evaluate the therapeutic benefit of MSCEVs for clinical translation. Major challenges toward their translation include the
generation of clinically relevant quantities of EVs, as well as the localization and sustained
delivery of EVs at the target site for therapeutic efficacy.
Recently, the use of biomaterials such as injectable hydrogels to deliver EVs has
emerged as a promising strategy in regenerative medicine to overcome the low retention
of bolus injections of EVs.11 Injectable hydrogels as therapies have already been shown
to modulate the dynamic process of LV remodeling and subsequent progression to heart
failure through mechanical bulking and the delivery of therapeutics.12 Towards clinical
translation of the therapeutic delivery of MSC-EVs for cardiac repair, the goal of this work
is to (i) investigate optimal EV biomanufacturing conditions to generate doses required for
large animal studies, (ii) assess the therapeutic potential of MSC-EVs in vivo via injectable
hydrogels to achieve local and sustained delivery of MSC-EVs to cardiac tissue, (iii)
investigate the importance of the rate of EV release on therapeutic outcomes, and (iv)
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design a radiopaque hydrogel system to better understand hydrogel administration for
minimally invasive applications of these therapies. To this end, the following aims are
developed. These aims build on each other with a common goal of understanding the
therapeutic efficacy of MSC-EVs released from injectable hydrogels towards clinical
translation.

Aim 1: Investigate the scale-up of porcine MSC-derived EVs with dynamic culture
conditions, and assess EV content based on isolation method.
Hypothesis: Dynamic cell culture conditions for MSC-EV manufacturing will increase
MSC-EV yield and influence the content of isolated EVs.
One of the biggest challenges for large animal studies (and eventual translation)
is the need to generate sterile and reproducible clinically-relevant quantities of EVs for
delivery. While EV production has predominantly relied on the use of tissue culture flasks
(i.e., 2D culture), this results in a major bottleneck in the advancement of EV-based
therapeutics, due to the low scale and inefficient production of clinical-grade EVs with this
method and the potential for batch-to-batch variations. In order to establish an EV
biomanufacturing platform, a systematic investigation of porcine bone marrow-derived
MSC expansion methods is conducted, including a tubular perfusion bioreactor culture
system with 3-D printed scaffolds and the microcarrier-based spinner flasks, with
comparison to traditionally-used tissue culture flasks. Across these MSC expansion
methods and using four biological MSC donors, EV size, distribution, particle yield, protein
concentration,

miRNA

composition

(RNAsequencing),

and

protein

composition

(proteomics) are analyzed and compared. To investigate the therapeutic potential of EVs,
selected biological donor and production method based on yield and content, will be
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tested for their ability to protect induced pluripotent stem cell (iPSC)-cardiomyocytes in an
in vitro culture model of myocardial hypoxia based on previously described methods,17 as
well as the vasculogenic potential of EVs via a Matrigel tubule formation assay by
endothelial cells.18 The findings from this Aim will better inform EV translation and provide
a source for animal studies in subsequent Aims of this thesis.

Aim 2: Investigate the in vivo therapeutic potential of MSC-EVs, including in a
clinically-relevant porcine model of MI.
Hypothesis: MSC-EVs will have a positive effect on cardiac repair and hydrogel delivery
will improve structural and functional outcomes when compared to injection of EVs alone
in a porcine model of MI.
MSC-EVs have been shown to have therapeutic efficacy in a variety of disease
models ranging from acute kidney injury,13 liver fibrosis,14 osteoarthritis15 to critical limb
ischemia2 and myocardial infarction.3 While many of the pathways are not fully elucidated,
the role of MSC-EVs in cardiac repair have been largely attributed to angiogenesis2 and
cardioprotection via improvements in ATP and calcium handling.16 We first attempt to
validate these hypothesized mechanisms in vitro using our selected biological MSC donor
and cell culture method from Aim 1. In order to effectively translate MSC-EVs from bench
to bedside, large animal studies are required to validate therapeutic efficacy. Towards this,
MSC-EVs are delivered via a previously developed shear-thinning hydrogel based on
guest-host (GH) chemistry19 to achieve local and sustained delivery in an established
porcine ischemia/reperfusion model. Outcomes of ejection fraction (EF), left ventricular
end-systolic elastance, and infarct size served as primary endpoints at the terminal
timepoint (8 weeks). Infarct size is quantified via electroanatomical mapping,
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hemodynamic outcomes via Cardiac Magnetic Resonance (CMR), and finally wall
thickness via histology. The findings of this Aim will lead to an injectable hydrogel and EV
therapy for treatment of MI, using clinically-relevant metrics to identify success.

Aim 3: Investigate extended delivery of MSC-derived EVs and assess their release,
biodistribution, and therapeutic potential in vivo in a rat model of MI.
Hypothesis: The sustained release of MSC-EVs based on controlled hydrogel degradation
will improve functional outcomes in a rat model of MI.
It has been shown that single-bolus injections of EVs result in minimal local
concentrations, with up to 90% of particles immediately washing away.20 On the other
hand, encapsulating EVs in a biomaterial has been shown by our group and others to
extend bioavailability following delivery, permit sustained and controlled release, maintain
stability of EV cargo, and potentially augment therapeutic potency.2111 While the GH
hydrogel used in Aim 2 for therapeutic delivery of MSC-EVs into a porcine model of MI
has been shown to prolong delivery, modifications of the hydrogel can further extend EV
release and presentation in the myocardium, which may influence the therapeutic effect.
We develop a hydrogel that builds on the GH hydrogel in Aim 2, now adapted as an
interpenetrating network (IPN) hydrogel with the addition of gelatin crosslinked via
transglutaminase that can prolong the hydrogel degradation. It is crucial to first understand
the distribution of EVs when delivered in vivo.22 In order to overcome the challenges
associated with current EV labeling methods, we utilize a highly versatile metabolic
labeling methodology previously used in our lab to label based on the incorporation of
non-natural amino acids that act as functional handles to modify EVs with dyes.23 The
release and biodistribution of MSC-EVs are studied from the GH and IPN hydrogels in a
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healthy rat model and then the influence of hydrogel release is assessed therapeutically
in a rat MI model. The findings of this Aim will further EV therapies for treatment of MI, by
identifying whether the kinetics of EV release are important on their therapeutic efficacy.

Aim 4: Design a radiopaque injectable hydrogel system to evaluate hydrogel
localization, retention, and degradation towards therapeutic delivery to the heart.
Hypothesis: Encapsulating a contrast agent at a concentration that does not significantly
affect hydrogel properties into hydrogels will render them radiopaque and allow in vivo
non-invasive SPECT/CT imaging in a pig model of MI.
Towards clinical translation, creation of a trackable hydrogel will improve our
understanding of the location, volume, and pattern of hydrogels after delivery. We
introduce radiopacity with a clinically used radiopaque agent (i.e., Iohexol). In an acute
porcine model of MI, hybrid SPECT/CT perfusion imaging immediately and 3-4 days after
hydrogel delivery is then used to assess radiopacity and verify the hydrogel location within
the perfusion defect. Finally, the mechanical bulking effects of intramyocardial delivery of
the radiopaque hydrogel is characterized using a CineCT platform for in vivo and ex vivo
measurements of 3D high resolution Lagrangian strains in the left ventricle and the
therapeutic efficacy of the radiopaque theranostic hydrogel is determined using cineCT
images and pressure-volume loops. Various hydrogels are used with the approach to
illustrate the versatility across a range of hydrogel platforms, furthering our understanding
of injectable hydrogels in cardiac repair after MI.
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2.2 CHAPTER OUTLINE
Chapter 1 provides a detailed description of MI, current treatment strategies and
the pathological remodeling processes that occur afterward that can result in HF.
Additionally, novel strategies including clinically-relevant trials for cellular and extracellular
vesicle-based therapies as well as pre-clinical and clinical application of injectable
hydrogels as bulking agents and delivery vehicles for cardiac repair are reviewed.
Chapter 3 describes a broad review of the design of shear-thinning and selfhealing hydrogels for biomedical applications and lays the foundation for the design of
injectable materials used throughout this dissertation.
Chapter 4 describes the research proposed in Aim 1, which involves scaling up the
manufacturing of MSC-derived EVs using different biological donors and cell culture
methods, characterizing those MSC-EVs and their protein and RNA content using
proteomics and RNA sequencing.
Chapter 5 describes the research proposed in Aim 2, which involves assessing the
in vitro therapeutic potential of MSC-EVs described in Aim 1 and developing an injectable
hydrogel for the delivery of MSC-EVs and assessing the functional outcomes in a porcine
model of MI when delivered with an injectable hydrogel.
Chapter 6 describes the research proposed in Aim 3, which uses novel metabolic
labeling methods to track MSC-EVs to assess their release, biodistribution and therapeutic
efficacy from the injectable hydrogel from Aim 1, in addition to a novel IPN hydrogel for
extended release in a rat model of MI.
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Chapter 7 describes the research proposed in Aim 4, which uses a novel
radiopaque injectable hydrogel to understand the pattern, localization, and retention of
hydrogels in the myocardium after delivery in a pig model of MI towards minimally invasive,
image-guided hydrogel delivery for clinical translation. The acute mechanical benefits of
this radiopaque hydrogel are assessed using a novel cineCT platform and hemodynamic
measurements.
Finally, Chapter 8 presents a summary of the work presented in this thesis,
highlighting the contributions of each Aim toward developing injectable hydrogels for the
delivery of MSC-EV based therapeutics for cardiac repair. Limitations of these studies are
discussed, as well as possible future directions toward further clinical translation and
eventual commercialization of these therapies.
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CHAPTER 3
RECENT ADVANCES IN SHEAR-THINNING AND SELF-HEALING HYDROGELS
FOR BIOMEDICAL APPLICATIONS

Adapted from:

Uman, S., Dhand, A. & Burdick, J. A. Recent advances in shear-thinning and self-healing
hydrogels for biomedical applications. J. Appl. Polym. Sci. 137, 1–20 (2020).

3.1 INTRODUCTION
Hydrogels are three-dimensional networks of crosslinked polymers or polypeptides
that swell in aqueous environments due to molecule hydrophilicity. Hydrogels have been
designed to be cytocompatible and to exhibit tunable physicochemical properties (e.g.,
mechanics, degradation), allowing them to be explored for a range of biomedical
applications from drug delivery to tissue engineering1,2. Hydrogels may also be designed
as injectable systems for minimally-invasive delivery to tissues or for the fabrication of
engineered constructs3. While many injectable hydrogels are designed to undergo in situ
chemical crosslinking (e.g., photo- or redox-initiation, Michael-type addition), the need for
small molecule initiators and/or light irradiation and limited control over gelation kinetics
can reduce their potential - slow gelation might cause rapid material dispersion and loss
of cargo, whereas rapid crosslinking might clog the injection device4.
To overcome these challenges, a growing body of research now focuses on
designing hydrogels that exhibit viscous flow under shear stress (i.e., shear-thinning) and
recovery when the applied stress is removed (i.e., self-healing)5. This can be observed
rheologically, where shear-thinning hydrogels experience a decrease in viscosity upon
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application of stress and then recovery of mechanical properties when the stress is
reduced (visualized through alternating periods of low and high strains) (Figure 3.1) 4.
Thus, these hydrogels can be prepared as stable formulations in advance, shear-thin
during injection, and subsequently recover with self-healing, improving material retention
and mechanical properties5. Shear-thinning and self-healing hydrogels have been
investigated in various biomedical applications including drug delivery6, tissue
regeneration7, and 3D bioprinting8 (Figure 3.1) and have been used in a range of in vivo
applications (Table 3.1).
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Figure 3.1. Applications of injectable hydrogels. A wide variety of shear-thinning and selfhealing hydrogels are being developed that can be used alone or to encapsulate various cargo,
such as cells (e.g., embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), adiposederived stem cells, and bone marrow-derived stem cells) or therapeutic molecules (e.g., small
molecules, proteins/growth factors, genes, and extracellular vesicles). Such hydrogels exhibit
viscous flow under increased shear (i.e., shear-thinning) and recovery of properties when the
applied stress is removed (i.e., shear-thinning), as illustrated through rheological tests. Shearthinning and self-healing hydrogels are being investigated in various biomedical applications,
including tissue engineering and drug delivery.

Table 3.1. Representative examples of shear-thinning and self-healing hydrogels and
applications in vivo.

Chemistry

Material

In Vivo Application

Ref.

Hydrogen Bonds

UPy-PEG

Intrarenal BMP7 delivery
for rat model of acute
kidney injury

227

47

Guest-Host
Interactions

UPy- PEG

HGF/IGF-1 catheter
delivery in a porcine
model of MI

13

b-cyclodextrin-PEI

siRNA delivery for rat
model of MI

63

miRNA302 for mouse
model of MI

64

Tissue repair in porcine
model of MI

228

Engineered MSCs for
cancer therapy in a
mouse melanoma model

229

11

Fe(III)

DOX and DTX delivery for
murine lung and breast
cancer

Dexamethasone-Phosphate and
Ca(II)

Rat sciatic nerve
blockade

230

Gelatin and silicate nanoplatelets

Mouse model of liver
laceration

149

Adamantane-Norbornene-HA

Rat model of myocardial
infarction

160

Brain repair in a mouse
stroke model

158

Rabbit osteochondral
defect model for cartilage
repair

168

Injectable antibacterial
adhesive as wound
dressing

172

Rabbit model of liver
laceration

175

Adamantane-PEG
b-cyclodextrin-HA
Adamantane-HA
Adamantane-thiol-HA
b-cyclodextrin-methacrylate-HA

CB[6]-HA
Diaminohexane-HA
Metal-Ligand
Coordination

Nanocomposite

Chitosan-catechol

Systems
Granular
Hydrogels

b-cyclodextrin-HA
Acrylamide-HA
Dicysteine MMP degradable
crosslinker

Schiff Base

Chitosan
HA-Aldehyde
Quaternized Chitosan
PEG-Benzaldehyde
Carboxymethyl chitosan
PEG-benzaldehyde

48

Quaternized chitosan-g-polyaniline
PEG-PEGS-Benzaldehyde

Mouse model of liver
laceration

171

HA-Aldehyde

rTIMP-3 delivery in a
porcine model of MI

15

Doxorubicin delivery in a
mouse model of
fibrosarcoma

190

Full thickness skin defect
model in rats

198

HA-Hydrazide
PEG-Aldehyde
α,β-polyaspartylhydrazide
Aminated Gelatin
Oxidized Dextran

Shear-thinning and self-healing properties allow homogenous encapsulation of
payloads, injection through needles without clogging, and recovery to their initial state,
making them ideal for controlled release of small molecules9–12, proteins13–15, and genes16.
Local and sustained delivery through hydrogels provides greater concentrations of
therapeutics at the desired site of action while minimizing the side effects often associated
with systemic delivery. Because a shear-thinning, self-healing hydrogel can take the
shape of the local environment, maximal interfacial contact is achieved between the
hydrogel and the tissue, allowing drug to elute directly into the local environment17.
Furthermore, shear-thinning hydrogels can also be easily delivered into sites that are
difficult or infeasible to access via surgery.
Shear-thinning and self-healing hydrogels, owing to their dynamic nature and
similarity to extracellular matrices, are also attractive for tissue engineering and cell
delivery

18–22

. Injectable constructs have been shown to be efficient cell carriers, enable

minimally-invasive delivery, and provide efficient filling of irregular cavities and tissue
defects17. Furthermore, self-healing hydrogels are not vulnerable to stress-induced

49

formation of cracks, prolonging their lifetime for implantation of tissue engineered
constructs17,23.
Shear-thinning and self-healing hydrogels also have great potential in
biofabrication techniques, such as 3D printing. Ideal hydrogel-based inks for 3D printing
are those that can self-support with layer-by-layer deposition to form stabilized structures.
Shear-thinning gels may also be cytoprotective during the injection process24 and provide
a suitable platform for 3D printed tissue constructs under cytocompatible conditions. This
behavior is likely due to shear banding and plug-flow velocity profiles that limit the
disruption of cellular membranes during shear flow25.
Building from this motivation, this review focuses on recent advances in the design
and development of shear-thinning and self-healing hydrogels for biomedical applications.
We review various classes of shear-thinning and self-healing systems including: (i)
physical associations to assemble hydrogels (e.g., hydrogen bonds, guest-host
interactions, biorecognition motifs, hydrophobic interactions, electrostatic interactions, and
metal-ligand interactions), (ii) physical associations to assemble particle-based hydrogels
(e.g., nanocomposite, and granular systems), and (iii) dynamic covalent chemistry to form
hydrogels (e.g., Schiff base, oxime chemistry, disulfide bonds, reversible Diels Alder)
(Figure 3.2). The various mechanisms of hydrogel formation, shear-thinning and selfhealing properties, and biomedical applications are summarized for each sub-group. This
overview provides motivation for the various shear-thinning and self-healing hydrogels
implemented within this thesis.
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Figure 3.2. Mechanisms for formation of injectable hydrogels. Shear-thinning and selfhealing hydrogels rely on dynamic and reversible interactions between polymers and
polypeptides, such as (i) physical associations at the molecular level (e.g., hydrogen bonds,
guest-host interactions, biorecognition motifs, hydrophobic interactions, electrostatic interactions,
and metal-ligand interactions) (examples shown in blue), (ii) assembly of particle-based
hydrogels (e.g., nanocomposite, and granular systems) (examples shown in green), and (iii)
dynamic covalent chemistry (e.g., Schiff base, oxime chemistry, disulfide bonds, reversible Diels
Alder) (examples shown in red).
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3.2 PHYSICAL ASSOCIATIONS TO ASSEMBLE HYDROGELS
Likely the most common interactions between polymers that allow for both
hydrogel assembly and shear-thinning behaviors are those of physical associations.
These include a range of different bonding types that have been explored in hydrogel
fabrication including hydrogen bonds, guest-host interactions, biorecognition motifs,
hydrophobicity, electrostatics, and metal-ligand coordination (Figure 3.2). Each type of
physical association has specific bond strengths that control the bulk material properties
and the ability to self-heal. It should also be noted that often a combination of these
interactions (e.g., both hydrogen bonding and hydrophobicity) plays a role in hydrogel
formation and final properties. In this section, various types of physical associations that
have been applied to hydrogels for biomedical applications are reviewed, including
examples where the hydrogels have been applied to in vivo applications (Table 3.1).
3.2.1 Hydrogen Bonds
Hydrogen bonding is an attractive interaction between hydrogen atoms and
electronegative atoms (e.g., nitrogen, oxygen, and fluorine). While a single hydrogen bond
is weak compared to other physical associations and covalent bonds, they may contribute
greatly within a network to the stability and mechanics of polymer assemblies. Hydrogen
bonds also play a critical role in many biological self-assembled systems such as DNA
base-pairing and protein folding26,27. Several examples where hydrogen bonding has been
utilized in hydrogel design and explored for biomedical applications are provided here.
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Ureiodopyrimidone.

A well-described quadruple hydrogen bonding motif,

Ureidopyrimidone (UPy), has been used as a reversible and dynamic crosslinker to
prepare hydrogels that are injectable and undergo rapid self-healing in response to
damage28. UPy units allow a sol-gel transition to occur based on temperature or pH and
can be incorporated into different polymer backbones to obtain multi-responsive selfhealing hydrogels29–32.
As an example, polymers consisting of poly(ethylene glycol) (PEG) endfunctionalized with UPy moieties were decorated with a urea motif for lateral hydrogen
bonding and formed fibrous hydrogels in aqueous solutions based on pH13. Network
formation was modulated by changing the length of the hydrophobic alkyl spacer or the
molecular weight of the hydrophilic PEG component. These hydrogels were utilized for
minimally-invasive delivery of bone morphogenetic protein 7 to the renal cortex33,34, for
sustained release of hydrophilic chemotherapeutics in the intraperitoneal cavity9, for
growth factor delivery to the heart13, and for MRI visualization of hydrogels in the infarcted
heart35. Hepatocyte growth factor and insulin-like growth factor-1 were encapsulated into
UPy-hydrogels and delivered via a catheter as intramyocardial injections in a porcine
model of myocardial infarction13. The hydrogel in low viscosity state at pH greater than 8.5
was easily injected through the catheter and underwent self-healing and further gelation
under physiological conditions (Figure 3.3A-C)13.
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Dextran has also been used as the backbone for UPy modification without the
need for hydrophobic spacers and successfully encapsulated both chondrocytes and bone
marrow stem cells with high viability in culture for 2 weeks (Figure 3.3D,E)36. These
constructs were also implanted subcutaneously and shown to support the growth of both
bone and cartilage tissues in a nude mouse model. Towards tuning the mechanical
properties of UPy hydrogels, monofunctional37, bifunctional34, and chain-extended 34 UPyPEG hydrogels have been studied. Compared to telechelic UPy-PEG polymers, multiblock
PEG-based copolymers having UPy moieties in the backbone were shown to have high
strength and high resilience upon deformation38.

Figure 3.3. Physical associations. Hydrogels formed from polymers containing
ureiodopyrimidone (Upy). (A) Fibers in hydrogels (i) assemble through multiple UPy-stacks (red),
surrounded by a hydrophilic PEG corona (blue), (ii) align, (iii) crosslink with neighboring fibers,
and (iv) assemble into networks. (B) Structure of the UPy-hydrogelators with the hydrophilic PEG
block in blue and the UPy-alkyl-urea end groups in red and (C) injection of a liquefied 10 wt%
UPy-10k sample in PBS (colored in red) into a neutral PBS solution. Immediate gelation occurs
when the basic solution comes in contact with the neutral solution. Adapted with permission13.
Copyright 2014, Wiley. (D) Schematic illustration of Dextran-UPy hydrogel formation and the
mechanisms of the shear-thinning and self-healing properties. (E) Integration of hydrogel pieces
to form various structures through self-healing behavior. Scale bar = 5 mm. Adapted with
permission36. Copyright 2015, Wiley.
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Benzene-1,3,5-tricarboxamide. Benzene-1,3,5-tricarboxamide (BTA) is another
versatile supramolecular building block that can self-assemble into one-dimensional
aggregates, driven by three-fold intermolecular hydrogen bonding via a cooperative
mechanism39,40. The BTA motif has been well studied due to its interesting properties,
including solid-state luminescence41,42 and temperature- and pH- responsiveness43. The
introduction of a hydrophobic spacer effectively allows self-assembly to be driven by a
combination of hydrogen bonding and hydrophobic interactions44. This allows a
hydrophobic core to encapsulate small hydrophobic molecules, while charged molecules
can be coupled to the hydrophilic exterior via electrostatic interactions45,46. Furthermore,
the mechanical properties and self-assembly behavior of the hydrogels can be tuned via
modifying the molecular structure of the BTA unit and the length of the hydrophobic
spacers44. The potential of PEGylated BTA supramolecular polymers for electrostatically
complexed siRNA delivery has also been investigated47.
Other Types of Hydrogen Bonding. Interactions may also be engineered based
on those found in natural systems. For example, the self-repair of mussel byssal threads
is mainly attributed to the reversible metal-catechol coordination between Fe(II) and
catechol groups from an amino acid called 3,4-dihydroxyphenyl-L-alanine (DOPA)48.
Recently, self-healing has been demonstrated in metal-free environments for catechol
modified synthetic polyacrylates and polymethacrylates through interfacial hydrogen
bonds49. Utilizing catechol-mediated hydrogen bonding and aromatic interactions, poly(Nisopropylacrylamide) (PNIPAm) and PEG-based triblock co-polymers have been used to
form shear-thinning, self-healing hydrogels with antimicrobial properties to prevent
formation of biofilms50. Similar to catechol groups51, gallol moieties, which are aromatic
rings with three hydroxyl groups associated with fruit-browning phenomenon52, have also
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been utilized to form hydrogels via dynamic hydrogen bond formation53,54. Hyaluronic acid
and gelatin modified with gallol have been shown to gel through non-covalent hydrogen
bonding between gallols and protein backbones, followed by slow covalent crosslinking
through a spontaneous oxidation process55. Due to its shear-thinning and self-healing
properties as well as tissue-adhesive properties, the gallol ECM hydrogel ink was utilized
for 3D bioprinting with potential applications for on-tissue printing.
3.2.2 Guest-Host Interactions
A subset of supramolecular chemistry, guest-host interactions, have emerged with
great promise in both tissue engineering and drug delivery applications56. These bonds
are based on the transient association and formation of inclusion complexes between a
molecule containing a cavity (i.e., host) with suitable molecular guests. The family of
cavitands includes both naturally derived (e.g., cyclodextrin) and synthetic (e.g.,
curcurbit[n]urils, calix[n]ares, and pillar[n]ares) macrocyles57. The criteria for a guest-host
pair involves complementary size of the host cavity and guest molecule and interactions
through hydrophobicity56. Based on these broad criteria, macrocycles can be paired with
many different potential guests, which may be inert or stimuli-responsive molecules,
pharmaceuticals, biomolecules, or polymers56.
Cyclodextrin. Cyclodextrin (CD) is one of the most prevalent guest macrocycles
due to its high water- solubility, low toxicity, and extensive history of use56. CDs refer to
cyclic macromolecules formed from 6,7, or 8 a-D-glucopyranoside units, termed a-, b-, gCD respectively56. CD has a hydrophobic inner cavity, by which it can form an inclusion
complex with guest molecules such as adamantane, PEG, and cholesterol5. Recently,
injectable hydrogels that take advantage of an inclusion complex of CD have emerged as
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promising materials for various biomedical applications58. Guest-host assembled
hydrogels have properties that are critical for injectable biomaterials such as ease of
injection, rapid bond reformation for material retention, and tunable degradation through
material concentration, guest-host affinity, and the number of guest-host bonds56. These
molecular interactions have been employed to form hydrogels between polymers modified
with b-CD and adamantane, a-CD and PEG, and b-CD and azobenzene, among other
polymer systems59–62.
In addition to self-assembly, the ability of CD to form inclusion complexes with
pharmaceuticals has been leveraged for therapeutic delivery57. Controlled release of small
molecules, proteins, and growth factors from CD-based hydrogels has been widely
investigated, where release kinetics can be tuned through porosity, mesh size, and
degradation56. More recently, CD-based hydrogels were developed as gene carriers,
including with b-cyclodextrin modified polyethylenimine (PEI) and adamantane-modified
PEG for local siRNA release to the infarcted myocardium63. The modified polymers
assembled with siRNA to form hydrogels that released polyplexes for transfection. In
another study, hyaluronic acid (HA) was modified with adamantane and CD to selfassemble into shear-thinning and self-healing hydrogels to complex with cholesterolmodified microRNA for release into the myocardium to stimulate cardiomyocyte
proliferation64.
Harnessing the shear-thinning and self-healing capacity of guest-host chemistry,
3D printing techniques in which a shear-thinning hydrogel ink is directly printed into a
second self-healing support hydrogel have been developed8. The dynamic nature of the
support rapidly stabilizes the printed ink, allowing the printing of multiple inks, pockets of
inks, and cell-laden inks. Given the high viability of encapsulated cells in the bioink as well
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as the support hydrogel, this method offers a unique opportunity for extension of 3D
bioprinting applications to more complex structures in which secondary crosslinking
methods can be introduced for further stabilization3,65.
While supramolecular hydrogels are inherently self-healing and shear-thinning due
to the dynamic nature of the guest-host interactions, they often lack mechanical strength
that may be needed in some applications. In order to overcome these limitations while
retaining the advantages of shear-thinning properties with guest-host assembly, dual
crosslinking approaches or double-network hydrogels involving both guest-host
interactions and covalent chemistry to stabilize the network has been explored66,67. In one
example, the hydrogels showed potential in attenuating the expansion of myocardial
infarction by limiting dilation of the left ventricle in a sheep model (Figure 3.4A)66. There
has also been growing interest in making guest-host hydrogels stimuli responsive.
Inclusion complexation between CD and ferrocene (Fc) has been utilized to impart
electrical responsiveness68,69. Using the inclusion complexation between CD and trans
azobenzene, a photo-switchable crosslinker, hydrogels have been designed to convert
from the gel phase to the sol phase with light70,71. This type of chemistry has been
expanded to design hydrogels with reversible crosslinks upon light exposure at different
wavelengths72.
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Figure 3.4. Hydrogels formed from guest-host (GH) interactions. (A) i) Interaction of
adamantane (Ad, guest) and β-cyclodextrin (CD, host) modified polymers to assemble into
hydrogels with shear-thinning properties. Adapted with permission59. Copyright, 2013. American
Chemical Society. ii) GH hydrogels injected into the infarcted region of cardiac tissue, and iii)
histological image (left) and MRI reconstruction (right) of GH hydrogels after cardiac injection.
Adapted with permission66. Copyright, 2016. Wolters Kluwer. (B) i) Formation of double network
hydrogels through supramolecular interactions, including a network of carboxymethyl cellulose and
CB[8] and another network using DNA hybridization. ii) Images of 1.5 wt% single network
hydrogels (CB[8] hydrogel and DNA hydrogel) and corresponding double network hydrogel. iii) The
stretching behavior of the double network hydrogel. Adapted with permission80. Copyright, 2015.
Wiley.

Cucurbit[n]urils.

Cucurbit[n]uril (n=5-8, 10; CB[n]) is a symmetrical

macromolecule that can form a complex with ammonium ion with exceptionally high
binding affinity and selectivity in aqueous solution73. The cavity size of CB[n] and the length
of the guest molecule for hydrophobic interaction and hydrogen bonding are important
factors for the formation of a CB–guest complex74. In contrast to the smaller CB[n]
homologues, CB[8] has a larger cavity volume (479 Å)75 capable of simultaneously
accommodating two planar and hydrophobic guests in a π−π-stacked geometry76. This
host has been used in a complex using an electron-deficient first guest, such as methyl
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viologen (MV), and an electron-rich second guest such as naphthol, pyrene, and
dibenzylfuran77. The high binding affinities of the CB–guest interaction and its negligible
cytotoxicity have been exploited as a useful tool for non-covalent conjugation in many
biomedical applications.
Appel et al. first reported supramolecular hydrogels assembled from cucurbit[n]uril
and polymers functionalized with a variety of guest molecules78. Polymers containing
viologen and naphthalene moieties were crosslinked in CB[8] in a 1:1:1 binding interaction.
A follow-up study illustrated hydrogel formation with 99.7 wt% water content using
naphthyl-functionalized cellulose derivatives and a viologen bearing poly(vinyl alcohol)79.
These hydrogels were found to be responsive to external stimuli such as temperature,
competitive guests, and chemical potential. Recently, double network hydrogels based on
cellulose-CB[8] and DNA hybridization were created with interpenetrating behavior
resulting in tough hydrogels (Figure 3.4B)80. The shear-thinning and thixotropic properties
as well as dual degradability of the DNA and cellulose backbones allow these hydrogels
to be used in a wide variety of controlled release and tissue engineering applications.
CBs have been widely used to complex with platinum-based chemotherapeutics to
improve their solubility57,81. Towards controlled release to avoid systemic toxicity, cisplatinCB[7] has been encapsulated in PVA/gelatin hydrogels82. However, CB chemistry has not
yet been utilized for self-assembly simultaneously with chemotherapeutic inclusion
complexes. One of the challenges in applying cucurbit[n]uril supramolecular chemistry in
polymer self-assemblies might arise from the limited solubility and difficulty in large-scale
functionalization of cucurbit[n]uril homologues83. To overcome the scalability issue,
Rowland et al. recently described the development of a mild and translatable method to
functionalize high molecular polysaccharides such as HA, carboxymethyl cellulose (CMC),
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and hydroxyethyl cellulose (HEC) with the dipeptide cysteine-phenylalanine, resulting in
hydrogel formation upon the addition of CB[8]77.

3.2.3 Biorecognition Motifs
Protein-protein interactions form the basis of a wide variety of cellular processes
and can be exploited in the assembly of hydrogels. These interactions depend on peptides
sequences that are found in specific protein-binding structures84. These transient protein
interactions can be adopted for the design of biorecognition-based hydrogels, either
through the direct engineering of polypeptides containing these sequences or through the
modification of polymers with peptides that represent these interactions and can be
assembled into networks. These hydrogels are shear-thinning as interactions are
disrupted and then self-healing as the motifs are re-engaged.
WW Domain and Proline-Rich Domain Polypeptides. The WW domains are
protein motifs of 38-40 amino acids with conserved tryptophan residues, found in a broad
spectrum of proteins84. This domain is characterized by an anti-parallel triple-stranded bsheet structure85. The WW domain associates with proline-rich peptides in a specific and
tunable manner and can be designed into polypeptides with random-coil hydrophilic
spacers. This approach was utilized to develop a two-component molecular-recognition
gelation strategy in a mixing-induced two component hydrogel (MITCH) for cell
encapsulation and growth factor delivery (Figure 3.5A)86. Rheological and computational
studies showed that the frequency of association domains, binding strengths, and lengths
of hydrophilic spacers linking the multiple association domains were key parameters to
control material properties14. This strategy was used to support the self-renewal,
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differentiation, and elongation of neurite extension of neural stem cells in 3D in vitro
culture86 and promoted post-injection survival of adipose-derived stem cells in a mouse
model87. While fast gelation kinetics allowed for good cell distribution during gelation, the
shear-thinning and self-healing properties of the MITCH materials make them ideal for cell
injection applications. In a more recent study, the MITCH design was used as an injectable
peptide drug delivery system for sustained delivery of a VEGF-mimetic peptide (QK) to
elicit an angiogenic response in HUVECs, whereby release kinetics were tuned by
changing the affinity tag binding strength through a series of mutagenesis and library
screens to identify a higher affinity mutant14.
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Figure 3.5. Hydrogels formed from interactions of biorecognition motifs. (A) Schematic of the
mixing-induced, two-component hydrogel (MITCH), where association occurs between WW
domains (CC43 and a Nedd4.3 variant) and proline peptide (PPxY) (left). These domains are
engineered into polypeptides with various hydrophilic spacers, either with (Spacer 1, WW domain)
or without (Spacer 2, PPxY domain) the cell-adhesion peptide RGDS, that form hydrogels when
mixed under physiological conditions (right). Adapted with permission86. Copyright, 2009. National
Academy of Sciences. B) Dock-and-Lock self-assembly mechanism for hydrogel formation, where
docking domains dimerize and lock with the anchoring domain (left). Engineered anchoring
domains and docking domains self- assemble to form dynamic, shear-thinning, self-healing
hydrogels when mixed (right). Adapted with permission96. Copyright, 2012. Elsevier.

PDZ Domain-containing TIP1 Protein and Peptide Ligand. The PDZ domain is
a small protein-protein recognition module that binds to defined carboxyl-terminal residues
and is important in organizing diverse signaling assemblies88. PDZ domains are ~90
residues in size and adopt a common fold consisting of b-barrel capped by a-helices89.
Human tax-interacting protein (TIP-1) consists of a single PDZ domain, encompassing
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residues 13-112 of the 124-amino acid protein90. TIP-1 and its ligand have been used to
construct a two component self-assembling hydrogel, where the interaction can be
reinforced via disulfide linkages91. This hydrogel exhibited high stability at neutral and acid
pHs across a wide range of temperatures (4-50°C), paving the way for diverse applications
in tissue engineering and drug delivery. In another recent study, TIP-1 was fused with a
ubiquitin-like domain (ULD). Upon mixing with TIP-1 ligand, a dense fiber network was
formed, whereby the ULD-TIP-1 protein served as a crosslinker to enhance the inter-fiber
interactions between self-assembled nanofibers, leading to formation of biohybrid
hydrogels92,93. Similarly, TIP-1 protein was fused to each C-terminus of CutA, a stable
triangular-shaped trimer, followed by introduction of an RGD motif, while the PDZ ligand
was conjugated to a four-armed PEG. The mixing of these two molecules resulted in
spontaneous self-assembly between the multi-functional PDZ peptide-PEG and trifunctional CutA-TIP1. Chondrocytes were successfully encapsulated and cultured in the
hydrogel with high cell viability up to 8 days94.
Docking and Dimerization Domain Polypeptide and Anchoring Domain
Peptide. The naturally occurring Dock-and-Lock (DnL) structural binding motifs between
A-kinase associated proteins and protein kinase A family proteins, based on their specific,
rapidly-associating, and strong molecular interactions have been used to induce molecular
recognition into polymers. A polypeptide based on recombinant docking and dimerization
domains (rDDD) linked together by random-coil spacers containing RGD sequences was
shown to form a stable type-X four-helix bundle95. The two component system designed
through the interactions of the RIIa subunit of cAMP-dependent kinase A and the
anchoring domain (AD) of A-kinase protein (AKA) (Figure 3.5B) was shown to
homogenously encapsulate human mesenchymal stromal cells (hMSCs) and support
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viability after injection96. In a follow-up study, HA was used as a substrate for modification
with the AD-peptide, which rapidly formed hydrogels (<10s) under physiological conditions
upon mixing with rDDD. Towards further stabilization, free-radical polymerizable
methacrylate groups were introduced to the HA backbone, which exhibited an increase in
modulus and decrease in erosion rates97, making Dock-and Lock gels suitable for a range
of applications.
Other Types of Biorecognition Motifs. As another example, tetratricopeptide
repeats (TPRs) are 34-residue helix-turn-helix motifs, which only become stably folded
when stacked together to form elongated domains98. An ionic-responsive hydrogel based
on TPR and the pepta-peptide Asp-Glu-Ser-Val-Asp (DESVD) was formed by grafting the
penta peptide onto four-armed PEG molecules to serve as crosslinkers. Hydrogelation
kinetics were affected by ionic strength of the surrounding buffer, where the TPR-DESVD
interaction was disrupted by a solution of high ionic strength, thereby exhibiting stimuliresponsive assembly and disassembly99. Topp et al. also designed a triple block tandem
protein using calmodulin (CaM) and tetrameric leucine zipper domains as the termini, a
hydrophilic peptide sequence as the spacer, and another triple block polyprotein
containing two CaM binding domains that were linked through a hydrophilic spacer100.
Gelation occurred upon mixing the two synthetic block proteins. The architecture, sensing
behavior, and rheological properties were easily tuned by choosing the appropriate
modules101.
3.2.4 Hydrophobic Interactions
Hydrophobic interactions are critical in the assembly of hydrogels through physical
associations. These have already been mentioned in sections above, including with guest65

host complexes and biorecognition motifs where hydrophobicity may play a role; however,
hydrophobicity can be used in less specific interactions to form hydrogels. In these
approaches, hydrophobic domains are often introduced onto polymers for assembly into
networks. While self-assembly of peptide amphiphiles depend largely on hydrophobic
interactions, these have been well reviewed elsewhere and we direct the reader to other
reviews of interest on this topic 102–104.
Coiled-coil Domains. One of the most suitable modular building elements to
facilitate the rational design of new protein folds is the coiled-coil, which is a type of
structural motif widely found in fibrous proteins and as oligomerization domains in a variety
of proteins105. Coiled-coils are composed of two or more helices that are wound around
each other in either parallel or antiparallel orientation. They are characterized by a periodic
heptad repeated with residue positions labeled as abcdefg, where each heptad spans two
helical turns measuring approximately 1 nm in length105. Association of coiled-coil chains
is governed by hydrophobic interactions between amino acids in positions a and d,
resulting in a hydrophobic core and electrostatic interactions among oppositely charged
residues at positions e and g or e and e’, depending on the orientation. A system of
telechelic proteins with associated coiled-coil end blocks was used to formulate shearthinning and self-healing hydrogels24. This material system demonstrated up to 3 orders
of magnitude drop in their elastic modulus with increasing shear due to a sharp transition
from a linearly elastic solid to yielding flow24. Flow visualization and rheology
demonstrated that the yielding behavior was consistent with shear banding behavior 24,106.
The stability and unfolding of coiled-coil motifs are dependent on temperature, pH, and
ionic strength, which is often used in the design of stimuli-responsive controlled release
delivery systems107. The unique association-dissociation of coiled-coils make them an
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ideal candidate for physical crosslinkers to form protein-based supramolecular fibrils108.
The incorporation of leucine-zipper (LZ) domains to the protein backbone created a
functional chimeric protein with self-assembling properties, allowing this self-assembly
strategy to be used in a variety of biomedical applications. LZ hydrogels have been shown
to support MSC adhesion, proliferation, and migration, suggesting their potential use as
scaffolds for various tissue engineering applications109.
Self-assembly of triblock peptide-PEG-peptide copolymers with amino acid
substitutes to form coiled-coil structures resulted in well-folded viscoelastic hydrogels110.
However, the triblock peptide-PEG-peptide was shown to elicit a moderate antibody
response, suggesting that the extensive oligomerization led to the observed increase in
its immunogenicity110. Another study reported hydrogels prepared by Michael-type
addition between 4-arm PEG-vinyl sulfone and multi-arm thiol carrying macromers selfassembled through a coiled-coil domain, which permitted 3D epithelial morphogenesis by
Madin-Darby Canine Kidney (MDCK) cells111.
Amphiphilic Block Copolymers. Amphiphilic block copolymers present a costeffective and scalable system compared to peptide amphiphiles. The self-assembly of
oligopeptide amphiphiles into interconnected networks is stabilized via hydrogen bonding,
electrostatic interactions, p-p stacking, and hydrophobic interactions112.
The most widely studied amphiphilic block copolymers for hydrogel systems
consist of a middle biodegradable polyester block such as poly(L-lactic acid) (PLA) and
poly(glycolic acid) (PGA) or their co-polymers, being flanked by two poly(ethylene oxide)
blocks. The micelle formation of the block copolymers is driven by hydrophobic
interactions. At high concentrations, the aqueous polymer solutions form a hydrogel due
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to the association of micelles113. PEG-b-PLA co-polymers can form spherical micelles with
a PLA-core and PEG-corona structure114. The hydrophobic drug can easily be loaded into
the hydrophobic core whereas the hydrophilic corona helps to prolong the circulation. In
order to prevent the burst release of payloads, guest-host interactions have also been
employed by incorporating a-CD to interact with PEG chains in PEG-b-PLA micelles115.
This supramolecular dual-crosslinked hydrogel system allowed controllable and sustained
release of chemotherapeutics to tumor cells in vitro. Similarly, PEG-poly[(R)-3hydroxybutyrate]-PEG triblock copolymers have been complexed with a-CD and shown
to be promising as a sustained drug delivery system116.
More recently, a star copolypeptide-based hydrogel bioink was formed from
poly(benzyl-L-glutamate)-b-oligo(L-valine)

amphiphilic

block

co-polymer

due

to

hydrophobic interactions stemming from the self-assembly of the valine domains for 3D
bioprinting applications117. The constructs were further stabilized via UV-treatment for
secondary crosslinking and were found to exhibit favorable release of encapsulated cargo
and were not found to be cytotoxic to balb/3T3 cells.
Towards improving the toughness of hydrogels, double-network hybrid proteinpolymer block copolymer hydrogels were prepared by conjugating PNIPAm to the N- and
C- termini of the artificially engineered protein with coiled coil association domains118. The
thermoresponsive secondary network formation upon injection resulted in a transition from
a shear-thinning gel to a reinforced gel with unique mechanical properties. Shear-thinning
hydrogels that exhibit tough properties have important applications as high-performance
load-bearing soft materials. In an effort to incorporate poorly water-soluble drugs into
hydrogels, star-shaped amphiphilic block copolymers comprising PEG and poly(propylene
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sulfate) were also created. The self-assembled hydrogel effectively dissolved hydrophobic
molecules and supported wound closure in a murine splinted wound model119.
3.2.5 Electrostatic Interactions
Electrostatic interactions allow for the assembly of polymers and biomolecules into
hydrogels with weak bonds that support shear-thinning behavior and are self-healing if
additional ions are available to form new crosslinks. Alginate, a naturally occurring,
anionic, and hydrophilic polymer crosslinks in the presence of cations, most typically Ca2+,
and is a very attractive ionically crosslinked polymer for tissue engineering and drug
delivery applications120–123. Alginate is biocompatible, and a lot of recent work has focused
on optimizing gelation kinetics, homogeneity, and mechanical properties for cell and
therapeutic delivery 6,25,124,125. Recently, alginate was grafted to hyaluronic acid backbones
to create hydrogels that physically crosslink in the presence of calcium ions for cartilage
regeneration126.
Polyelectrolyte complexes (PEC), mixtures of two polyelectrolytes with opposite
charges, have also received considerable attention in the past decade. As a strongly
positively charged natural polysaccharide, chitosan is able to form PECs with various
natural and synthetic anionic polyelectrolytes through strong electrostatic interactions127.
The complex formation and the physical properties depend on factors such as the
ionization degree of the cationic and anionic counter parts, pH, temperature, ionic
strength, time of interaction, and concentration of polymeric solutions128,129. Genipin
crosslinked chitosan/HA PECs has been shown to achieve high loading efficiency and
prolonged and sustained BMP-2 release130, whereas chitosan/gelatin PECs have been
used in 3D bioprinting of skin constructs131,132. It was found that chitosan/gelatin PECs
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exhibited shear-thinning properties as the shear rate increased, after overcoming their
yield stress. The presence of higher gelatin concentrations resulted in more interactions
between the positively charged chitosan and negatively-charged carboxylate groups from
gelatin, forming hydrogels with higher viscosity for higher printing fidelity.132 Leveraging
similar electrostatic interactions, PNIPAm has been grafted onto carboxymethyl chitosan
to create pH/temperature responsive hydrogels for minimally-invasive 5-fluorouracil
delivery10.
The challenge in developing PEC hydrogels is the fast complexation reaction in
which mixing of the polyanion and the polycation leads to inhomogeneous precipitation,
where strong complexes are formed at the interface of the two solutions133. In order to
circumvent low solubility and charge density problems of chitosan, quaternized chitosan
has been prepared and was shown to form tough hydrogels with polyacrylic acid (PAA)134.
It has been shown that in PECs, strong ion complexes serve as permanent crosslinks,
while weak complexes act as sacrificial bonds, thereby imparting double-network-like
toughness into hydrogels135,136.
3.2.6 Metal-Ligand Coordination
Metal-ligand coordination is important in many biological material phenomena
including adhesion, self-assembly, and toughness137. Compared to other reversible
crosslinked networks based on electrostatic, hydrogen bonding, or hydrophobic
interactions, metal-ligand complexes such as metal-catecholates offer near-covalent
stabilities with pH-tunable kinetics137. These dynamic and reversible interactions permit
formed networks to be shear-thinning and to self-heal when new complexes are
introduced.
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Inspired by the extensibility and the self-healing capacity of the mussel byssal
threads, Holten-Andersen et al. recently developed a method to control cathecol-Fe3+
interpolymer crosslinking via pH and showed that tris-catechol-Fe3+ crosslinked gels reestablished their stiffness and cohesiveness within minutes after failure137. In a follow-up
study, iron oxide nanoparticles were incorporated into a cathecol-modified 4-armed PEG
network, which resulted in slower stress-relaxation compared to hydrogels coordinated by
Fe3+ ions138. Similarly, Fullenkamp et al. demonstrated that four-arm PEG modified with
histidine, an amino acid that is often involved in metal ion coordination in proteins, formed
a chelate-type interaction with divalent metals, resulting in viscoelastic properties139. The
authors postulated that coordinate bonds, which are capable of reforming after rupture,
functioned as sacrificial bonds, enhancing material toughness without compromising
material stiffness.
Tang et. al utilized the coordination between Ni2+ and four-arm PEG to endow the
hydrogel with multi-stimuli (pH, EDTA) triggered sol-gel transition (Figure 3.6)140.
Because of the exchangeable property of the coordination, Ni-coordinated hydrogels
demonstrated shear-thinning and self-healing properties, characterized by a decrease in
viscosity upon increase in shear and near-complete recovery between dynamic strain
steps during rheological studies. Casuso et al. showed that HAuCl4 and 4-arm thiolterminated PEG [(PEGSH)4] resulted in a network containing a mixture of Au(I)-thiolate
(Au−S) and disulfide bonds (SS), whereby the materials exhibited frequency-dependent
stiffness, paving the way for applications such as viscosupplements and tissue
engineering scaffolds for cartilage applications141. More recently, Yavvari et al. showed
that a chitosan-catechol based shear-thinning and self-healing hydrogel assembled
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through catechol-Fe(III) coordination with encapsulated chemotherapeutics, allowed
sustained delivery over 40 days in murine lung and breast cancer models.11
With a more theoretical approach, Grindy et al. demonstrated that a model system
of four-arm PEG crosslinked with multiple, kinetically distinct dynamic metal-ligand
complexes allowed control over the mechanical properties under load by tuning the
relative concentrations of two types of crosslinkers142. In a new theoretical framework,
modeling hydrogels with kinetically distinct crosslinks was shown to enable the separation
of temporal hierarchy from spatial hierarchy.142

Figure 3.6. Hydrogels formed from metal coordination. (A) Illustration of the general strategy
for the preparation and properties of the PHis-based Ni-coordinated hydrogels. B) Photos for pH
(left) and EDTA (right) triggered gel-sol transition for 4PEG-PHis6 gel. Adapted with permission140.
Copyright, 2018. Wiley.

72

3.3 PHYSICAL ASSOCIATIONS TO ASSEMBLE PARTICLE-BASED HYDROGELS
Beyond hydrogel systems where interactions occur only on the molecular scale,
particle-based hydrogels are emerging where the interactions between particles (with or
without polymers included) drive overall material properties.

These interactions are

typically non-covalent, particularly when properties of shear-thinning and self-healing are
desired. The types of interactions introduced into these systems represent those already
covered in the previous section, such as guest-host interactions or electrostatics. Here,
we introduce both nanocomposite and granular hydrogels (Figure 3.2) that have recently
emerged as interesting classes of materials for biomedical applications, with several even
being investigated towards clinical applications in vivo (Table 3.1).
3.3.1 Nanocomposite Systems
Nanocomposite hydrogels can be defined as hydrated polymeric networks,
typically physically crosslinked to assemble with nanoparticles or nanostructures143. A
wide range of nanoparticles such as carbon-based nanomaterials (carbon nanotubes,
graphene, nanodiamonds), polymeric nanoparticles, inorganic/ceramic nanoparticles
(hydroxyapatite, silica, silicates, calcium phosphate), and metal/metal oxide (gold, silver,
iron-oxide) nanoparticles can be combined with polymers to obtain nanocomposite
hydrogels143. While nanoparticle incorporation into hydrogels has gained interest in order
to tailor mechanical properties, enable targeted delivery and controlled release, impart
stimuli-responsiveness, and introduce electrical conductivity, only a few of these systems
have been found to exhibit shear-thinning and self-healing properties.
Recently, Appel et al. reported injectable hydrogels formed by non-covalent
interactions between hydroxypropylmethylcellulose derivatives (HPMC-x) and carboxy73

functionalized polystyrene as well as core-shell PEG-b-PLA NPs, which exhibited shearthinning and self-healing behavior and tunable in vivo and in vitro drug release profiles
(Figure 3.7A)144. Electrostatic interactions between negatively charged hyaluronic acid
and carboxymethyl cellulose to biodegradable PEG-b-PLA were further enhanced with a
positively charged cetyltrimethylammonium bromide (CTAB)145. Liu et al., on the other
hand, combined a dopamine-modified four-armed PEG with a synthetic nanosilicate
(Laponite) to form an injectable nanocomposite tissue-adhesive hydrogel146. Hydrogels
based on polymer-Laponite interactions have been well-studied and shown to be
cytocompatible with Laponite degrading into nontoxic components (Na+, Mg2+, Si(OH)4,
Li+) under physiological conditions 147, 148.

Figure 3.7. Hydrogels formed through the physical assembly of particles. (A) Schematic
(left) of shear-thinning and self-healing polymer-nanoparticle composite hydrogels formed with
core-shell nanoparticles (NPs) and hydrophobically modified hydroxypropylmethyl cellulose
(HPMC) and cryogenic scanning electron microscopy images (right). Adapted with
permission144. Copyright, 2015. Springer Nature. (B) Schematic showing the preparation of
nanocomposite hydrogels from the interaction of nanoplatelets with gelatin, including a
transmission electron microscopy image of the silicate nanoparticle assembly (scale bar 50 nm)
and images of the shear-thinning of the nanocomposites when injected through a surgical
needle (22 gauge) and recovery to form freestanding structures. Adapted with permission149.
Copyright, 2014. American Chemical Society.
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In another recent study, Gaharwar et al. showed that synthetic silicate
nanoplatelets and gelatin can form shear-thinning hydrogels through non-covalent
interactions, as the positive and negative charges of gelatin interacting with the oppositely
charged synthetic silicate nanoplatelets. This nanocomposite material has been shown to
decrease in vitro blood clotting times by 77% and promote hemostasis in a liver laceration
model (Figure 3.7B)149. In order to enhance mechanical and bioactive properties of this
system, a sulfated polysaccharide, kappa carrageenan (kCA) was used to form ionotropic
and thermotropic gels that released therapeutics over a period of 21 days150.
Future studies of nanocomposite hydrogels are required to understand the
interactions between the polymer chains and nanoparticles in order to tailor
physicochemical, electrical, and biological properties for various biomedical and
pharmaceutical applications.
3.3.2 Granular Hydrogels
Granular hydrogels comprise an agglomeration of hydrogel microparticles in a
packed state, where the packing can either be loose to retain porosity between particles
or in a highly jammed state to restrict particle movement151. The physical interactions
between particles in granular systems lead to shear-thinning behavior that permits
injectability without introduction of chemical modification or secondary inter-particle
crosslinking to alter granular hydrogel properties. Furthermore, they can maintain
viscoelastic rheological properties after injection.
The injectable characteristics of granular hydrogels have been exploited in various
biomedical applications including 3D scaffolds152–155, tissue repair156–159, and local
drug160,161 and growth factor162,163 delivery. Self-healing granular hydrogels comprised of
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hyaluronic acid-based hydrogel microparticles have been generated based on guest-host
interlinking chemistry160. Two particle types were combined with different degradation
characteristics, demonstrating the heterogeneous material-tissue responsivity of the
granular hydrogels in an in vivo myocardial infarction model.
The injectable characteristics of granular hydrogels have also been exploited in 3D
printing techniques, where bioinks can be comprised of heterogeneous populations of
particles164,165. With no further modifications of materials, jammed microgel systems offer
a new approach to biofabrication and expand on the availability of inks for printing. There
will likely be significant advances in this area as new microparticle platforms are
engineered across a wide range of chemistries.
3.4 DYNAMIC COVALENT CHEMISTRY TO FORM HYDROGELS
Dynamic covalent chemistry includes covalent bonds that are able to be formed,
broken, and re-formed, either autonomously or under stimuli28. Compared to physical
associations, dynamic covalent reactions generally have slower kinetics of bond cleavage
and formation, which gives rise to more stable materials166. When dynamic covalent
chemistry is incorporated into crosslinks in the formation of hydrogels, bond cleavage can
occur under mechanical shear and then bonds re-form through various mechanisms to
exhibit self-healing. This chemistry has been incorporated into a wide range of materials
and exists across various types of reactions and modes of bond reformation (i.e.,
healing)166 and here we focus on examples (e.g., Schiff base, oxime chemistry, disulfide
bonds, reversible Diels Alder) (Figure 3.2) that have been specifically used in biomedical
applications as crosslinkers in hydrogels and even for in vivo applications (Table 3.1).
3.4.1 Schiff Base
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Imine Derivatives. Schiff base reactions between amine and aldehyde groups to
form imine derivatives have been used extensively for cell encapsulation167, tissue
repair168, drug delivery169,170, and wound dressing171,172 applications. The dynamic Schiff
base reactions are commonly formed between the amine groups on chitosan backbones
and benzaldehyde groups at telechelic difunctional poly(ethylene glycol) (DF-PEG) chain
ends173–175; however, HA176, dextran177, chondroitin sulfate178, poly(vinyl alcohol)179, other
chitosan derivatives180, and recently vanillin (4-hydroxy-3-methoxybenzaldehyde)181, have
all been used for the preparation of hydrogels via Schiff base reaction. Towards 3D cell
encapsulation, HeLA cells167, bovine articular chondrocytes182, murine neural stem
cells183, as well as zebrafish embryos183 have been encapsulated in Schiff base hydrogels
and reported to maintain their normal morphology. Furthermore, Schiff base hydrogels
have been shown to protect cells during extrusion through a needle, paving the way for
3D printing applications175.
Because of the intrinsic dynamic equilibrium between the aldehyde and the amine
reactants, the interactions can be considered pseudocovalent. While Schiff base formation
can be followed by reductive amination to afford stable N—C single bonds, the
requirements of reducing agents (NaCNBH3) and long reaction time present translational
hurdles184. Therefore, aromatic Schiff bases via benzaldehyde groups are preferred
compared to unstable aliphatic Schiff bases185,174. The dynamic hydrogels have been
found to be sensitive to many chemical and biological stimuli such as pH, vitamin B6,
amino acids, and enzymes, which, despite making them unstable186, allows the hydrogels
to be used easily in controlled delivery systems169,174,187. As an example, Zhao et al.
developed a series of injectable conductive self-healed hydrogels based on quaternized
chitosan-g-polyaniline (QCSP) and benzaldehyde group functionalized poly(ethylene
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glycol)-co-poly(glycerol sebacate) (PEGS-FA), which demonstrated excellent adhesive,
antibacterial, and electroactive properties (Figure 3.8A)171.

Figure 3.8. Hydrogels formed through dynamic covalent crosslinks. (A) Schematic
representation of QCSP/PEGS-FA hydrogel formation where the mixing of functional polymers
leads to dynamically crosslinked networks and image of formed hydrogel (scale bar: 5 mm).
Adapted with permission171. Copyright, 2017. Elsevier. (B) Reaction of modified dextran and
PEG through reversible Diels-Alder reactions (left) and example of self-healing of hydrogels
after cutting (right). Adapted with permission199. Copyright, 2013. Wiley.

Hydrazone Bonds. Hydrazone bonds between aldehyde and hydrazide functional
groups have been widely used due to their rapid reaction and high efficiency under
physiological conditions188. McKinnon et al. showed that PEG hydrogels containing
reversible hydrazone bonds mimicked the viscoelastic properties of native tissues with
dynamic stress-relaxing crosslinks189. Linkages were stable enough to maintain the
integrity of a crosslinked PEG network for several weeks of cell culture but labile enough
to relax in response to cell-applied stress and allow for cell spreading. In another report,
McKinnon et al. showed that the temperature and pH of the reaction medium influenced
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the reaction rate constant of acyl hydrazone formation, and the reverse reaction rate
affected the stress relaxation characteristics of the acyl-hydrazone containing hydrogel189.
The pH-responsive nature of the reaction has enabled promising results in localized
controlled delivery of chemotherapeutic agents in solid tumors190. Towards tuning stability,
gelation kinetics, and mechanical properties of hydrazone-based systems, recent studies
have been reported on incorporation of neighboring heteroatom (N3) for delocalization of
the developing N2 positive charge191, combination of ketone (slow reacting) and aldehyde
(fast reacting) groups192, and reinforcement through cellulose nanocrystals193.
Hydrazone crosslinked hydrogels have an excellent record of biological
performance in tissue engineering scaffolds194–196, 3D bioprinting197, as well as drug190,15
and growth factor198 delivery. Towards leveraging this chemistry for clinical translation,
Purcell et al. developed bioresponsive HA hydrogels based on hydrazone linkages and
encapsulated heparin binding recombinant TIMP-3 to prevent the progression to heart
failure in a porcine model of myocardial infarction15. These hydrogels included proteasesensitive crosslinks to permit degradation and drug release in response to local enzymatic
activity.
3.4.2 Oxime Chemistry
The oxime bond, formed through the condensation of hydroxylamine with a ketone
or aldehyde, exhibits improved hydrolytic stability over hydrazones and imines199,200. The
bio-orthogonal oxime reaction is commonly used to prepare protein-polymer
conjugates201, modify cell surfaces202, and label tissues in vivo203. The biocompatibility of
this reaction has been demonstrated for stem cell encapsulation in vitro204. This approach
also allows for covalent incorporation of signaling molecules during hydrogel formation, as
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proteins and peptides can be easily modified with ketones, oxoamine, or aminooxy
groups205. While Grover et al. demonstrated that a PEG-oxime system could be injected
through long catheters, large-animal studies still need to be conducted in order to
investigate the clinical potential of oxime-based hydrogels for minimally-invasive
delivery206.
3.4.3 Disulfide Bonds
Disulfides, formed by the reaction of two thiol groups, play a ubiquitous role in
protein folding and assembly207. Disulfide crosslinked hydrogels require the presence of
an oxidation agent to form; however, oxygen itself is sufficient to drive crosslinking208. This
way, disulfide bonds can be broken down or reform via physiologically-relevant
reduction/oxidation and/or thiol-disulfide exchange reactions.
The fast, reversible, and tunable disulfide exchange equilibria of disulfides can be
used to form hydrogels either via naturally existing thiol groups in peptide sequences or
via incorporation of cyclic disulfides into water-soluble polymers209. Utilizing the 35 thiol
groups naturally existing in albumin, disulfide-crosslinked albumin hydrogels were formed
without the need to introduce new chemical moieties. The albumin hydrogel was highly
swollen and mechanically weak in deionize water; however, it collapsed in neutral buffer
with two orders of magnitude increase in storage modulus208. A drug-loaded BSA hydrogel
was shown to be injectable through a 26 Gauge needle. The model drug doxorubicin was
released from albumin hydrogels over 29 days with incomplete release likely due to the
presence of strong doxorubicin-albumin interactions. Baldwin et al. demonstrated that
maleimide functionalized low molecular weight heparin (LMWH) formed hydrogels with
various thiol-functionalized multi-arm PEG polymers, which can be used for injectable
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anticoagulant therapies210,211. On the other hand, Barcan et al. reported hydrogels
generated from triblock copolymers containing pendant 1,2-dithiolanes crosslinked with
dithiols that exhibit shear-thinning and self-healing behavior with rapid recovery between
1% and 800% strain cycles212.
In another study, Choh et al. showed that HA can be modified with pyridyl dithiol,
which reacts with a dithiol crosslinker to form hydrogels via thiol-disulfide exchange
reaction213. The biocompatibility of this chemistry was demonstrated by encapsulating
different types of cells including fibroblasts (NHDF), endothelial cells (HUVECs), and adult
stem cells (pMSCs), which remained viable up to 7 days in cell culture213. Furthermore,
the injectable HA gels were used to encapsulate a cysteine-containing chemokine, stromal
cell-derived factor 1a. The dual-degradability of this system by enzymatic cleavage via
hyaluronidase and chemical cleavage via biological reductants such as glutathione (GSH)
and cysteine allows easy tunability for applications that includes changes in local redox
environment for drug release213 and tissue regeneration214–216.
Overall, disulfide crosslinking provides a promising route to shear-thinning, selfhealing hydrogel formation, given that gelation can occur under mild oxidative conditions
and in the absence of catalysts or small molecules. Disulfide chemistry is slow at
physiological pH; however, it has been shown that reducing the thiol pKa can promote
thiolate anion formation at physiological pH, therefore favoring disulfide formation217. It is
important to note that the delivery of proteins from hydrogels may be limited due to
covalent modification of the loaded protein’s cysteine residues with thiol groups located
on the precursor polymer chains. While this might lead to encapsulation of the payload
efficiency, it can induce potential protein denaturation.
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3.4.4 Reversible Diels Alder
Compared to the copper-catalyzed click chemistry, the aqueous Diels-Alder
chemistry occurs readily without the involvement of metal catalysts and coupling reagents,
making reversible Diels-Alder reactions a promising route for shear-thinning and selfhealing hydrogel formation for biomedical applications218–221. Furthermore, the Diels-Alder
reaction is a “click” type reaction between orthogonal molecules that is free from side
reactions and byproducts.
Furan-modified dexamethasone was synthesized and incorporated into maleimide
containing PEG hydrogels and was shown to induce osteogenic differentiation of human
MSCs with sustained release of dexamethasone12. These hydrogels were also used for
adipose tissue engineering and shown to be noncytotoxic and preserve proliferation of
entrapped human adipose-derived stem cells222. A major drawback, however, is the
requirement of high temperatures and long duration to cleave and reform for self-healing
properties, as well as poor solubility of functional groups such as fulvenes in aqueous
solution28. To overcome this, Wei et al. developed fulvene-modified hydrophilic dextran as
dienes and dichloromaleic acid-modified PEG as dienophiles to prepare self-healing
hydrogels under physiological conditions (Figure 3.8B)218. Other reversible interactions
such as electrostatic interactions223,

coordination bonds

224

, imine bonds225 and

acylhydrazone bonds226 have been combined with Diels-Alder chemistry to form selfhealing hydrogels.
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3.5 CONCLUSIONS
A wide range of chemistries have been utilized to create shear-thinning and selfhealing hydrogels. Due to the nature of the chemistry incorporated to crosslink polymers
and polypeptides they can be prepared as stable formulations in advance, shear thin upon
injection, and subsequently recover due to self-healing properties. This review
summarizes the potential uses of such shear-thinning and self-healing systems in drug
delivery, cellular encapsulation and delivery, and 3D bioprinting. While significant progress
has been made in improving the properties of hydrogels for these applications, only a few
of these systems have been used in in vivo models. To broaden the applicability of these
systems, it is necessary to develop hydrogel systems that have high fracture toughness
while

maintaining

their

shear-thinning,

self-healing

properties

in

addition

to

biocompatibility, tunable release, and cyto-protective behavior. Double networks, and
mechanical reinforcement through composite materials have been shown to improve
mechanical performance and will likely represent approaches to further improve properties
in the future. Overall, these materials exhibit interesting properties that will expand in
future years, possibly towards new applications and toward ultimately clinical
implementation into therapies and advanced approaches to scaffold fabrication. In this
thesis, several shear-thinning and self-healing hydrogels will be utilized, including those
with guest-host bonds (Aims 2, 3, 4), inter-penetrating networks (Aim 3), and dynamic
covalent bonds (Aim 4).
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CHAPTER 4
SCALE-UP AND CHARACTERIZATION OF EV PRODUCTION FOR THERAPEUTIC
APPLICATIONS

4.1 INTRODUCTION
Extracellular vesicles (EVs) are a heterogeneous population of vesicles secreted
by cells that range in size from 30 to 2000 nm.1 Small EVs (30-150 nm), or exosomes, are
formed by the inward budding of the endosomal membrane, which forms multivesicular
bodies that fuse with the plasma membrane and are released into the extracellular space.2
Cells secrete EVs to function in paracrine and autocrine signaling and they can be found
in all bodily fluids and cell culture supernatants. EVs contain vast amounts of cargo
material, ranging from functional RNA, DNA, and proteins.2 According to the Minimal
Information for Studies of Extracellular Vesicles (MISEV) 2018 guidelines, it is advisable
to use operational terms to describe EVs, including physical characteristics, such as size,
biochemical composition, and cell of origin.3
Recently, significant attention has been directed into the use of EVs as
therapeutics. EVs, particularly those derived from mesenchymal stromal cells (MSCs),
recapitulate many of the therapeutic effects of MSCs themselves and have intrinsic
therapeutic properties for wound healing, inflammation, cancer, brain injury and cardiac
repair.4 The underlying mechanisms by which EVs exert their therapeutic effects have
been attributed to the transfer of EV cargo to cells and the triggering of signaling pathways
via cell surface interactions.5 The suggested mechanisms include reducing inflammation,
inhibiting apoptosis, minimizing oxidative stress, and promoting cell migration and
proliferation, as well as stimulating angiogenesis.4 Furthermore, MSC-EVs are thought to
circumvent many of the drawbacks of cell-based therapies as they display low
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immunogenicity6 and low tumorigenicity,7 minimize the risk of occlusion,8 and avoid
potentially harmful long-term side effects since they degrade over time in vivo.9 They are
also stable at -80°C for extended periods and can therefore be used as a potential “offthe-shelf” therapy.10 With this growing interest in the use of MSC-EVs as both drug delivery
vehicles and as a cell-free therapy, there is now an emphasis on clinically-scalable
production of purified EVs with minimal batch-to-batch variability for clinical use.
Cell source and culture method, as well as EV isolation and quantification methods
all contribute to variability in EV yield and content - there has also been a big gap in the
literature regarding consistency of reporting MSC source and EV isolation method, as well
as yield and purity, despite the recommendations by MISEV.4 For example, the current
gold standard for EV isolation is differential centrifugation, which involves a series of
centrifugation steps at increasing speeds to remove cellular debris, apoptotic bodies and
microvesicles, followed by ultracentrifugation to pellet EVs.4 While this technique is
laborious, time consuming, and carries the risk of contamination by soluble proteins in the
final product, it offers the advantage of scalability due to the large volumes that can be
accommodated in ultracentrifuges. Other common EV isolation protocols include size
exclusion chromatography (SEC), immuno-affinity capture, polymer precipitation, and
anion exchange chromatography.11 Newer methods such as SEC allow for more specific
subpopulations of EVs and therefore higher purity; however, this method can only be used
for low sample volumes.1 Polymer capture methods such as poly(ethylene glycol) (PEG)
precipitation allows for higher volume preparations, but this method is notorious for coprecipitation of protein complexes that contaminate EV isolates.1 Overall, it is well
established that different isolation protocols will yield different amounts of EVs and affect
their size distributions.12
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The scalability, inherent heterogeneity, and biological complexity of EVs present a
huge obstacle in the development of EV-based therapeutics. These challenges can be
categorized as quality control (i.e., identity, cell source, cell culture and expansion method,
isolation method, purity, potency, stability, batch to batch variability), pharmacodynamics
(i.e., mechanism of action, bioactive ingredients) and systematic evaluation of biological
activity with rigorous in vitro and in vivo potency assays (Table 4.1).13–15 Therefore, it is
critical to optimize EV studies for maximum yield, purity and reproducibility, and define the
manufacturing and characterization protocols for EV-based therapeutics for pre-clinical
testing and ultimately clinical translation.
Table 4.1: Challenges associated with clinical translation of MSC-EVs
Challenge
Scalability/Heterogeneity
of EVs

Sterility/Safety
Storage

Pharmacodynamics/
Potency

-

Source of EVs (donors, donor cells)
Cell culture conditions (culture method, cell culture media,
confluency, cell stimulation, culture length)
Isolation method
Batch to batch variability/scalability of technology
Characterization (size, shape, membrane, markers, content)
Microbial contamination
Serum-derived EV contamination
Donor selection
Storage temperature
Storage buffer
Change in pH
Storage time
Cell culture conditions
Isolation method
Source of EVs
Composition (markers, bioactive components)
Mechanism of action
Applicable in vitro assays

Robust manufacturing processes that would increase the consistency and
scalability of EV production are needed to translate the promising potential of MSC-EVs
to the clinic. Similar to cell-based therapeutics, a large number of EVs per dose are
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required for pre-clinical large animal studies and clinical translation. While there is no
consensus on effective therapeutic doses for EV delivery, cell-based trials generally
require very high cell numbers (~several million cells per kg of body weight).
Defining the appropriate cell culture platform is critical for the scalable
manufacturing of MSC-EVs. Most studies focus on the expansion of MSCs on static 2dimensional (2D) tissue culture flasks and test cell culture media formulations. However,
in order to achieve large product batches for clinical use, culture platforms require greater
scalability, as well as the ability to monitor and control culture parameters, which
cannot be accomplished in traditional static culture systems.16 These static culture
systems in standard tissue culture flasks are labor intensive and have a high risk of
contamination due to manual interventions.17 In an effort to improve scale up of cell
expansion methods, bioreactors and dynamic culture conditions have recently been
developed for this purpose.
As an example, the expansion of MSCs on microcarriers has been explored in
spinner flask bioreactors and has shown promise in reaching high yields of high quality
cells for therapeutics.

16,18–20

This method has been widely established for expanding

mammalian cells at industrial scales,21 such as for monoclonal antibody generation22 or
viral vectors23. In addition to creating dynamic culture conditions and enabling high surface
area to volume ratio for cell attachment, stirred culture systems, such as spinner flasks
and stirred bioreactors, allow uniform mixing of cell culture medium and avoid the
generation of concentration gradients that are typically seen with tissue culture flasks.24
Furthermore, many of these systems allow for easy operation (mechanical agitation via
stir plate, close-container system with maximum sterility, monitoring parameters such as
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pH) and rapid scalability since increases in the vessel size can rapidly increase the number
of cells being expanded.
In addition to microcarrier-based spinner flasks, other alternatives to 2D tissue
culture plates have emerged in the last few years. One of these methods is hollow fiber or
perfusion bioreactors, whereby cells are expanded on cylindrical scaffolds or hollow fibers
with high surface area and constantly supplied with nutrients via circulating culture
medium.25–28 These hollow fiber or tubular bioscaffold systems in perfusion pump set-ups
allow the cells to be perfused in a gentle, low-shear environment 29 and are amenable to
large-scale cell-based therapeutic production.30 Despite these advantages, perfusion
bioreactor systems suffer from their complexity and many parts, such as different sizes of
tubing fitted via connectors, which make them prone to leakage and therefore
contamination.31
In this work, we expanded bone-marrow derived MSCs from four different porcine
donors and assessed the EV manufacturing yield and content via three different cell
culture methods: standard tissue culture flasks, a perfusion bioreactor, and microcarriers
in spinner flasks (Figure 4.1). We explored EV characteristics and yield, RNA and protein
content as a function of biological donor for bone marrow-derived MSCs and cell culture
conditions. This thorough investigation of the effect of biological donor and cell culture
parameters emphasizes the importance of specifying cell source and culture conditions
for MSC-EV studies and offers microcarrier-based spinner flasks as a scalable method to
manufacture MSC-EVs, which can be applied as cell-free therapies in many pre-clinical
and clinical settings.
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Figure 4.1. Schematic of Culture Methods. The three different cell culture methods used to
culture MSCs and collect MSC-EVs, including 2D tissue culture plates, 3D printed bioreactors,
and microcarrier systems.

4.2 METHODS
4.2.1 MSC ISOLATION AND EXPANSION
Bone marrow was isolated from juvenile Yucatan minipigs (Sinclair BioResources,
average age: 6.8±0.4 months, average weight 27.0±4 kg, n=4) using a bone marrow
aspirate (BMA) kit for isolation from the acetabulum. The marrow was collected inside a
syringe

containing

10

ml

of

heparinized

media

containing

DMEM,

2%

penicillin/streptomycin, and 1% heparin. After centrifugation at 500 x g for 5 minutes, the
pellet was placed into 15 cm tissue culture flasks. The cells (P0) were left to attach and
expanded after colonies were confluent. MSCs were passaged using 0.05% Trypsin on
tissue culture plates until Passage 3, after which they were frozen in 90%FBS/10% DMSO
freezing media at a density of 1-2 million cells/mL until ready for use.
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4.2.2 SEEDING MSCS ON MICROCARRIERS IN SPINNER FLASKS
Gelatin-coated microcarriers (160-200 µm C-221-050 Pall SoloHill) were
purchased from Sartorius and disposable polystyrene, non-treated Spinner Flasks
(CLS3153) were purchased from Corning. Cell culture media was prepared using Alpha
Minimum Essential Medium (Millipore M4526), 1% penicillin/streptomycin, 1% GlutaMAX
supplement (Invitrogen 35050061), 10% FBS, and 1 ng/mL bFGF-2 (Millipore GF003).
Microcarrier stock was prepared by autoclaving microcarriers in distilled water at 121°C
for 30 minutes after which the distilled water was aspirated using a serological pipette and
media added to the microcarriers to allow them to acclimate for 30 minutes. After P4 MSCs
reached 80% confluence, cells were lifted using 0.05% Trypsin and counted. Microcarriers
were added to the spinner flask at a density of 27.8 mg/ml (15 cm2 surface area/mL) and
mixed with the cell slurry (0.2x106 cells/ml) using FBS-free cell culture media, resulting in
cell seeding density of 20,000 cells/cm2. The spinner flask was placed inside the cell
culture incubator on a stir plate with the impeller rotating at 50 rpm (Figure 4.2). After 2
hours, FBS was supplemented to the media.

Figure 4.2. Microcarrier Culture for EV Production. Microcarriers in a Spinner Flask on a
magnetic stir plate at 50 rpm placed inside the cell culture incubator. Confocal microscopy
imaging of Live (Green)/Dead (Red) staining on sample microcarriers taken from the culture on
Days 1, 2, 3, and 4.
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4.2.3 SEEDING MSCS ON BIOSCAFFOLDS IN A PERFUSION BIOREACTOR
3-D stereolithography printed bioscaffolds fabricated out of E-Shell 300, a clear,
biocompatible acrylate-based material (EnvisionTEC) were provided by Bhushan
Mahadhik from the NIH Center for Engineering Complex Tissues (CECT), Fischell
Department of Bioengineering at the University of Maryland and fabricated based on
previously described methods.30 The bioscaffolds containing cell growth surface area of
72 cm2 in a highly ordered pillar array were coated with 0.1% gelatin solution inside
Masterflex I/P® High-Performance Precision Pump Tubing which was closed off with
binder clips and incubated at 37°C for 30 minutes. After the coating solution was drained,
the open ends of the tubing were connected via ¼” tubing using ½” to ¼” connectors (ColeParmer, Vernon Hills, IL). MSCs were seeded on the bioscaffolds at a seeding density of
20,000 cells/cm2 inside the tubing overnight at 37°C. The next day, the tubing was
connected to a 2-hole rubber stopper affixed to a 125 mL Erlenmeyer flask containing 50
mL of cell culture media. The closed-loop tubing was then connected to a Dynamax
Peristaltic Pump RP-1 (Rainin, Oakland, CA) that circulated medium at 4 mL/min. The
assembly was then placed inside the cell culture incubator at 37°C with 5% CO2 (Figure
4.3).
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Figure 4.3. Perfusion Bioreactor Production of EVs. 3D Printed Bioscaffolds (A) are coated
with 0.1% Gelatin (B) and seeded with MSCs (C) overnight. The set-up is then connected to a
peristaltic pump (D) to circulate media at a rate of 4 mL/minute through a reservoir in a closed
loop system. The scaffolds can be viewed in Brightfield (E) and cells (green) can be visualized
spreading using an epi-fluorescent microscope.

4.2.4 TISSUE CULTURE FLASK SEEDING
In parallel to microcarriers in spinner flasks and bioscaffolds in perfusion bioreactor
methods, cells were seeded onto 15 cm treated Tissue Culture Plates (surface area 176
cm2) at a seeding density of 5000 cells/cm2. The comparison of cell culture parameters
across three methods are detailed here (Table 4.2).
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Table 4.2: Table comparing the cell culture conditions across methods
TCP

Perfusion
Bioreactor

Microcarriers

Surface Area (cm2)

176.7

216

5000

Cell seeding density (cells/cm2)

6000

20,000

20,000

Total #cells seeded

1e6

4.5e6

100e6

Volume of Media (mL)

15

100

500

4.2.5 CELL CONFLUENCE ASSESSMENT
For tissue culture plates, cell confluence was assessed using a Phase Contrast
Microscope. For microcarriers in spinner flasks, cell confluence was assessed by taking a
sample from the circulating medium and incubating the sample in green-fluorescent
calcein-AM to indicate intracellular esterase activity and red-fluorescent ethidium
homodimer-1 to indicate loss of plasma membrane integrity using LIVE/DEAD™
Viability/Cytotoxicity Kit (L3224 Invitrogen™, Waltham, MA) in PBS. Cells attached to
microcarriers were then imaged using a Leica SP5 Confocal Microscope. For bioscaffolds
in a perfusion bioreactor, the scaffolds were removed from the tubing, placed in a 50 mL
conical tube and incubated with CellTracker Green CMFDA Dye (C2925, Invitrogen™,
Waltham, MA) for 30 minutes. Scaffolds were then placed onto a 4-well tissue culture
plate and imaged using an Olympus BX51 Epi-fluorescent microscope.
4.2.6 EV COLLECTION
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The cell culture medium was switched to FBS-free medium when cells reached
80% confluence for all three cell culture methods. The conditioned medium containing
EVs was collected from the MSCs after 72 hours. EVs were isolated from conditioned
media by differential ultracentrifugation (Figure 4.4), whereby two 10-minute spins were
performed at 200 x g to remove cellular debris, two 10-minute spins were performed at
500 x g to remove apoptotic bodies, one 30-minute spin at 10,000 x g was performed to
remove microvesicles with the last centrifugation step of 100,000 x g for 65 minutes to
obtain the EV pellet, as previously described.32

Figure 4.4. MSC-EV Isolation Workflow Used in this Study.

4.2.7 EV SIZE, CONCENTRATION, AND PROTEIN CONTENT
EVs suspended in PBS were analyzed via nanoparticle tracking analysis (NTA) to
determine EV size, size distribution, concentration, and surface Zeta Potential using
ZetaView® QUATT– NTA Nanoparticle Tracking - Video Microscope PMX-420 (Particle
111

Metrix GmBH, Inning am Ammersee, Germany) at the Extracellular Vesicle Core at the
Penn Veterinary School. Protein was extracted from MSC-EVs using RIPA Buffer (R0278)
(Sigma Aldrich, St. Luis, MO) and EV protein content was quantified using a Micro BCA
Protein Assay Kit (ThermoFisher Scientific) per manufacturer instructions.
4.2.8 EV TRANSMISSION ELECTRON MICROSCOPY (TEM)
EV samples re-suspended in PBS were prepared and imaged by the Perelman
School of Medicine Electron Microscopy Core. Briefly, the EV samples were fixed 1:1 with
2% glutaraldehyde (v/v; Sigma Aldrich, Saint Louis, MO) for 30 min. A fixed sample of 6
µL was pipetted onto a 200-mesh copper grid with carbon-coated formvar film (Electron
Microscopy Sciences, Hatfield, PA), and incubated for 10 min. Excess liquid was removed
by blotting. The grid was washed twice with 100 µL MilliQ water, followed by blotting to
remove excess liquid. Samples were imaged using T12 TEM (FEI, OR).
4.2.9 EV PROTEOMICS SAMPLE PREPARATION AND ANALYSIS
MSC-EVs isolated from four different donors across three cell culture methods
(n=12) were evaluated for protein content using mass spectrometry. Biological replicates
were defined as separate EV isolations, and each sample consisted of 0.5e12 particles.
Further sample preparation, mass spectrometry analysis, and sequence database search
and statistical analysis were completed in collaboration with The Proteomics Core Facility
at The Children’s Hospital of Philadelphia.
Briefly, EV samples were run on a polyacrylamide gel for 0.8 cm and stained with
Coomassie blue. Each gel band was then excised and further cut into 1 mm cubes, which
were destained with 50% methanol/1.25% acetic acid, reduced with 5 mM dithiothreitol,
and alkylated with 20 mM iodoacetamide. Gel pieces were washed with 20 mM ammonium
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bicarbonate, dehydrated with acetonitrile, and digested with trypsin (Promega, 5 ng/mL in
20 mM ammonium bicarbonate) overnight at 37oC. Peptides were extracted with 0.3%
trifluoroacetic acid and 50% acetonitrile. Extracts were combined and the volume was
reduced by vacuum centrifugation.
For mass spectrometry analysis, peptides were analyzed on a Q Exactive HF mass
spectrometer (ThermoFisher Scientific) coupled with an UltiMate 3000 Nano UHPLC
system and EASY-Spray source. Whole proteome samples were collected using data
dependent acquisition (DDA) and data independent acquisition (DIA). Enriched acetylome
peptides were analyzed by DDA. Tryptic digests were spiked with iRT standards
(Biognosys) and separated by reverse phase (RP)-HPLC on a PepMap RSLC C18 nano
column (2 μm particle size, 75185 μm ID, 50 cm length) at 50°C. Mobile phase A consisted
of 0.1% formic acid and mobile phase B of 0.1% formic acid/acetonitrile. Peptides were
eluted into the mass spectrometer at 210 nL/min with each RP-LC run comprising a
gradient from 1 to 5% B in 15 min, then 5-45% B in 110 min for DDA and 140 min for DIA.
For DDA, the mass spectrometer was set to repetitively scan m/z from 300 to 1400
for one full MS scan followed by data-dependent MS/MS scans on the twenty most
abundant ions. For full MS scans, the resolution, AGC target, and maximum injection times
were set at 120,000, 3e6, and 32 ms, respectively. For MS/MS scans, the resolution, AGC
target, maximum injection time, and isolation window were set at 15000, 2e5, 32 ms, and
1.4 m/z, respectively. 1 microscan was used for each MS/MS scan with rejection of singly
charged ions and unassigned charge states and a normalized collision energy of 27.
For DIA, the mass spectrometer completed 1 full MS scan from 300 to 1650 m/z
with a resolution, AGC target, and maximum injection time of 120,000, 3e6, and 60 ms,
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respectively. This was followed by 22 (DIA) isolation windows with varying sizes at 30,000
resolution, an AGC target of 3e6, injection times set to auto, and loop count and MSX
count of 1. The default charge state was 4, the first mass was fixed at 200 m/z and the
normalized collision energy (NCE) for each window was stepped at 25.5, 27, and 30.
For sequence database search, the DDA raw files were searched against a pig
protein sequence database including canonical and manually reviewed isoform
sequences from the Uniprot Knowledgebase using MaxQuant version 1.6.1.0 with the
following set parameters: fixed modifications: carbamidomethyl (C); decoy mode: revert;
MS/MS tolerance: FTMS 20 ppm; false discovery rate for both peptides and proteins: 0.01;
minimum peptide length: 7; modifications included in protein quantification: acetyl (protein
N-term), oxidation (M);186 peptides used for protein quantification: razor and unique. The
search result from MaxQuant was used to generate a spectral library for DIA analysis. A
separate spectral library was generated for each DIA raw file using DirectDIA mode in
Spectronaut. Subsequently, the DIA raw files were searched against a merged library
using the default settings in Spectronaut. Protein intensity values measured at the MS2
level were then exported for downstream statistical analysis using Perseus 1.6.6.0 (Max
Planck Institute of Biochemistry).
For statistical analysis, protein intensity values were transformed and normalized
by subtracting the median for each sample. Exploratory analysis of protein contents was
completed to determine the number of proteins detected in each group and the variance
between groups was plotted using a principal component analysis plot. Differentially
expressed proteins were determined using a Student’s t-test and volcano plots were
generated to visualize affected proteins while comparing different groups of samples.
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4.2.10 EV RNA EXTRACTION, LIBRARY PREPARATION, AND SEQUENCING
EV pellets were re-suspended in Qiazole after ultracentrifugation and RNA was
extracted using miRNeasy Micro Kit (217084 Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. RNA concentration was quantified using Qubit™ RNA High
Sensitivity (HS) Assay Kit on a Qubit 2.0 fluorometer. The DNA library was prepared using
NEBNext® Multiplex Small RNA Library Prep Set for Illumina® (E7300) followed by cleanup using Monarch® PCR & DNA Cleanup Kit (5 μg) (NEB# T1030) as per manufacturer’s
instructions. DNA concentration and quality control was conducted using Bioanalyzer®
(Agilent® Technologies, Inc.). Finally, RNA sequencing was performed using Illumina
NextSeq 550 System with NextSeq 500/500 High Output Kit v2.5 (75 cycles) with singleend reads. Data were mapped using the ExceRpt small RNA sequencing data analysis
pipeline on the Genboree Workbench (http://genboree.org/site/exrna_toolset/). Mapping
parameters included a minimum read length of 15 nucleotides, with 0 mismatches allowed
based on methods previously described.33
4.2.11 STATISTICAL ANALYSIS
Data are presented as means ± SE. Differences between two mean values were
evaluated via the Student’s t test, and analysis of variance (ANOVA) or repeated ANOVA
with the Tukey’s post hoc test was used for multiple comparisons or repeated
measurements. All statistical analyses were performed with GraphPad Prism v9, and P <
0.05 was considered statistically significant.

4.3 RESULTS AND DISCUSSION
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4.3.1 MSC-EV SIZE, DISTRIBUTION, CONCENTRATION CHARACTERIZATION
This work aimed to establish a scalable culture platform for the manufacturing of
MSC-EVs. We investigated two dynamic cell culture methods (microcarriers and perfusion
bioreactor) and compared the EV yield and content to those produced by MSCs on tissue
culture flasks. We observed that both perfusion bioreactor and spinner flask systems
enabled sustained maintenance of large numbers of cells (on the order of 108 at seeding).
MSCs maintained high viability throughout the culture period for all culture platforms
(Figures 4.2 and 4.3) and MSC-EVs were successfully isolated from the conditioned
medium (CM) of MSC cultures.
Across four different biological donors (labeled Donors 1, 2, 3, 4) and three
different fabrication methods, the distribution of MSC-EVs based on NTA are described in
Figure 4.5A. Despite the variability of size ranges across different donors, median and
mode sizes remained within 50-150 nm and were not statistically significant across donors
or fabrication methods (Figure 4.5B). Based on yield normalized to CM volume, both
microcarrier based spinner flasks and perfusion bioreactor set-ups improved EV yield after
ultracentrifugation when compared to standard tissue cultures, up to 6 times in efficiency
(Figure 4.5C).
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Figure 4.5: EV Characterization. Size distribution of MSC-EVs for each biological donor
across cell culture methods (A). Mode and median particle size for microcarriers (M),
perfusion bioreactor (P), and tissue culture plates (TCP) are not statistically different (B). Both
microcarriers and perfusion bioreactor yielded greater numbers of EVs when normalized to
mL of conditioned media (CM) (C). One-way ANOVA with Tukey’s multiple comparisons test.
**p<0.005, ns: not significant.

When the number of cell-culture set-ups and needs of scaffolds are considered,
the microcarrier based spinner flask method stands out as the most scalable system. For
example, the generation of 1012 particles (estimated one dose for a large animal) would
only require 488 mL of CM in one spinner flask, while it would take 424 mL of CM in seven
perfusion bioreactor setups or 3243 mL of CM in 216 tissue culture plates to produce the
same amount, demonstrating the efficiency of the microcarrier in spinner flask system
(Table 4.3). These results are consistent with previous studies demonstrating high
efficiency of dynamic bioreactor settings for EV collection.18,25,34 For example, Watson et
al. reported a 10-fold increase in EV concentration in a hollow-fiber bioreactor platform
using HEK293 cells when compared with static conditions.25 However, this is an
immortalized cell line and the authors reported a wide variability in EV size distribution
profiles.
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Table 4.3: Summary of set-ups required for each cell culture method based on data
provided in Figure 4.5

Volume

Microcarrier

Perfusion
Bioreactor

TCP

488

424

3243

1
Spinner
Flask

5 Bioreactor

216 plates

Required to Generate
1e12 particles
(mL)
# Set ups
Required to Generate
1e12 particles

Set-Ups

Interestingly, the dynamic cell culture conditions increased EV yield beyond the
proportion to higher cell numbers, meaning that each cell secreted more EVs when culture
in dynamic conditions (1-3e4 particles/cell) when compared to static tissue culture flasks
(0.5e4 particles/cell). This increase in EV productivity might be explained by increased
shear or higher oxygen concentrations in dynamic platforms, stimulating EV production.
However, further studies are needed to establish the mechanism by which dynamic
conditions increase EV production.
In this work, we established a spinner flask bioreactor process in 500 mL vessels.
This process can be scaled up to a working volume of up to 500 L that incorporates a
monitoring system, enabling a controlled manufacturing process. The ability to increase
vessel size without having to redefine the cell culture parameters highlights the power of
microcarrier-based spinner flasks as a rapidly scalable EV manufacturing platform.
To demonstrate the minimal batch-to-batch variability of the microcarrier set-up,
MSCs from one donor (Donor 4) were cultured in the microcarrier based spinner flask
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system three separate times (Figure 4.6A). Even though there were some differences in
EV concentrations (±2e11 particles/mL), these differences are much lower than those
reported in the literature18 and the median particle size remains consistent (±10 nm),
validating the microcarrier method as a scalable method to manufacture large doses of
MSC-EVs (Figure 4.6C).
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Figure 4.6: Batch to Batch Variability of EVS. EV size distribution (A), concentration (B), and
median particle size (C) across different isolations of Donor 4 from microcarrier culture.

4.3.2 MSC-EV PROTEIN AND RNA CONTENT CHARACTERIZATION
The RNA and protein profiles of EVs are being newly explored to understand the
bioactive components of EVs and to characterize EV pharmacodynamics. To further
characterize the MSC-EVs from different biological donors and cell culture methods, we
quantified the MSC-EV protein and RNA concentrations via microBCA and Qiazole
Extraction assays, respectively (Figure 4.7). The microcarrier method resulted in the
highest protein and RNA concentrations, further validating this method as the most
scalable way to manufacture MSC-EVs.
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Figure 4.7: EV Protein and RNA Contents. Quantification of MSC-EV protein (left) and RNA
(right) concentrations across cell culture methods. One-way ANOVA with Tukey multiple
comparisons. *p<0.05

4.3.3 MSC-EV PROTEOMICS ANALYSIS
We successfully conducted proteomics analysis via liquid chromatography with
tandem mass spectrometry (LC MS/MS) on MSC-EV samples using Spectronaut for
peptide identification and Perseus for statistical analysis, utilizing the DirectDIA method
with Sus scrofa reference genome. Overall, a total of 5314 protein groups were identified,
with 1543 proteins significantly different across the three cell culture methods. Samples
from all methods and donors contained tetraspanins such as CD9, CD63, and CD81,
which are widely established small EV surface markers, validating the successful isolation
of the small EV subpopulation. 35
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Figure 4.8 illustrates the Principal Component Analysis across biological donors
and cell culture methods. We found that the proteomic profiles of MSC-EVs clustered
closely together based on cell culture method as opposed to the donor, indicating that the
cell culture method is a more important determinant of protein expression than the cellular
source of EVs. Particularly, different biological donors cultured using microcarriers
resulted in proteomic profiles that were highly correlated. In fact, the microcarrier method
resulted in the tightest clustering across biological donors, whereas perfusion bioreactor
resulted in the widest variation between donors. This is perhaps due to the differences in
the culture methods resulting in varied cellular microenvironments (e.g., shear), with
microcarrier being more uniform across cells.

Figure 4.8. Principal Component Analysis (PCA). PCA of four biological donors across three
cell culture methods (microcarriers circled in orange, tissue culture plate (TCP) circled in purple,
and perfusion bioreactor circled in green) proteomics data (Log2 fold changes). The PCA plot
represents 5314 proteins with biological replicates that indicated clear proteomics profile
differences across cell culture methods.

Figure 4.9 demonstrates the Pearson correlation analysis illustrating the
correlations between groups. In parallel with the PCA, the correlation coefficients within
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microcarriers were high (>0.9 between each donor within microcarrier group) while
correlation coefficients within each donor were low. For example, for Donor 1, the
correlation coefficient between Donor 1 Microcarriers and Donor 1 Perfusion Bioreactor is
0.63 while it is 0.91 between Donor 1 and Donor 2 within Microcarriers, indicating that cell
culture method drove protein expression more significantly.

Figure 4.9. Pearson Correlation Matrix. Normalized, log2-transformed expression values
of >5000 proteins across twelve samples. Each dot plot displays the protein expression
profiles of the horizontally and vertically projected pair of MSC-EVs indicated in the
diagonal. The axes pair plots have a logarithmic scale.
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Figure 4.10 demonstrates hierarchical clustering analysis of proteomics data
using pairwise comparisons between microcarriers and perfusion with volcano plot
(Figure 4.10A) and heatmap (Figure 4.10B), as well as enrichment analysis of significant
proteins (Figure 4.10C). Among classified proteins, those related to biological regulation,
metabolic processes, and response to stimulus seemed to be most common inside MSCEVs.

Figure 4.10: Microcarriers vs Perfusion Proteomics. Pairwise comparison between
microcarriers and perfusion. Number of valid pairs: 4989. Number of changed proteins with
adjusted p-value < 0.05: 988. Number of changed proteins with adjusted p-value < 0.05 and
|log2FC|>1: 912.

123

Figure 4.11 demonstrates the hierarchical clustering analysis of proteomics data
using pairwise comparisons between microcarriers and perfusion with volcano plot
(Figure 4.11A) and heatmap (Figure 4.11B), as well as enrichment analysis of significant
proteins (Figure 4.11C). Similar to the pairwise comparison between microcarriers and
TCP, proteins related to metabolic processes, biological regulation, and localization
seemed to be most commonly enriched. Interestingly, the microcarrier method resulted in
the enrichment of (i) angiogenic proteins,36 including EGF, STAT3, FGFR1, FGF7, vWF,
Agrin and TIMP1-3, (ii) anti-apoptotic proteins37 such as SOD, HSP90 and SDF1-3, and
(iii) immunomodulatory proteins, including IL6 signal transducing protein and HGF
activator protein,38 when compared to both perfusion bioreactor and TCP. In addition,
microcarrier-based EVs had significantly higher levels of other angiogenic proteins such
as VEGF and PDGFRbeta, when compared to perfusion bioreactor-derived EVs.
These results suggest that cell culture method plays a critical role in the protein
expression of generated EVs and the cell culture parameters need to be kept constant for
reproducibility in therapeutic applications. Given the tight clustering across donors,
microcarriers emerge as an ideal way for scaling up MSC-EVs for therapeutic applications.
One of the limitations of this study was the number of unclassified proteins found
in EV samples due to the paucity of proteins identified in the pig (sus scrofa) reference
proteome as compared to the abundance of sequence data from other model organisms
such as human, mouse, and yeast.39 As more sus scrofa sequencing data become
available, this proteomics analysis can enable identification of a greater proportion of
proteins found in our EV samples.
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Figure 4.11: Microcarriers vs TCP Proteomics. Pairwise comparison using t-test Microcarriers
vs. TCP. Number of valid pairs: 5099.Number of changed proteins with adjusted p-value < 0.05:
1040. Number of changed proteins with adjusted p-value < 0.05 and |log2FC|>1: 708.

There are a lot of recent studies focusing on the protein cargo of EVs. However,
due to differences in cell source, culture conditions, and isolation techniques, it is difficult
to understand the bioactive proteins of MSC-EVs that make them potent in many preclinical applications. To our knowledge, this is the first comprehensive analysis of MSC-
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EV protein cargo in an effort to understand the importance of donor and cell culture
parameter selection.
4.3.4 MSC-EV RNA SEQUENCING ANALYSIS
A diverse composition of microRNAs have been found in MSC-EVs in the
literature.40 While miRNA arrays are commonly used to characterize miRNAs found in
EVs, next-generation sequencing provides a wider breadth of miRNAs available and
allows for comparisons across groups with unbiased discovery of miRNAs. Previous
investigations by other groups have shown that standard RNA-seq methods perform
poorly on EV samples due to low-concentration inputs and lack of reproducibility.33
However, small RNA-seq has more recently been investigated and found to be successful
for EV sample profiling. Using methods based on Srinivasan et al. who isolated EVs from
different biofluids via different extraction protocols for next-generation sequencing,

33

we

successfully isolated RNA from MSC-EV samples using miRNeasy RNA extraction
protocol and performed complementary DNA library preparation using NEB small RNA
library kit. BioAnalyzer 2100 (Agilent Technologies) was used to identify the traces for
complementary DNA library (Figure 4.12). Although the RNAsequencing analysis is still
ongoing, we hope to receive results that mirror the proteomics profiling, allowing
integrative analysis of both the transciptome and proteome of MSC-EV samples.
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Figure 4.12. BioAnalyzer Traces for RNAsequencing. 143-146 bp peaks (green arrow)
represent miRNA contained in the samples indicating successful library preparation.

4.3.5 MSC-EV MORPHOLOGY ANALYSIS
Based on concentration, as well as protein- and RNA-content, we selected
Microcarriers in spinner flasks as the highly scalable MSC-EV collection method and
chose Donor 4 due to the highest concentration of EVs yielded with the Microcarrier
method. We performed Transmission Electron Microscopy (TEM), which is the most
common type of EV imaging, on these EVs to assess quality and purity of the produced
EVs. Figure 4.13 illustrates representative TEM images on MSC-EVs. We were able to
confirm that no large clusters/aggregates were formed during the isolation process and
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that most host cell debris/impurities were removed. We further confirmed the integrity and
morphology of the MSC-EVs as evidenced by the presence of intact phospholipid bilayer
membranes, circularity, and size distributions, consistent with the size distributions as
demonstrated by the NTA results.

Figure 4.13: TEM Characterization. TEM images of Donor 4 EVs isolated from cells cultured on
microcarrier-derived MSC-EVs confirming the size, morphology, and lipid bilayer membrane of
vesicles.

There are several limitations to this study. Firstly, while conditioned medium was
kept serum-free during the EV collection stage, the MSCs were previously cultured in Fetal
Bovine Serum (FBS) containing media, leaving potential residues of FBS in our final
product in addition to potential variations in MSC phenotype due to batch-to-batch
variability of FBS itself. Although we expect these effects to be minimal, the ideal option
for production of clinical grade MSC-EVs should be in chemically defined, completely
animal-component free medium throughout the whole expansion period. However,
currently there are limited options for sustaining large number of MSCs in such conditions.
Secondly, we have not used further purification methods such as iodixanol density
gradient after ultracentrifugation. While this would have resulted in higher-purity MSC128

EVs, unfortunately further purification methods lower EV yields significantly and present a
huge obstacle for scalability.41 As SEC becomes more available and enables purification
of larger volumes of MSC-EVs, these methods can be used to isolate and characterize
specific subpopulations of EVs.

4.4 CONCLUSION
In conclusion, we have demonstrated that an MSC-EV production pipeline based
on microcarriers in a spinner flask can be used for the efficient and reproducible EV
production from porcine bone marrow-derived MSCs. The donor MSCs and their cell
culture parameters not only affected the yield of EVs produced by MSCs but also their
molecular cargo content. The paracrine effect through the release of factors comprising
the EV cargo was underlined in this work where angiogenic, anti-apoptotic, and
immunomodulatory proteins were identified in MSC-EVs through proteomics analyses.
More importantly, through proteomics analyses, we found that cell culture parameters
drove protein expression and that different biological donors cultured via the same cell
culture method clustered closely together. Taken together, MSCs can be rapidly expanded
and scaled up using microcarriers to produce a high yield of EVs and MSC-EVs cultured
in dynamic spinner flask conditions have great therapeutic potential in many disease
states, including cardiac repair through their bioactive cargo. Defining cell culture
parameters and characterizing the MSC-EV product is of utmost importance for future use
of MSC-EVs in therapeutic studies.

129

4.5 REFERENCES
1.

Mateescu, B. et al. Obstacles and opportunities in the functional analysis of
extracellular vesicle RNA - An ISEV position paper. J. Extracell. Vesicles 6, (2017).

2.

Hill, A. F. et al. ISEV position paper: extracellular vesicle RNA analysis and
bioinformatics. J. Extracell. Vesicles 2, 22859 (2013).

3.

Witwer, K. W. et al. Updating the MISEV minimal requirements for extracellular
vesicle studies: building bridges to reproducibility. J. Extracell. Vesicles 6, 1396823
(2017).

4.

Wiklander, O. P. B., Brennan, M., Lötvall, J., Breakefield, X. O. & Andaloussi, S. E.
L. Advances in therapeutic applications of extracellular vesicles. Sci. Transl. Med.
11, 1–16 (2019).

5.

de Abreu, R. C. et al. Native and bioengineered extracellular vesicles for
cardiovascular therapeutics. Nat. Rev. Cardiol. (2020). doi:10.1038/s41569-0200389-5

6.

Gundogan, B. et al. Exosomes as Immunotheranostic Nanoparticles. Clin. Ther. 36,
(2014).

7.

Jeong, J. O. et al. Malignant tumor formation after transplantation of short-term
cultured bone marrow mesenchymal stem cells in experimental myocardial
infarction and diabetic neuropathy. Circ. Res. 108, 1340–1347 (2011).

8.

Wang, S. et al. Excess Integrins Cause Lung Entrapment of Mesenchymal Stem
Cells. Stem Cells 33, 3315–3326 (2015).

9.

Yeo, R. et al. Mesenchymal stem cell: an efficient mass producer of exosomes for
drug delivery. ElsevierSign in

10.

Kusuma, G. D. et al. To protect and to preserve: Novel preservation strategies for
extracellular vesicles. Front. Pharmacol. 9, 1199 (2018).

11.

Gudbergsson, J. M., Johnsen, K. B., Skov, M. N. & Duroux, M. Systematic review
of factors influencing extracellular vesicle yield from cell cultures. Cytotechnology
68, 579–592 (2016).

12.

Patel, G. K. et al. Comparative analysis of exosome isolation methods using culture
supernatant for optimum yield, purity and downstream applications. Sci. Reports
2019 91 9, 1–10 (2019).

13.

Witwer, K. W. et al. Defining mesenchymal stromal cell (MSC)-derived small
extracellular vesicles for therapeutic applications. J. Extracell. Vesicles 8, (2019).

14.

Crivelli, B. et al. Mesenchymal stem/stromal cell extracellular vesicles: From active
130

principle to next generation drug delivery system. J. Control. Release 262, 104–117
(2017).
15.

Wiest, E. F. & Zubair, A. C. Challenges of manufacturing mesenchymal stromal
cell–derived extracellular vesicles in regenerative medicine. Cytotherapy 22, 606–
612 (2020).

16.

de Soure, A. M., Fernandes-Platzgummer, A., da Silva, C. L. & Cabral, J. M. S.
Scalable microcarrier-based manufacturing of mesenchymal stem/stromal cells. J.
Biotechnol. 236, 88–109 (2016).

17.

Schenke-Layland, K. et al. Bioreactors in tissue engineering—principles,
applications and commercial constraints. Biotechnol. J. 8, 298–307 (2013).

18.

de Almeida Fuzeta, M. et al. Scalable Production of Human Mesenchymal Stromal
Cell-Derived Extracellular Vesicles Under Serum-/Xeno-Free Conditions in a
Microcarrier-Based Bioreactor Culture System. Front. Cell Dev. Biol. 8, 1197
(2020).

19.

Grein, T. A. et al. Multiphase mixing characteristics in a microcarrier-based stirred
tank bioreactor suitable for human mesenchymal stem cell expansion. Process
Biochem. 51, 1109–1119 (2016).

20.

Lin, Y. M. et al. Expansion in microcarrier-spinner cultures improves the
chondrogenic potential of human early mesenchymal stromal cells. Cytotherapy 18,
740–753 (2016).

21.

Van Wezel, A. L. Growth of Cell-strains and Primary Cells on Micro-carriers in
Homogeneous Culture. Nat. 1967 2165110 216, 64–65 (1967).

22.

Gronemeyer, P., Ditz, R. & Strube, J. Trends in Upstream and Downstream Process
Development for Antibody Manufacturing. Bioeng. 2014, Vol. 1, Pages 188-212 1,
188–212 (2014).

23.

Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T. & Peixoto, C.
Current
challenges
in
biotherapeutic
particles
manufacturing.
https://doi.org/10.1080/14712598.2020.1693541
(2019).
doi:10.1080/14712598.2020.1693541
de Soure, A. M., Fernandes-Platzgummer, A., da Silva, C. L. & Cabral, J. M. S.
Scalable microcarrier-based manufacturing of mesenchymal stem/stromal cells. J.
Biotechnol. 236, 88–109 (2016).

24.

25.

Watson, D. C. et al. Efficient production and enhanced tumor delivery of engineered
extracellular vesicles. Biomaterials 105, 195–205 (2016).

26.

Patel Editor, T. Extracellular RNA Methods and Protocols Methods in Molecular
Biology 1740.

27.

Gobin, J. et al. Hollow-fiber bioreactor production of extracellular vesicles from
131

human bone marrow mesenchymal stromal cells yields nanovesicles that mirrors
the immuno-modulatory antigenic signature of the producer cell.
doi:10.1186/s13287-021-02190-3
28.

Tharakan, J. P. & Chau, P. C. A radial flow hollow fiber bioreactor for the largescale culture of mammalian cells. Biotechnol. Bioeng. 28, 329–342 (1986).

29.

Zhao, F., Vaughan, T. J. & McNamara, L. M. Quantification of fluid shear stress in
bone tissue engineering scaffolds with spherical and cubical pore architectures.
Biomech. Model. Mechanobiol. 15, 561–577 (2016).

30.

Patel, D. B., Luthers, C. R., Lerman, M. J., Fisher, J. P. & Jay, S. M. Enhanced
extracellular vesicle production and ethanol-mediated vascularization bioactivity via
a 3D-printed scaffold-perfusion bioreactor system. Acta Biomater. (2019).
doi:10.1016/j.actbio.2018.11.024

31.

Veziroglu, E. M. & Mias, G. I. Characterizing Extracellular Vesicles and Their
Diverse RNA Contents. Front. Genet. 11, 700 (2020).

32.

van der Vlist, E. J., Nolte-’t Hoen, E. N. M., Stoorvogel, W., Arkesteijn, G. J. A. &
Wauben, M. H. M. Fluorescent labeling of nano-sized vesicles released by cells
and subsequent quantitative and qualitative analysis by high-resolution flow
cytometry. Nat. Protoc. (2012). doi:10.1038/nprot.2012.065

33.

Srinivasan, S. et al. Small RNA Sequencing across Diverse Biofluids Identifies
Optimal Methods for exRNA Isolation. Cell 177, 446-462.e16 (2019).

34.

Mitchell, J. P., Court, J., Mason, M. D., Tabi, Z. & Clayton, A. Increased exosome
production from tumour cell cultures using the Integra CELLine Culture System. J.
Immunol. Methods 335, 98–105 (2008).

35.

Campos-Silva, C. et al. High sensitivity detection of extracellular vesicles immunecaptured from urine by conventional flow cytometry. Sci. Reports 2019 91 9, 1–12
(2019).

36.

Todorova, D., Simoncini, S., Lacroix, R., Sabatier, F. & Dignat-George, F.
Extracellular Vesicles in Angiogenesis. Circ. Res. 120, 1658 (2017).

37.

Roefs, M. T., Sluijter, J. P. G. & Vader, P. Extracellular Vesicle-Associated Proteins
in Tissue Repair. Trends Cell Biol. 30, 990–1013 (2020).

38.

Bruno, S., Deregibus, M. C. & Camussi, G. The secretome of mesenchymal stromal
cells: Role of extracellular vesicles in immunomodulation. Immunol. Lett. 168, 154–
158 (2015).

39.

Grønlund Jørgensen, F. et al. Comparative analysis of protein coding sequences
from human, mouse and the domesticated pig. BMC Biol. 3, 1–15 (2005).

40.

Ko, J. et al. MiRNA profiling of magnetic nanopore-isolated extracellular vesicles
132

for the diagnosis of pancreatic cancer. Cancer Res. 78, 3688–3697 (2018).
41.

Onódi, Z. et al. Isolation of high-purity extracellular vesicles by the combination of
iodixanol density gradient ultracentrifugation and bind-elute chromatography from
blood plasma. Front. Physiol. 9, 1479 (2018).

133

CHAPTER 5
EVALUATION OF HYDROGEL-DELIVERY OF MSC EVS IN A LARGE ANIMAL MI
MODEL

5.1 INTRODUCTION
There is a tremendous clinical need to find new therapies to limit the progression
to heart failure after myocardial infarction (MI). Early studies have shown therapeutic
benefits of mesenchymal stromal cells (MSCs) in cardiac repair, which are now attributed
primarily to paracrine factors such as extracellular vesicles (EVs).
While the field of therapeutic MSC-EVs is rapidly growing for a variety of diseases,
EVs administered via systemic or local injections are rapidly cleared from the target organ;
thus, repeated dosing is often required for therapeutic efficacy.1,2 Biomaterials are
attractive to improve EV therapies, by promoting EV localization, enhancing EV retention
at the injection site, and maintaining EV stability over time, all of which can augment the
efficacy of EVs in tissue repair.3 Furthermore, biomaterial characteristics such as
chemistry, crosslink density, pore size, and degradability can be tuned to achieve desired
release kinetics. EVs can also be chemically linked to biomaterials to prolong retention;
for example, functionalizing EVs with azide-bearing groups allows immobilization to
DBCO-containing materials via click chemistry.4 In addition, EVs may also bind to
fibronectin and collagen via integrins5 and to hyaluronic acid (HA) via CD44,6 further
enhancing EV retention with biomaterials designed from these molecules.3
Several hydrogel-based EV delivery systems have been developed for cardiac
repair post-MI.7 For example, a gelatin-based Gelfoam hydrogel patch containing iPSCEVs was shown to release EVs over 21 days in vitro and 7 days in vivo and improve
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functional outcomes in a rat model of MI.8 Alginate hydrogels encapsulating rat MSC-EVs
retained EVs for up to 14 days in vivo and enhanced the therapeutic efficacy of MSC-EVs
by improving metrics such as ejection fraction (EF) when compared to MSC-EVs or
hydrogels alone.9 Self-assembling peptide hydrogels have also improved outcomes after
MI when compared to MSC-EV treatment alone by reducing inflammation and promoting
angiogenesis.10 Chen at al. used HA-based hydrogels to release endothelial progenitor
cell-EVs (EPC-EVs) over 21 days in vitro, which improved functional outcomes in a rat
model of MI.11 Across these biomaterials, the delivery mode can vary - Gelfoam patch was
sutured onto the myocardium, whereas alginate and HA-based hydrogels were shearthinning and self-healing to allow intramyocardial delivery.
In addition to enhancing the retention of MSC-EVs or other payloads, hydrogels
themselves may limit ventricular remodeling through bulking or stiffening of the infarct
region.12 Specifically, our group has shown that shear-thinning and self-healing guest-host
(GH) hydrogels assembled via interactions between cyclodextrin (CD) and adamantane
(Ad) functional groups conjugated to HA improved myocardial thickness in an ovine model
of MI.12 However, functional improvements through mechanical bulking and reduction in
myocardial stresses are highly dependent on the mechanical properties and degradation
of hydrogels.12
While MSC-EVs released from hydrogels have been promising in small animal
studies, one hurdle for progress to the clinic is the transition from small animal research
to advanced preclinical studies in large animals to test the safety and efficacy of MSCEVs. Recently, Zheng et al. (2022) performed a thorough literature review of EV therapies
for MI and identified 10 studies for meta-analysis on the therapeutic efficacy of stem cellderived EVs on small animal models. The authors found that EV delivery improved EF
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and fractional shortening (FS) by 3.67% and 3.69%, respectively, and reduced infarct size
by 4.52%.13 Despite this positive outcome, due to a large variation in cell-source and
culture parameters for EV collection, in vitro models, animal models, timing and route of
administration, dosing, terminal timepoint, and modality of endpoint measurements in the
literature, there is no consensus or gold standard for any of these parameters.
We performed our own literature review on study design parameters of EV studies
for MI in small and large animal models, which can be found in Table 5.1. This review
shows a wide range of EV sources, animal models, EV delivery modes, and functional
outcomes in these previous studies. Based on reported EV particle and protein
concentration in the literature and our previous studies,11,14 intramyocardial delivery of a
dose of 1e12 particles/mL (~2.8 mg of protein) released from hydrogels was selected for
the 90-minute ischemia/reperfusion (I/R) porcine model for this study. Using a specific
porcine biological donor of interest for bone marrow-derived MSCs and microcarrier-based
spinner flask bioreactor for EV collection, as identified in Aim 1, we first investigated the
therapeutic potential of MSC-EVs in vitro using established cardiac spheroid contraction
and tubule formation assays and then applied our previously established HA-based shearthinning, self-healing GH hydrogel11,14–17 to investigate the therapeutic potential of MSCEV hydrogel delivery in a large animal study.
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Table 5.1: A review of EV-based therapies for cardiac repair post-MI
EV
Source

EV
Collection
Method

In Vitro
Models

MI
Model

Injection
Method

Injection
Time

Injection
Amount

FollowUp
Time

Cardiac
Function

Ref

Rat EPC

Serumfree

HUVEC

Rat
LAD
MI

HA-gel

Immediately
3h, 4 days,
or 2 weeks

9e9 in
100 μL

28 days

↑ ESS

14

5x20 IM

↓ Infarct
%

after
Rat EPC

Serumfree

HUVEC

Rat
LAD
MI

HA-gel

Immediately
after

9e9 in
100 μL

28 days

5x20 IM

↑ EF

11

↓ Infarct
%
↑ Vessel
density

hiPSC
CMs

Human
MSCs

Serumfree

Serumfree

Activated
-caspase
CM

Rat
LAD
MI

Gelfoam
(sutured)

H9C2
cells
treated
with H2O2

Rat
LAD
MI

Amphiphi
lic
peptide

Immediately
after

3e10

28 days

~ EF

18

↓ Infarct
%
Immediately
after

40 ug
protein in
20 μL

28 days

↑ ESS

19

↓ Infarct
%
↓ CD68+

Rat
MSCs

Serumfree

Rat
LAD
MI

Alginate
gel

30 mins
after

89 ug
protein in
100 μL

28 days

↑ EF

9

↓ Infarct
%

IM

↑ CD31+
HAF-SC

Hypoxic

HUVEC
EPDC

Mouse
LAD
MI

PBS IM

Immediately
after

Not
reported

28 days

↑ EF

20

↓ Infarct
%
↑ BrdU+
CMs

Human
BM
MSCs

Hypoxic

HUVEC

Rat
LAD
ligatio
n

PBS IM

Immediately
after

80 μg

28 days

protein

↑ EF

21

↓ Infarct
%
↑ vWF+

Rat CPC

Hypoxic

HUVEC

Rat I/R

Not
reported

Cardiac
fibroblast
cytokine

Not
reported

Not
reported

21 days

↑ FS
↓ Infarct
%

137

22

Rat CM

Hypoxic

HUVEC
TEER

Rat
LAD
MI

PBS IM

Immediately
after

15 μg

28 days

protein

~ EF

23

↑ CD31+

MMP
release
EC Ki67
Aortic
ring
assay
Rat
MSCs

GATA4
overexpre
ssion

Hypoxic
rat
neonatal
CM ->
LDH,
TUNEL

Rat
LAD
MI

PBS IM

Human
MSCs

miRNA181a

Treg
polarizati
on

Mouse
75-min
LAD
I/R

PBS IM

NRVMs

Rat
45-min
LAD
I/R

PBS IM

Overexpre
ssion
Human
CS-CM

Y-RNA
overexpre
ssion

H2O2 for
15 min

3 days after

50 μg
from 4e6
MSCs

28 days

↑ EF

24

200 μg

7 days

↑ EF

25

↓ CD68+

Immediately
after

100 μL

2 days

10 μg

Serumfree

TUNEL
and Ki67
staining
on
NRCM

Mouse

Fibrin gel
spray

Immediately
after

5e10

26

↓
Apoptosi
s

protein
Rat
MSCs

↓ CD68+

28 days

LAD
MI

↑ EF

27

↓ Infarct
%
↑ Ki67+
↑ vWF+

Human
CS-CM

Serumfree

TUNEL
and Ki67
staining
on

Rat
and
Pig
LAD
MI

PLGA
micropart
icles IM

Immediately
after

CM

21 days
in rats
7 days
in pigs

NRCM

hiPSCEC,
hiPSCCM,
hiPSCSM

Serumfree

Human
CS-CM

Serumfree

HUVEC
iPSC-CM
TUNEL

↑ EF

28

↓ Infarct
%
↑ Ki67+
↑ vWF+

Pig
60-min
LAD
I/R

PBS IM

Immediately
after

7.5 mg
EV

28 days

↑ EF

29

↓ Infarct
%
↑ CD31+

HUVEC

Mouse
LAD
MI

PBS IM

Immediately
or 21 days
after

2.8e9

21 days

↑ EF

30

↓ Infarct
%

EPC: Endothelial Progenitor Cell, MSC: Mesenchymal Stromal Cell, hiPSC-CM: human induced pluripotent cell-derived
cardiomyocyte, NRCM: neonatal rat cardiomyocytes, CS-CM: cardiosphere-derived cell, EC: endothelial cell, SM: smooth
muscle cell, HUVEC: human umbilical endothelial cell, LAD: left anterior ascending artery, MI: myocardial infarction
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(permanent ligation), I/R: ischemia reperfusion, IM: intramyocardial, EF: ejection fraction, ESS: end-systolic elastance, FS:
fractional shortening, CM: conditioned media.

5.2 METHODS
5.2.1 MSC-EV COLLECTION AND ISOLATION
Bone-marrow derived porcine MSCs were cultured in a microcarrier-based spinner
flask bioreactor system as described in Aim 1. Based on Aim 1 results, Donor 4 was
selected for EV collection due to the tight distribution and high yield of EVs. Briefly,
passage 5 MSCs were seeded onto gelatin-coated microcarriers and cultured in 1 ng/ml
FGF-, 1% GlutaMAX, 10% FBS, 1% penicillin/streptomycin-containing DMEM up to 80%
confluence (Day 4), after which the media was switched to FBS-, FGF-free media for 72
hours for EV collection. Conditioned media was collected on Day 7 and MSC-EVs were
isolated using a differential ultracentrifugation protocol. EVs were re-suspended in PBS
and their concentration characterized using Nanoparticle Tracking Analysis.
5.2.2 CARDIAC SPHEROID FORMATION AND CONTRACTION
Human iPSC-CMs were purchased from Fujifilm Cellular Dynamics (iCell 01434
(Donor A), purity >97%). Human cardiac fibroblasts were purchased from Promocell and
expanded in α-MEM (10% FBS, 1% penicillin/streptomycin, 5 ng/ml basic fibroblast growth
factor) at 37 °C/5% CO2 until 80% confluency. Cardiac spheroids were formed by mixing
iPSC-CMs and CFs at a ratio of 4:1 in ultra-low attachment 96-well round-bottom plates
based on previously described methods.31 For the first 48 h, cardiac spheroids were
cultured in iCell plating medium (Cellular Dynamics) to optimize post-thawing survival of
the iPSC-CMs. After four hours, cardiac spheroids were maintained in iCell maintenance
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media (Cellular Dynamics). Approximately 24 h after thawing, the iPSC-CM and CF cocultures had aggregated into a single spheroid with synchronized contractions observed
after 96 hours.
Cardiac spheroid contraction was recorded at 37°C/5% CO2 in iCell maintenance
media using a Nikon TE2000 (4× lens, 20 HZ). The software package musclemotion was
used for all contraction analysis.32 The contraction amplitude (absolute unit, a.u) is an
optical measure of contraction and is widely used for cardiac spheroid studies and
correlates with the force of contraction, which has been validated across single adult CMs,
iPSC-CMs, cardiac spheroids, and engineered heart tissues.32 The contraction amplitude
(a.u) is automatically normalized to the pixel density of the video recording, and a
consistent pixel density was used across all recordings.
5.2.3 TUBULE FORMATION STUDY
EV angiogenic potential was quantified in vitro using a Matrigel tubule formation
assay. 10 μL of Matrigel (Corning) was plated into each 0.125 cm2 inner well of a μ-slide
for angiogenesis (Ibidi). Human umbilical vein endothelial cells (hUVECs, passage 4,
grown to 100% confluence) resuspended in EBM-2 with 1% FBS were seeded onto
Matrigel at a density of 10,000 cells/well (51,000 cells/cm2). EVs isolated from MSCs preconditioned with all four treatment groups were suspended in PBS and were added to
each well at a concentration of 80 μg protein/mL, with EV protein content quantified as
described above (e.g., for 50 μL volume/well, 0.5e9 EV particles were added to each well).
EV samples with varying protein concentrations were diluted such that the volume of PBS
added to each well was the same. For a negative control, the same total volume of PBS
without EVs was added to wells. Samples were incubated for 14 hours and imaged at 4x
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using brightfield microscopy. Images were analyzed using the Angiogenesis Analyzer
plug-in (Gilles Carpentier) and ImageJ (NIH).
5.2.4 MATERIAL SYNTHESIS AND HYDROGEL PREPARATION
Cyclodextrin (CD) and adamantane (Ad) modified hyaluronic acid (HA) polymers
were prepared by methods previously described.16 CD-HA (27% modification) and Ad-HA
(20% modification) were separately dissolved in PBS or EV-containing PBS solutions at
4.5% w/v. CD-HA and Ad-HA were loaded onto 1 mL BD syringes via aspiration through
an 18”G needle. GH hydrogels were formed under sterile conditions via connecting two
syringes using a luer lock and mixing back and forth 100 times. Syringes for all treatment
groups were prepared 1-2 hours before the procedure and kept on ice until injection.
5.2.5 ANIMAL CARE AND BIOSAFETY
Adult Yorkshire pigs (age range: 4-6 months, weight range: 40-45 kg, 100% male)
were obtained from Meck, Inc. Food and water were provided ad libitum. This investigation
adheres to the National Institutes of Health guidelines on animal care and use, conforms
to institutional ethical review, and was approved by the University of Pennsylvania
Institutional Animal Care and Use Committee (Protocol 806365). Surgery was performed
aseptically following the IACUC Guidelines for USDA species survival surgery. All persons
at the operating table were fully gowned, masked, gloved and capped. All measurements
were performed by 2 independent investigators blinded to animal treatment conditions.
5.2.6 EXPERIMENTAL DESIGN
The animals (n=28) were randomized and all surgeons (thoracotomy and
treatment injection) and operators (infarct induction, CMR, electroanatomical mapping)
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were blinded to the treatment groups which were as follows: PBS, PBS+EVs, Gel, and
Gel +EVs. The study was powered at 80% to detect an effect size of 5% difference in the
primary outcome of ejection fraction with type I error rate of 0.05.
5.2.7 PIG MODEL OF MYOCARDIAL INFARCTION
The animals were sedated with IM ketamine, with diazepam as alternative pre-op
sedative. After direct intubation with a laryngoscope, anesthesia was initiated and
maintained with inhaled isoflurane at 0.5-5%, for the entire procedure. Peri-operative
analgesia was maintained with fentanyl (patch placed 1-24 hours in advance) and
meloxicam. Arterial access was obtained at the carotid or femoral artery for measurement
of intraventricular pressure (Millar Instruments, Houston TX). Venous access was
obtained at the internal jugular veins for administration of medication for administration of
fluids, antiarrhythmic and vasopressors. An epicardial echocardiogram was performed
under sterile technique. Anticoagulation via IV Heparin was established.
For balloon catheter occlusion, a 6Fr Hockey-stick guide catheter (Cordis
Corporation, Fremont, CA) was positioned in the left main ostium under fluoroscopic
guidance. A 0.18′′, 180cm Choice-PT angioplasty wire (Boston Scientific, Marlborough,
MA) was carefully advanced into the LAD coronary artery. A rapid-exchange 2.5 × 12 mm
angioplasty balloon (Apex, Boston Scientific, Marlborough, MA) was placed over the
angioplasty wire into the mid-LAD. Serial coronary angiography was performed to position
the angioplasty balloon immediately distal to the second diagonal branch of the LAD. The
angioplasty balloon was inflated and maintained at 10–12 atm throughout the infarct
procedure. After initial balloon inflation, repeat coronary angiography was performed to
confirm adequate distal occlusion of the LAD. Uninterrupted coronary occlusion was
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maintained for 90 min with confirmation of acute MI by ST segment elevation in the
precordial ECG leads. Animals that developed ventricular arrhythmias underwent external
defibrillation. Intravenous lidocaine, atropine, metoprolol/esmolol, epinephrine, and
procainamide were used if needed to stabilize abnormal heart rhythms. At the end of the
90 minute infarct time, the percutaneous balloon was deflated and tissue reperfused with
confirmation of reperfusion via fluoroscopy.
5.2.8 LEFT LATERAL THORACOTOMY AND MSC-EV/HYDROGEL INJECTION
For a left thoracotomy, the smallest possible incision was made via scalpel,
approximately 8-12 cm. Subcutaneous tissue and muscles were divided with cautery to
improve hemostasis. The pericardium was opened and the heart supported in a pericardial
cradle. Epicardial injection was performed with twenty 50 µL injections from 1 mL BD
syringes with a 23”G needle with a stopper to ensure 4 mm depth of injection of one of the
following groups: PBS, PBS+EVs, Hydrogel, or Hydrogel +EVs.
Prior to chest closure an intercostal nerve block at the surgical site was performed
with bupivacaine. The thoracotomy incision was closed with blunt tip #2 Polysorb sutures
for the intercostal muscles. Silk #0 sutures were used to close the remaining muscle
layers, muscle by muscle in an interrupted manner. The subcutaneous tissue was closed
with an interrupted 2-0 Polysorb suture. A subcuticular suture of 2-0 Vicryl was then placed
and the wound sealed with collodian. Any vascular access sites were closed. Once
weaned from anesthesia and breathing spontaneously, the animals were moved to the
recovery room. All clinical signs of pain/distress were monitored and additional analgesics
were administered if needed. The animals survived for 8 weeks after which cMRI and
electrophysiological mapping were performed, followed by euthanasia and tissue harvest.
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5.2.9 CARDIAC MAGNETIC RESONANCE IMAGING
MRI studies were performed on a 3T whole-body system (Trio; Siemens
Healthcare, Erlangen, Germany) with 40 mT/m gradients and 18 channel RF receiver
arrays. Intraventricular pressure was interfaced to physiological monitoring software and
filtered to facilitate dual respiratory and cardiac gating (LabView, National Instruments,
Inc., Austin Texas). All 2D images were acquired in the short axis during apnea and 3D
with dual cardiac and respiratory gating. Apnea was achieved by temporarily disabling the
animal ventilator.
In vivo retrospective, short axis, multi-slice cine MRI was performed with a
TR = 41 ms, TE = 2.84 ms, FOV = 34 × 20 cm2, spatial resolution = 1.3 × 1.3 mm2, slice
thickness = 6 mm, number of slices = 18–20, flip angle = 12°, bandwidth = 399 Hz/pixel,
parallel imaging acceleration factor = 2, NEX = 1 and 3–4 slices with 60 cardiac phases
per slice were acquired during a breath hold of 20 s followed by a 1 min break between
each breath hold. The animals received a 0.1 mmol/kg intravenous injection of gadolinium
contrast for LGE imaging (MultiHance; Bracco Diagnostics, Inc.; Princeton, NJ). Imaging
was performed 10 min after injection of contrast agent using a inversion time (TI) scout
sequence to determine the optimal TI to null normal myocardial tissue signal. LGE MRI
was obtained using a cardiac and respiratory gated 3D multishot phase-sensitive inversion
recovery (PSIR) bSSFP sequence with a TR = 443 ms, TE = 2.42 ms, FOV = 35 × 219 cm2,
voxel

size = 1.4 × 1.4 × 4 mm3,

number

of

slices = 26,

flip

angle = 20°,

bandwidth = 244 Hz/pixel, parallel imaging acceleration factor = 2, NEX = 2, and total
acquisition time ranged from 7 to 9 min. Respiratory and cardiac-gated 2D T2*-weighted
single-echo gradient-echo images were obtained using TR = 160 ms, TE = 10 ms,
FOV = 24.0 × 17.3 cm2, spatial resolution = 0.9 × 0.9 mm2, slice thickness = 4 mm, number
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of slices = 10–15, flip angle = 13°, bandwidth = 260 Hz/pixel, parallel imaging acceleration
factor = 2, NEX = 12, and each slice was acquired during a breath hold of 60 s followed by
a 3 min break between each breath hold.
5.2.10 ELECTROPHYSIOLOGICAL MAPPING
High-resolution mapping of ventricular scar was conducted based on previously
described methods.33 Briefly, electroanatomic mapping (EAM) was performed under
general anesthesia using Carto 3 mapping system (Carto 3 system, Biosense Webster,
Diamond Bar, CA). Mapping of the LV was performed during sinus rhythm with a 20-pole
steerable mapping catheter arranged in 5 soft radiating spines covering a diameter
of

3.5

cm

(Pentaray,

Biosense

Webster;

interelectrode

spacing

2-6-2

mm;

multielectrode mapping). The density fill threshold remained constant at ≤5 mm in regions
of low bipolar voltage amplitude and ≤10 mm elsewhere as a requisite for a complete map.
Although the multielectrode-mapping catheter does not have contact force sensing
technology, we used an internal point filter software available on the mapping system to
limit data acquisition to within 5 mm from the original shell made with contact force
technology. This algorithm, although not an equivalent to tissue contact, can potentially
reduce mapping of cavitary structures. To calculate the low-voltage surface area, we
used the measurement tool included in the mapping system software.
5.2.11 EUTHANASIA AND HEART TISSUE HARVEST
At the completion of the surgery and all data collected, the scheduled terminal
animals underwent euthanasia while under a surgical plane of anesthesia with inhaled
isoflurane at 0.5-5% for the entire procedure. A median sternotomy was performed and a
sternal saw was used to open up the sternum. A rib spreader was used to expose the
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heart and the pericardium was opened. Once the chest was open, the proximal ascending
aorta was cross clamped and potassium chloride was injected into the aortic root and
down into the coronary arteries. Additional doses were given, if needed. Once the heart
was arrested, it was excised for further analysis. The animal carcass was placed into a
ULAR bag/cylinder and immediately transferred for appropriate ULAR disposal.
5.2.12 HISTOLOGY
After the heart was explanted, it was washed in saline solution with any clots
removed. The pericardium and adhesions surrounding the tissue were carefully removed.
The heart was filled with wet gauze to reconstruct the pressurized shape of the right and
left ventricles and placed into a bucket of 10% formalin for fixation for >72 hours for tissue
fixation. After fixation, the gauze was removed and the heart tissue was serially sliced into
8 mm rings (approximately 10 rings from apex to base) and labeled S1 (apex) through
S10 (base) parallel to the atrioventricular groove. S3 sections were placed into
MegaCasettes and were processed and paraffin embedded by the Children’s Hospital of
Philadelphia (CHOP) Pathology Core. Paraffin embedded cassettes were sectioned using
a Leica RM2500 microtome with 10 μm thickness. Tissue sections were stained with H&E
and Masson’s Trichrome stains. Scar thickness and area were calculated using a custom
MATLAB code.
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5.3 RESULTS AND DISCUSSION
5.3.1 CARDIAC SPHEROID CONTRACTION
We investigated the in vitro therapeutic potential of Donor 4 Microcarrier-based
MSC-EVs using a cardiac spheroid contraction assay. Specifically, iPSC-derived
cardiomyocytes were formed into spheroids and 5 mM H2O2 for 1 hour was used to mimic
a myocardial infarction, based on previously established methods.34 MSC-EVs were
added at the same time as H2O2 for the experimental group. Figure 5.1 illustrates
representative images of cardiac spheroids from each group. Using live-cell imaging
microscopy, we assessed healthy, H2O2 injured, and injured/MSC-EV treated cardiac
spheroids. Spheroids treated after injury had a significantly decreased contraction
amplitude as well as a significantly increased peak-to-peak time when compared to injury
alone spheroids. The addition of MSC-EVs resulted in a significant increase of contraction
amplitude and decrease in peak-to-peak time, suggesting that MSC-EVs improve
electrical activation of cardiac spheroids after injury. In support of these findings, Gao et
al. recently demonstrated that EVs protect cardiomyocytes from hypoxic injury by
increasing Ca2+ transient amplitudes, reducing apoptosis, boosting ATP content with the
proposed mechanism of up-regulation of hypoxia inducible factor (HIF-1α).29
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Figure 5.1: Cardiac Spheroid Contraction Assay. Representative videostills from healthy,
H2O2-treated, and H2O2 +EV-treated cardiac spheroids from live cell imaging microscopy.
Contraction amplitude (a.u) and peak-to-peak time (ms) quantified using MuscleMotion Plugin
on ImageJ. One-way ANOVA with Tukey’s multiple comparisons test. *p<0.05 **p<0.005
***p<0.001 ****p<0.0005. a.u: arbitrary units.

5.3.2 TUBULE FORMATION
A Matrigel tubule formation assay was used to evaluate the in vitro angiogenic
potential of Donor 4 Microcarrier MSC-EVs with saline used as a negative control.
Representative images of hUVEC tubule formation (Figure 5.2A) and quantification of the
number of nodes, segments, and meshes per area (Figure 5.2B) show that treating
hUVECs with MSC-EVs significantly increased the formation of vascular structures when
compared to the control group. These results are in agreement with previous studies from
our group15 as well as others.3
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Figure 5.2: Tubule Formation Assay. Representative phase contrast images of HUVEC tubule
formation of negative control, EV treated, and positive control. Quantification of number of nodes,
meshes, mean mesh size, number of segments, number of branches and total length quantified
using the angiogenesis plugin on ImageJ. One-way ANOVA with Tukey’s multiple comparisons
test. *p<0.05 ns: not significant. ns unless marked otherwise.
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5.3.3 MSC-EV DELIVERY VIA INJECTABLE HYDROGEL IN A PORCINE MODEL OF
MI
Figure 5.3 demonstrates the study design and timeline whereby acute myocardial
infarction was successfully induced in Yorkshire pigs (n=32) via balloon occlusion of the
LAD directly distal to the second diagonal for 90 minutes (Figure 5.4) followed by
reperfusion. Four animals had complications due to ventricular fibrillation during or after
ischemia or due to thoracotomy and had to be sacrificed, leaving n=28 for analysis.
Mortality rate of 12.5% was observed, which is within the expected range based on the
model.35 All animals underwent a baseline CMR, and CMR and electroanatomical
mapping at terminal timepoint (8 weeks) for functional analysis. Experimental groups
included: PBS control, Gel-only, PBS+EVs, and Gel+EVs. For PBS+EVs and Gel+EVs
groups, 1 mL of either PBS or Guest-Host hydrogel containing 1e12 particles was
prepared. For all groups, a total of 1 mL was injected around the borderzone (20 x 50 μL
injections) (Figure 5.5).

Figure 5.3: Therapeutic MSC-EV Delivery Study Design. Schematic describing large animal
study design whereby 32 Yorkshire pigs underwent 90-mins of ischemia followed by reperfusion
and MSC-EV injection via GH hydrogel.
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Figure 5.4: Balloon Occlusion via Fluoroscopy. After anatomical assessment of the left
anterior descending artery (LAD) via contrast agent (A), acute myocardial infarction was
successfully induced in Yorkshire pigs (n=32) via balloon occlusion of the LAD directly distal
to the second diagonal for 90 minutes (B) with electrocardiogram (ECG) formation of the
infarct confirmed via ST-elevation in precordial leads (V1-3) (C).

Figure 5.5: Left Lateral Thoracotomy and Injection. Approximately an 8 cm incision was
made near the 5th rib space. After access through the intercostal muscles, the apex was
exposed and twenty 50 ul injections were performed.
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5.3.3.1 INFARCT SIZE
High-resolution mapping of ventricular scars were successfully conducted using
Carto 3 mapping system (Biosense Webster, Diamond Bar, CA), based on previously
described methods.33 Preliminary analysis of infarct size demonstrated trends towards
improvement in both gel and PBS+EVs as compared to PBS, although these differences
were not statistically significant, likely due to a small sample size. The scar percentage,
however, was decreased significantly in Gel+EVs group as compared to the PBS control
(Figure 5.6). While dense scar percentage was not statistically different between groups,
it is unclear in the literature whether this parameter has clinical significance. Ongoing
studies are focused on increasing the sample size to adequately power this study.

Figure 5.6: Infarct Size via Electroanatomical Mapping. A) Example image demonstrating
electroanatomical mapping. Quantification of scar percentage (B) as <1.5 mV bipolar area
and dense scar percentage as <0.5 mV bipolar area (C). One-way ANOVA with Tukey’s
multiple comparisons test. *p<0.05 ns: not significant.
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5.3.3.2 CMR FUNCTIONAL OUTCOMES
Preliminary data on functional outcomes as determined by cardiac magnetic
resonance (CMR) imaging are demonstrated in Figure 5.7. The segmentation analysis is
still ongoing and more experiments are being conducted to finalize the study.
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Figure 5.7: Preliminary CMR Functional Outcome Analysis. Preliminary functional
outcomes of Ejection Fraction (EF), Cardiac Output (CO), End Systolic Volume (ESV), and
End Diastolic Volumes (EDV) as quantified by CMR segmentation analysis. Statistical
analysis not performed due to ongoing studies to improve sample size.
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5.3.3.3 HISTOLOGY
After terminal CMR and electroanatomical mapping, the heart was dissected and
fixed in 10% formalin for each animal. After fixation, the myocardium was sliced parallel
to the atrioventricular grove with 8 mm slices from apex to base. An example basilar view
of the sequential slices from apex to base can be seen in Figure 5.8. The scar (in white)
can be visualized in the anteriolateral left ventricular wall closer to the apex and closer to
the septum towards the base of the heart.

Figure 5.8. Gross histology images from EVI_05 (Gel+EVs). Basilar view of the sequential
slices of the myocardium from apex (S1) towards the base (S8). The scar can be visualized in
the apical anteriolateral wall of the left ventricle (white arrows) while appearing more septal
towards the base (orange arrow).
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Figure 5.9. Representative gross histology images. Basilar view of representative gross
histology images from PBS, Gel, PBS+EVs and Gel+EVs groups. Slices represent sections 1624 mm from the apex.

Figure 5.9 illustrates representative S3 slices from PBS, Gel, PBS+EVs, and
Gel+EVs groups. These slices were then paraffin-embedded and sectioned for further
staining. Figure 5.10 demonstrates preliminary Masson’s Trichrome staining of these
samples. After the study is completed, Masson’s Trichrome staining will be used to
determine scar thickness and scar area which can be correlated to scar percentage as
determined by electroanatomical mapping.

Figure 5.10. Representative histology staining. Preliminary Masson’s Trichrome
staining of PBS (A), PBS+EVs (B), Gel (C), Gel+EVs (D) imaged at 4x. Scale bar 200 um.
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5.3.4 LIMITATIONS
One of the main limitations of this study is the limited sample size inherent to the
use of large animal models. However, the study was powered at 80% and designed to
detect a 5% effect size for the primary outcome of ejection fraction. While the size of the
infarct (median of 12% infarct area) was small compared to that of small animal models,
this is consistent with infarct sizes reported in the literature for large animal studies.29 In
accordance with our studies, approximately 10% mortality rate was expected from this
model,35 making larger infarcts logistically impossible with acute infarct sizes >30% of LV
volume resulting in the loss of the majority of the subjects within 48 hours of the acute
MI.29 Furthermore, as discussed in the introduction, dose-response studies have not been
conducted in large animal studies to determine the optimum timing, dose or mode of
injection for MSC-EVs. Our decision for dose and timing was largely based on our
previously established small animal models and a literature review summarized in Table
5.1.
Another limitation of this study is the mode of delivery. While the
ischemia/reperfusion was achieved via minimally-invasive balloon occlusion, the
intramyocardial injection of MSC-EVs via hydrogels required a left lateral thoracotomy.
While injectable hydrogels offer the ability to be delivered in a minimally-invasive manner,
catheter compatibility presents a critical hurdle for clinical translation. Towards minimallyinvasive hydrogel delivery, others have explored transendocardial injections via a MyoStar
catheter36 guided by NOGA cardiac mapping system (Biologics Delivery Systems, Cordis
Corporation, Hialeah, Florida) and pericardial delivery through custom dual lumen delivery
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catheters. 37,38 However, these systems are not widely accessible and they are established
for other material platforms. We envision that our hydrogel can be delivered
percutaneously in future studies using a subxiphoid window via a long needle or a
catheter.
Finally, an important limitation includes the characterization of the mechanism of
improvement. Ongoing pharmacodynamic studies focus on understanding the enrichment
of downstream signaling proteins after injection of EVs in correlation to enriched proteins
found inside the EVs.
5.4 CONCLUSION
The in vitro tubule formation and cardiac spheroid contraction assays validate the
therapeutic potential of MSC-EVs optimized in Aim 1. The preliminary large animal study
results presented here demonstrate that delivery of MSC-EVs from hydrogels decrease
infarct size as determined by electroanatomical mapping; however, ongoing studies need
to be completed (e.g., CMR segmentation, histology) to increase sample sizes and make
any conclusions regarding functional and structural outcomes. Based on our scale-up and
EV characterization studies in Aim 1, we were able to deliver a high dose (1e12
particles/mL) of MSC-EVs per animal via encapsulation of MSC-EVs within our injectable
hydrogel, which likely prevented washout and maintained local concentration of EVs in the
infarct area. MSC-EVs are uniquely advantageous as they are acellular, nonimmunogenic, non-arrhythmogenic, and non-tumorigenic and furthermore, can be
prepared as an off-the-shelf therapy. However, fundamental knowledge of EV biology is
scarce and more basic research is required to understand the bioactive components of
EVs that make them potent.
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CHAPTER 6
INFLUENCE OF CONTROLLED EV RELEASE KINETICS ON MI THERAPEUTICS

6.1 INTRODUCTION
The most common mode of EV delivery to injured tissues is the direct injection of
EV suspensions in saline; however, this results in the rapid clearance of EVs from the
injury site, with up to 90% of particles washing away.1 In some cases, repeated EV
injections are used to obtain therapeutic doses locally. As an alternative, biomaterials are
being developed to locally deliver EVs to overcome the low retention rates of bolus
injections of EVs, mostly commonly through EV encapsulation and release.1
Towards the treatment of MI, our group and others have released EVs from
functionalized biomaterials that have maintained EV stability and augmented therapeutic
potency by recruiting endogenous stem or immune cells, providing a mechanically and
chemically

favorable

environment

for

regeneration,

and

promoting

tissue

vascularization.1–3 However, there are numerous parameters to consider in the design of
biomaterials for EV delivery, such as the mode of delivery and kinetics of EV release. Liu
et al. showed that the release of EVs from a patch placed on the heart over the course of
weeks allowed for continuous and direct treatment of the infarct area through the acute
and subacute phases of MI and recovery.4 As another example, Chen et al. encapsulated
adipose stem cell derived EVs that overexpressed miR-375 for osteogenic differentiation
within hydrogels and showed ~30% release of the encapsulated EVs within the first day
and complete release by day 14.5
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Despite these advances, there has been little investigation to probe the importance
of EV release kinetics on their therapeutic benefits, particularly to later times after a few
weeks. To address this, we look towards the engineering of hydrogels, such as extending
EV release form the guest-host (GH) hydrogel explored in Aim 2. Specifically, we
investigated the design of an interpenetrating network (IPN) injectable hydrogel to extend
MSC-EV release, particularly through the addition of a secondary network comprised of
gelatin crosslinked with microbial transglutaminase (mTGase) to the GH hydrogel.6 The
secondary network offers enhanced mechanical and degradation properties while
maintaining injectability to study the therapeutic benefit of extended delivery of MSC-EVs.
One of the major challenges in these types of studies is the tracking of the release
and biodistribution of EVs in vivo. Currently, only a few labeling technologies have been
developed for EV studies including CD63, an EV marker tagged with GFP, and lipophilic
membrane dyes - although simple, lipophilic membrane dyes, such as PKH67, quickly
diffuse out of the membrane and form aggregates, leading to false positive results.7 In
order to overcome this, we have utilized a highly versatile metabolic labeling approach to
label and functionalize extracellular proteins.8 Specifically, we use residue-specific protein
and glycan labeling that incorporate non-canonical amino acids and sugars into newly
synthesized proteins and glycans to label and engineer EVs. Since EVs are formed inside
cells in multivesicular bodies, a variety of membrane fusion and transport proteins (CD63,
lysosomal protein Lamp2b, and annexin) are integrated into EVs during formation and
secretion.7 We used previously established methods of metabolic labeling whereby Lazidohomoalanine (AHA), an azide-bearing amino acid analogue of methionine, or Nazidoacetylmannosamine-tetraacylated (Ac4ManNAz), an unnatural azido-containing
monosaccharide building block, were incorporated in newly synthesized proteins and
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glycans inside EVs.

7

The incorporation of AHA or Ac4ManNaz introduces unnatural

azides into EVs, providing chemically active sites for biorthogonal click conjugation via a
DBCO-containing fluorescent dye.
In this Aim, we designed an IPN hydrogel to extend delivery of MSC-EVs and used
metabolically labeled MSC-EVs to monitor release. This work will result in a better
understanding of whether the extended release of MSC-EVs improves functional
outcomes (i.e, ejection fraction) in a rat MI model.

6.2 METHODS
6.2.1 MSC-EV ISOLATION
Rat mesenchymal stromal cells (SCR027, Lot: 3426508) were purchased from
EMD Millipore Corp and expanded to passage 4. Gelatin-coated microcarriers (160-200
µm C-221-050 Pall SoloHill) were purchased from Sartorius and disposable polystyrene,
non-treated spinner flasks (CLS3153) were purchased from Corning. Cell culture media
was prepared using Alpha Minimum Essential Medium (Millipore M4526), 1%
penicillin/streptomycin, 1% GlutaMAX supplement (Invitrogen 35050061), 10% FBS, and
1 ng/mL bFGF-2 (Millipore GF003).
Microcarrier stock was prepared by autoclaving microcarriers in distilled water at
121°C for 30 minutes after which the distilled water was aspirated using a serological
pipette and media added to the microcarriers to allow them to acclimate for 30 minutes.
After P4 MSCs reached 80% confluence, cells were lifted using 0.05% Trypsin and
counted. Microcarriers were added to the spinner flask at a density of 27.8 mg/ml (15 cm2
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surface area/mL) and mixed with the cell slurry (0.2e6 cells/ml) using FBS-free cell culture
media, resulting in a cell seeding density of 20,000 cells/cm2. The spinner flask was placed
inside the cell culture incubator on a stir plate with the impeller rotating at 50 rpm. After 2
hours, FBS was supplemented to the media. On Day 4, the cell culture media was
switched to FBS-free medium for 72 hours after which conditioned medium was collected.
MSC-EVs were isolated from conditioned medium using differential ultracentrifugation,
whereby two 10-minute spins were done at 200 x g to remove cellular debris, two 10minute spins were done at 500 x g to remove apoptotic bodies, one 30-minute spin at
10,000 x g was done to remove microvesicles, and a last centrifugation step of 100,000 x
g for 65 minutes was used to isolate the EV pellet as previously described.
6.2.2 MSC-EV METABOLIC LABELING
For metabolic labeling, MSCs were cultured as previously described; however, the
media was switched to FBS-, glutamine-, methionine- and cystine-free high-glucose
DMEM (Life Technologies) supplemented with 0.201 mM cystine, 100 μg/ml sodium
pyruvate, 1% Glutamax, 50 μg/ml ascorbate 2-phosphate, 1% penicillin/streptomycin, and
75 µM Ac4ManNAz (1084-5, Click Chemistry Tools) or 50 µM L-azidohomoalanine (AHA)
(1066-25, Click Chemistry Tools) for 72 hours after which MSC-EVs were isolated as
previously described. After EV isolations, the EVs re-suspended in PBS (~1011
particles/mL) were incubated with a DBCO-Cy3 (A140-1, Click Chemistry Tools) or DBCOCy7 dye (480µM final concentration) for two hours at room temperature in the dark. After
labeling, excess dye was removed from the solution using exosome spin columns
(MW3000, 4484449, Invitrogen) as per the manufacturer’s instructions.
6.2.3 MSC-EV SIZE, DISTRIBUTION, CONCENTRATION CHARACTERIZATION
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EVs suspended in PBS were analyze via nanoparticle tracking analysis (NTA) to
determine EV size, size distribution, concentration, and surface Zeta Potential using
ZetaView® QUATT– NTA Nanoparticle Tracking - Video Microscope PMX-420 (Particle
Metrix GmBH, Inning am Ammersee, Germany) at the Extracellular Vesicle Core at Penn
Veterinary School. Metabolically labeled MSC-EV fluorescence was assessed using the
ZetaView PMX-420 Laser at 488 nm wavelength.
6.2.4 IPSC-CARDIOMYOCYTE UPTAKE:
Human iPSC-CMs were purchased from Fujifilm Cellular Dynamics (iCell 01434
(Donor A), purity >97%). Cardiomyocytes were cultured in iCell plating medium (Cellular
Dynamics) on gelatin-coated coverslips placed inside 12-well plates to optimize postthawing survival of the iPSC-CMs. After four hours, cardiomyocytes were maintained in
iCell maintenance media (Cellular Dynamics). Metabolically-labeled MSC-EVs were
added to the cell culture medium for 2 hours. Cells were then fixed in 4% PFA for 18
minutes at room temperature, blocked with 2% BSA for 30 minutes, permeabilized with
0.1% Triton-X for 20 minutes followed by incubation with cardiac troponin-t (cTnT)
(Thermofisher MA5-12960, 1:200) antibody for 2 hours. The coverslips were then mounted
with Gold Antifade Mounting Medium and imaged using an SP5 Leica Confocal
Microscope.
6.2.5. MSC-EV TEM CHARACTERIZATION
MSC-EV samples were resuspended in PBS for imaging by Perelman School of
Medicine Electron Microscopy Core, including: MSC-EVs cultured in normal medium
conditions, MSC-EVs cultured with 75 µM Ac4ManNAz, MSC-EVs cultured with 75 µM
Ac4ManNAz and labeled with DBCO-Cy3 dye, and MSC-EVs cultured with 75 µM
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Ac4ManNAz and labeled with DBCO-Cy7 dye. Briefly, the EV samples were fixed 1:1 with
2% glutaraldehyde (v/v; Sigma Aldrich, Saint Louis, MO) for 30 min. A fixed sample of 6
µL was pipetted onto a 200 mesh copper grid with carbon-coated formvar film (Electron
Microscopy Sciences, Hatfield, PA), and incubated for 10 min. Excess liquid was removed
by blotting. The grid was washed twice with 100 µL MilliQ water, followed by blotting to
remove excess liquid. Samples were imaged using FEI T12 TEM.
6.2.6 HYDROGEL PREPARATION
6.2.6.1 GUEST HOST HYDROGEL
Hyaluronic acid (HA) was modified with either b-cyclodextrin (CD, host, 27% of
disaccharide repeats) or adamantane (Ad, guest, 22% of disaccharide repeats) to form
CD-HA and Ad-HA, respectively, and assembled through supramolecular hydrophobic
interactions to form hydrogels that are shear-thinning and self-healing, based on
previously described methods.6 Dry powder Ad-HA and CD-HA were dissolved separately
in PBS at 5 weight% inside microcentrifuge tubes. Hydrogels were then assembled by
pipetting 50 µL of each component in the back of a ½ mL 27”G tuberculin syringe and
mixed by pushing the plunger up and down 50 times. For GH+EV groups, CD-HA was
dissolved in a PBS solution containing 2e12 particles/mL and assembled as previously
described.
6.2.6.2 INTERPENETRATING NETWORK (IPN) HYDROGEL
IPN hydrogels were prepared by dissolving CD-HA in PBS containing 1 Unit of
microbial transglutaminase (mTgase) (T001, Zedira Gmbh) and Ad-HA in 10 wt% gelatin
solution. Hydrogels were then assembled by pipetting 50 µL of each component in the
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back of a ½ mL 27”G tuberculin syringe and mixed by pushing the plunger up and down
50 times. For IPN+EV groups, CD-HA was dissolved in a PBS+mTGase solution
containing 2e12 particles/mL and assembled as previously described.
6.2.6.3 MECHANICAL PROPERTIES
Measurements were performed using an AR2000 stress-controlled rheometer (TA
Instruments) fitted with a 20 mm diameter stainless steel plate geometry, 59 min 42 s cone
angle, and 27 μm gap. Rheological properties were examined by time sweeps (1.0 Hz;
0.5% strain). For shear recovery experiments, high 500% strain was applied with recovery
at 0.5% strain, each at 1 Hz. To evaluate shear-thinning, material responses to shear were
examined in continuous flow experiments with a linearly ramped shear rate from 1 to 100
s−1.
6.2.7 ANIMAL CARE AND BIOSAFETY
Adult male Wistar rats (250-300 g) were obtained from Charles River Laboratories,
Inc. Food and water were provided ad libitum. This investigation adhered to the National
Institutes of Health guidelines on animal care and use, conformed to institutional ethical
review, and was approved by the University of Pennsylvania Institutional Animal Care and
Use Committee (Protocol 803394). All measurements were performed by 2 independent
investigators blinded to animal treatment conditions.
6.2.8 HYDROGEL BIODISTRIBUTION STUDY WITH HEALTHY RODENT MODEL
The GH and IPN hydrogels were labelled with a near-infrared fluorescent molecule
through a Michael addition between a thiolated Cy7.5 dye and methacrylated CD–HA
(CD–Me–HA). Cy7.5-labelled CD–HA was then assembled into GH and IPN hydrogels.
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100 ul (five 20 µL injections) of either GH or IPN hydrogel (n=5 each) was then injected to
the hearts of healthy adult Wistar rats weighing 350-400 g after induction with 5%
isofluorane, endotracheal intubation, mechanical ventilation with 1-3% isoflurane and left
thoracotomy at the 4th intercostal space. On days 1,7 and 14, the rats were sacrificed and
the heart, liver, lungs, kidneys, and spleen were explanted and imaged using a Perkin
Elmer IVIS Spectrum at an excitation filter of 745 nm and emission filter for indocyanine
green with pre-prepared hydrogel and non-labeled tissue used as controls. The radiant
efficiency (photons s−1 cm−2 steradian−1 per μW cm−2) was then quantified using Perkin
Elmer Living Image Software.
6.2.9 MSC-EV BIODISTRIBUTION STUDY WITH HEALTHY RODENT MODEL
MSC-EVs were metabolically labeled and purified based on methods described in
section 6.2.2. Metabolically labeled MSCs were encapsulated in either PBS, GH or IPN
hydrogels and injected into healthy hearts of adult Wistar rats as described in 6.2.9. On
days 1, 7, and 14, the rats were sacrified and the heart, liver, lungs, kidneys, and spleen
were explanted and imaged using a Perkin Elmer IVIS Spectrum at an excitation filter of
745 nm and emission filter for indocyanine green with pre-prepared hydrogel and nonlabeled tissue used as controls. The radiant efficiency (photons s−1 cm−2 steradian−1 per
μW cm−2) was then quantified using Perkin Elmer Living Image Software.
6.2.10 RODENT MODEL OF ISCHEMIA REPERFUSION INJURY (IRI)
Adult Wistar rats weighing 350-400 g underwent induction with 5% isoflurane,
endotracheal intubation, mechanical ventilation with 1-3% isoflurane to maintain surgical
anesthesia depth, left thoracotomy at the 4th intercostal space, and ligation of the left
anterior descending artery (LAD) 1 mm below the left atrial appendage with a 7-0 prolene
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suture. Successful ligation was confirmed by visualizing blanching of ~30% of the left
ventricle. The 7-0 suture was cut after one hour of ischemia to enable reperfusion. Upon
reperfusion, rats received five 20 µL injections into the MI border zone one of the following:
phosphate buffered solution (PBS), GH hydrogel, IPN hydrogel, PBS+MSC-EVs,
GH+EVs, IPN+EVs, or nothing (Sham). Rats were then surgically closed, extubated, and
recovered. Rats were assessed four weeks later via hemodynamic assessments from
echocardiogram

and

pressure-volume

loops,

as

well

as

histology

and

immunohistochemistry.
6.2.11 ECHOCARDIOGRAPHY
After 4 weeks, transthoracic echocardiography was performed to assess
myocardial function (Sonos 5500 revD system with S12 probe, 12 mHz, 2 cm penetration
depth, Philips Healthcare). Technicians were blinded to study conditions. Ventricular
measurements were performed according to the American Society of Echocardiography
leading-edge method. Parasternal long axis imaging was performed to calculate LVESV
and LVEDV volumes which were used to calculate stroke volume (SV) and ejection
fraction (EF). Short axis imaging on M-Mode was performed to calculate fractional
shortening (FS).
6.2.12 PRESSURE-VOLUME LOOPS
A pressure-volume catheter (Model Number: FTH-1912B-6018, Transonic
Scisence Inc, Canada) was inserted into the left ventricle in a retrograde fashion via the
right common carotid artery for analysis of ventricular function. In addition to steady- state
hemodynamic parameters (maximum pressure, dP/dt max), contractility was determined
from pressure-volume relationships obtained by reducing preload via occlusion of the
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inferior vena cava. Finally, a sternotomy was performed, blood was collected from the
heart using a 16-G needle, and the heart was dissected.
6.2.13 HISTOLOGY
At four weeks after analysis of global ventricular function, hearts were explanted,
flushed with PBS, placed into 10% formalin containing tubes for fixation overnight at 4°C.
After dehydration steps using 15% and 30% sucrose solutions for 24 hours each at 4°C,
the hearts were distended with optimal cutting temperature embedding compound (OCT,
Tissue-Tek, Sakura Finetek USA, Inc) and frozen in OCT at −80°C. Sections (10 μm thick)
were prepared from each heart using a cryostat to section along the short axis of the
myocardium. Sections at the mid-papillary level were stained with Masson's trichrome
(Accustain Trichrome Stains Kit) according to manufacturer instructions. Sections were
imaged and analyzed with a custom MATLAB code to assess scar fraction.
6.2.13 IMMUNOHISTOCHEMISTRY
Sections at the mid-papillary level were thawed and air dried for 60 minutes at
room temperature and then heated to 37°C for 30 minutes. Antigen Retrieval buffer was
prepared by diluting Antigen Retrieval Reagent-Universal (Catalog # CTS015, RD
Systems Inc, Tustin, CA) 1 in 10 in distilled water. Glass coplin jars were filled with room
temperature antigen retrieval buffer, slides placed gently inside the jars and microwaved
for one minute. Slides were then dried and tissue sections surrounded with a hydrophobic
barrier using a pap pen. Sections were blocked with 3% horse serum in PBS for 30
minutes. Primary antibodies included sheep anti–von Willebrand (vWF, ab6994, Abcam)
and rabbit Alexa Fluor® 594 anti-alpha smooth muscle actin antibody [1A4] (alphaSMA,
ab202368, Abcam), and Wheat Germ Agglutinin (WGA) Alexa Fluor™ 647 Conjugate
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(ThermoFisher). Primary antibodies were diluted in incubation buffer (1% bovine serum
albumin, 1% normal donkey serum, 0.3% Triton® X-100, and 0.01% sodium azide in PBS)
at the following ratios: vWF 1:400, alphaSMA 1:400, WGA 1:300 and incubated at 4°C
overnight. The slides were washed three times for 15 minutes with PBS. Secondary
antibody (Goat Anti-Rabbit IgG H&L Alexa Fluor® 488, ab150077, Abcam) was diluted at
a ratio of 1:400 and incubated at room temperature for 60 minutes. Samples were then
washed three times with PBS and mounted with a gold anti-fade mounting medium with
DAPI (P36935, Invitrogen, Waltham, MA). Samples were imaged at 10x on a Leica SP5
confocal microscope and analyzed using ImageJ (NIH).

6.3 RESULTS AND DISCUSSION
6.3.1 DESIGN OF INTERPENETRATING NETWORK HYDROGEL

Figure 6.1: Design of an interpenetrating network hydrogel. Schematic of the IPN comprised
of a supramolecular network (Guest-Host) and a covalent network (gelatin crosslinked by
transglutaminase).
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An injectable IPN hydrogel was designed to extend MSC-EV release and
circumvent the need to inject multiple doses of EVs at different time points (Figure 6.1).
This design builds on our existing hydrogel comprised of HA crosslinked via GH
interactions and adds a secondary covalent network consisting of gelatin crosslinked by
mTGase. The incorporation of this secondary network is meant to slow the erosion of the
hydrogels and to reduce the rate at which EVs can be released.
The rheological properties of GH and IPN hydrogels were characterized across
numerous experiments (Figure 6.2). First, gelation kinetics of GH and IPN hydrogels was
characterized by preparing hydrogels via mixing macromers and measuring rheological
properties via shear-oscillatory rheometry. Figure 6.2A demonstrates the immediate
gelation after mixing due to rapid physical GH bonds but increasing storage modulus over
time due to time-dependent covalent crosslinking of gelatin via mTGase. The gelation
kinetics was slow, with storage modulus reaching a plateau around two hours after mixing.
Both GH and IPN hydrogels exhibited shear- thinning (Figure 6.2B) and self-healing
(Figure 6.2C) properties within 15 minutes after mixing, demonstrating injectability during
this window. Additionally, the storage modulus was tunable by changing both the gelatin
and mTGase concentrations, as these would alter the crosslink density of the material
(Figure 6.2D and E). Based on rheological properties and operator assessments of
injectability, one formulation was selected of 4.5 wt% GH+ 5% Gelatin (100 bloom)
crosslinked by 10 U/mL mtGase and used in further analyses.
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Figure 6.2. Mechanical properties of GH and IPN hydrogels. A) Time sweeps (0.5%
strain, 1 Hz) of GH (4.5 wt%) and IPN (4.5 wt% GH + 5 wt% Gelatin, 10 U/mL mTGase)
hydrogels demonstrating immediate gelation after mixing due to immediate physical
interactions due to Guest-Host bonds but increasing mechanical properties due to timedependent crosslinking of gelatin via transglutaminase. B) Viscosity vs. shear-rate
demonstrating the injectability of GH and IPN hydrogels within 15 minutes after mixing. C)
Application of cyclic strains (0.5% and 500%) demonstrating that both hydrogels recover
between strain cycles and are self-healing properties. Storage modulus (G’) of IPN
hydrogels with D) increasing gelatin concentration (wt%) and E) increasing mTGase
concentration. Mean ± SD.

Rather than characterizing hydrogel degradation in an in vitro setting, particularly
as in vitro and in vivo degradation can be quite different, we looked to characterize this in
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the physiological cardiac environment in vivo. To do this, we conjugated a near-IR dye to
the CD-HA molecules, so that it could be included in the GH network in both the GH
hydrogel alone and the IPN hydrogel. Labelled hydrogels were injected into healthy rat
hearts and then explanted 1, 7, or 14 days after injection and imaged using an IVIS Lumina
(Figure 6.3A). We observed that GH hydrogels were retained in hearts for at least up to
7 days with a 60% decrease in radiant efficiency; however, by day 14, there was little or
no signal remaining in this group, indicating that GH hydrogels were mostly degraded. On
the other hand, 80% of IPN hydrogels remained within hearts by Day 7, with signals still
visible in this group for up to 14 days (Figure 6.3B and C). These results are consistent
with previous degradation and release assays for GH hydrogels published by our group,
showing hydrogel erosion in vitro and in vivo over 7 and 14 days, respectively,9 and now
illustrate the ability to attenuate degradation with the introduction of an additional network.
This provides the first confirmation that IPN hydrogels may extend the presence of
biomaterial in the heart. It should be noted though that one of the limitations of this study
is that healthy rats were used instead of rat MI models.
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Figure 6.3: Hydrogel Retention after Injection. A) Schematic describing study design for
hydrogel retention, where injections were performed at different times and then all harvested for
imaging at the same timepoint. B) Representative In Vivo Imaging System (IVIS) images and C)
quantification of radiant efficiency for Near-IR labeled Guest-Host (GH) and Interpenetrating
Network (IPN) hydrogels injected into healthy rat myocardium 1, 7, and 14 days prior to
harvesting. Mean ± SD. One-way ANOVA with Tukey multiple comparisons test where ns = not
significant *p<0.05

6.3.2 METABOLIC LABELING OF MSC-EVS
In addition to the labeling of the hydrogel, we sought to label EVs to better assess
their retention in the heart as a therapeutic. Due to challenges in the field with stable EV
label protocols, we looked towards the metabolic labeling of MSC-EVs via bio-orthogonal
click conjugation. Lee et al. assessed EV labeling using different acetylated unnatural
azido sugar molecules and concluded that 50 μM of Ac4ManNaz included in the cell
culture media for breast cancer cells resulted in 15% EV labeling yield.10 Another group
showed that AHA- and Ac4ManNaz- metabolized EVs conjugated to aldehyde-containing
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beads showed increased fluorescent signal and stained positive for CD63 using flow
cytometry.7
With this approach, as illustrated in Figure 6.4A, azide groups are incorporated
into molecules within EVs that can be conjugated to a dye for visualization. We
investigated the fluorescent labeling efficiency and yield using 75 µM Ac4ManNaz label
sugars in MSC-EVs10 to and 100 µM AHA to label proteins in MSC-EVs7 (Figure 6.4B)
based on previous concentrations used in the literature.8 When quantified, we observed
that 75 µM Ac4ManNaz resulted in a higher yield of MSC-EVs as well as higher fluorescent
labeling efficiency (Figure 6.4C and D). Therefore, 75 µM Ac4ManNaz was used for
metabolic labeling of MSC-EVs for the rest of this study.
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Figure 6.4 Metabolic Labeling: A) Schematic describing the metabolic labeling method for MSCEVs. B) Size distribution of Rat MSC-EVs of following groups: Control Group with no AHA or
Ac4ManNAz in cell culture media, Control Group with addition of DBCO-containing dye, MSCEVs that contained 75 μM Ac4ManNAz and clicked with DBCO-containing Cy3 dye, and MSCEVs that contained 100 μM AHA and clicked with DBCO-containing Cy3 dye. C) Total MSC-EV
particles obtained from each isolation D) % Fluorescence measured in each group. Mean ± SD.
One-way ANOVA with Tukey multiple comparisons test where ns = not significant *p<0.05
***p<0.005 ****p<0.0001

Using 75 µM Ac4ManNaz concentration in cell culture media for EV collection over
72 hours resulted in 25% of the secreted EVs expressing fluorescent signal (Figure 6.5A).
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The Zeta Potential of the MSC-EVs after incorporation of 75 µM azide-containing
Ac4ManNaz and conjugation of DBCO-containing dyes significantly decreased as
compared to controls. However, this is expected due to negative charges contained in the
DBCO-containing Cy3 and Cy7 dyes (Figure 6.5B). To ensure that labeled MSC-EVs
were still taken up by cells, the fluorescently labeled MSC-EVs were added to iPSCcardiomyocytes for 4 hours and subsequently imaged through confocal microscopy,
demonstrating that the fluorescently labeled MSC-EVs were taken up (Figure 6.6).
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Figure 6.5. Metabolically-labeled MSC-EV NTA and Zeta Potential. A) Characterization of
EV particle distribution, and labeling efficiency on NTA with 75 μM Ac4ManNAz added to the
cell culture media of rat MSCs over EV collection period, demonstrating 25% labeling efficienct
B) Zeta Potential of MSC-EVs of following groups: Control, 75 μM Ac4ManNAz with no dye, 75
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One-way ANOVA with Tukey multiple comparisons test where ns = not significant *p<0.05
****p<0.001
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Figure 6.6. Metabolically-labeled MSC-EV uptake: iPSC-derived Cardiomyocytes stained with
Troponin (gray) take up fluorescently labeled MSC-EVs (red).

We then performed transmission electron microscopy (TEM), which is the most
common type of EV imaging, on rat MSC-EVs to assess quality, stability, and purity of the
produced EVs. (Figure 6.7). We were able to confirm that no large clusters/aggregates
were formed during the isolation process and that most host cell debris/impurities were
removed. We further confirmed the integrity and morphology of the MSC-EVs as
evidenced by the presence of intact phospholipid bilayer membrane, circularity, and size

Figure 6.7. EV Morphology: TEM Characterization of control, metabolically-labeled MSC-EVs,
and metabolically-labeled MSC-EVs with dyes conjugated.
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distribution consistent with the size distributions as demonstrated by the NTA results.
Qualitatively, there were no differences in these parameters across groups.
6.3.3 MSC-EV RETENTION IN A RAT MODEL
After labeling of the EVs with near-IR fluorophores, we were able to assess their
retention and release into cardiac tissue. Labeled EVs suspended in PBS, GH hydrogel
or IPN hydrogel were injected into healthy rat hearts in vivo and explanted 1, 7, and 14
days after injection for visualization, similar to the study on labeled hydrogel retention
(Figure 6.8). Saline injection of EVs resulted in no signal retention even within 24 hours,
whereas GH hydrogels retained ~ 90% of MSC-EV signals by 7 days and complete signal
loss was observed by 14 days. Importantly, IPN hydrogels retained ~70% of their MSCEV signal by day 7 and ~10% by day 14, indicating the greater retention of EVs in vivo
with the IPN hydrogel. To our knowledge, this is the first study demonstrating the in vivo
release of metabolically-labeled EVs over time. However, similar to the hydrogel retention
study outlined above, this study was performed with healthy rats, limiting the
generalizability of the results to infarct models.
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Figure 6.8. Metabolically-labeled MSC-EV retention from GH and IPN hydrogels: A)
Representative IVIS imaging and B) quantification of radiant intensity of near-IR labelled MSCEVs in healthy rat hearts when delivered from PBS, GH hydrogel or IPN hydrogel. Mean ± SD.
One-way ANOVA with Tukey multiple comparisons test where ns = not significant *p<0.05
***p<0.005

6.3.4 THERAPEUTIC EFFICACY OF MSC-EVS DELIVERED FROM GH AND IPN
HYDROGELS IN A RAT MODEL OF MI
In order to assess the therapeutic efficacy of MSC-EVs, we created a 60-min
ischemia/reperfusion (I/R) model in rats and assessed the functional and histological
outcomes in the following control and experimental groups at 4 weeks (n=10 each): sham
(no MI), PBS, PBS+EVs, GH hydrogel, GH+EVs, IPN hydrogel, IPN+EVs. Figure 6.9
reports the functional outcomes, including Left Ventricular Ejection Fraction (LVEF),
Cardiac Contractility (dP/dt Max), Stroke Work (SW), End Systolic Elastance (ESPVR),
LV End Diastolic Volume (LVEDV), and Cardiac Relaxation (dP/dt Min) using a PressureVolume catheter. The study included 136 Wistar rats where 38 animals were lost due to
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mortality associated with I/R or surgical complications, 14 rats were retrospectively
excluded due to Masson’s Trichrome staining showing no infarct after terminal timepoint,
and 13 animals were excluded due to the inability to obtain high quality hemodynamic
measurements, which left 71 animals for hemodynamic and histological analyses.
Unfortunately, PV loop analyses demonstrated that the 60-minute ischemia reperfusion
injury did not result in statistically significant differences in any functional outcomes
between sham (no I/R) and I/R (PBS) groups, except for left ventricular relaxation (dP/dt
min) at 4 weeks. This is likely due to the large variability observed within each group,
potentially due to variance in infarct size as well as the challenges regarding the sensitivity
of measurements taken via the catheter system.
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Figure 6.9. Functional Outcomes in a Rat Ischemia/Reperfusion Model. PV loop analysis of
ejection fraction (A), stroke work (B), LVEDP (C), ESPVR (D), dP/dt max (E), and dP/dt min (F)
for the various control and treatment gropus. There were no statistically significant differences
in functional outcomes between sham and I/R or any of the experimental groups at week 4,
except for some differences in cardiac contractility (dP/dt max) and relaxation (dP/dt min). Mean
± SD. One-way ANOVA with Tukey multiple comparisons test where *p<0.05 **p<0.005
***p<0.001, not significant unless specified. EF: ejection fraction, LVEDP: left ventricular end
diastolic pressure, ESPVR: end systolic pressure volume relationship, dP/dt max: left ventricular
contractility, dP/dt min: left ventricular relaxation.

Figure 6.10 demonstrates the images of tissue sections taken from the midpapillary level of all rats from all treatment groups after staining with Masson’s Trichrome.
As expected, sham rats had no collagen scar while all the other animals included in the
analysis for the I/R groups had collagen scar stained with blue. Scar thickness (Figure
6.11A) and size (Figure 6.11B) varied widely within groups, making it difficult to detect
statistically significant differences between them. However, there were trends towards
some improvement in scar thickness in all treatment groups.
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Figure 6.10 Histological Outcomes in a Rat Ischemia/Reperfusion Model. Masson’s
Trichrome staining of tissue sections taken from mid-papillary level. Red represents healthy
tissue while blue represents collagen deposited due to scar formation. EVs: Extracellular
Vesicles, GH: Guest-Host Hydrogel, IPN: Interpenetrating Network Hydrogel.
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Figure 6.11 Quantification of scar thickness and scar area. Normalized scar thickness (A)
quantified as the ratio of left ventricular wall thickness to septal thickness as determined by
MATLAB analysis pixel quantification of tissue sections stained with Masson’s Trichrome.
Normalized scar area (B) is quantified as the percentage of collagen scar staining (blue) as
compared to the whole left ventricular area as determined by MATLAB pixel quantification. of as
Mean ± SD. One-way ANOVA with Tukey multiple comparisons test. Ns: not significant.

While we were unable to detect any hemodynamic or histological differences for
any of the treatment groups, there were variations in the density and size of vascular
structures. We performed immunohistochemical staining for vascular structures probing
for von Willebrand Factor (vWF), an endothelial cell marker, and alpha Smooth Muscle
Actin (αSMA), which is expressed by smooth muscle cells. This is a commonly performed
staining protocol to assess microvessel density and neovascularization.11 While vWF is
present in the lumens of most vascular structures ranging from capillaries to arteries,
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αSMA is generally only present in more mature vascular structures such as arterioles and
arteries. Representative images from immunohistochemistry staining in infarct and remote
regions are demonstrated in Figure 6.12.

Figure 6.12. Images of Vascular Structures. Representative images of staining for vascular
structures in the infarct (a-f) and remote (g-l) regions after delivery of PBS (a, g), PBS+EVs (b,
h), GH (c, i), GH+EVs (d, j), DN (e, k), DN+EVs (f, l) GH: Guest-Host Hydrogel, EVs:
extracellular vesicles, vWF: von Willebrand Factor, αSMA: alpha Smooth Muscle Actin, WGA:
wheat germ agglutinin.

Quantification of the number and size of vascular structures is shown in Figure
6.13. Increased numbers and areas of vWF- and αSMA-positive structures were observed
in the IPN+EVs group; however, there were also some trends towards improvement in
both number and area of vascular structures in GH+EVs group. Interestingly, GH and
GH+EVs groups exhibited vascular structures that were larger on average, while IPN and
IPN+EVs groups displayed higher numbers of vessels but that were smaller in diameter.
This is an interesting finding that can be related to the extension of delivery over 14 days
or the presence of gelatin in the IPN groups as gelatin contains RGD motifs, which have
been shown to increase cell infiltration for tissue engineering applications.12
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Figure 6.13. Quantification of Vascular Structures. Number (A), total area (B), and median
perimeter (C) of vascular structures based on ImageJ Analysis of vWF and αSMA double
positive staining. Mean ± SD. One-way ANOVA with Tukey multiple comparisons test where
*p<0.05 **p<0.005 not significant unless specified.

Taken together, these results suggest that intramyocardial MSC-EV delivery to the
infarct zone may impact the size and density of vascular structures in the infarct region
due to microvascular changes initiated post-I/R. The extended delivery of MSC-EVs via
injectable hydrogels improved both the number and the density of these structures.

6.4 CONCLUSION
Our results successfully demonstrate an effective labeling strategy of MSC-EVs
with incorporation of azide-containing monosaccharide building blocks in the cell culture
media and subsequent click-conjugation with a DBCO-containing dye. These EVs were
successfully visualized both in vitro and on explanted tissue after injection in vivo. This
biorthogonal labeling strategy can be used to further functionalize EVs by loading
therapeutic cargos such as small molecules and proteins or conjugating targeting ligands
for targeted delivery. Further, we designed and implemented two different EV
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encapsulation methods to retain MSC-EVs in the infarct environment for different time
periods. We also successfully demonstrated that extended MSC-EV delivery through an
IPN hydrogel augments vascularization in the infarct zone. Our group and others
previously investigated and highlighted the importance of injection time in addition to
retention for EPC-EVs.3 Future studies should focus on investigating multiple time points
for injection and release to understand the optimum timing and release for MSC-EVs in
MI models.
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CHAPTER 7
IMAGING OF INJECTABLE HYDROGELS AND TISSUE RESPONSE IN LARGE
ANIMAL MODELS OF MI
Adapted from:
Uman, S., Wang L.L., Thorn S.L., Liu Z., Duncan J.S., Sinusas A.J., Burdick J.A. Imaging
of Injectable Hydrogels Delivered into Myocardium with SPECT/CT. Adv. Healthc. Mater.
9, 2000294, (2020).
Dong, Y.C., Bouché, M., Uman, S., Burdick, J.A., Cormode, D.P. Detecting and Monitoring
Hydrogels with Medical Imaging. ACS Biomater. Sci. Eng. 7, 4027–4047 (2021).
Midgett, D.E., Thorn, S.L., Ahn, S.S., Uman, S., Avendano, R., Melvinsdottir, I., […]
Burdick, J.A., Sinusas, A.J. CineCT platform for in vivo and ex vivo measurement of 3D
high resolution Lagrangian strains in the left ventricle following myocardial infarction and
intramyocardial delivery of theranostic hydrogel. J. Mol. Cell. Cardiol. 166, 74–90 (2022).

7.1 INTRODUCTION
Hydrogels are water-swollen three-dimensional hydrophilic polymeric networks
that have found utility across many fields.1,2 In the past decades, hydrogels have become
increasingly important in diverse biomedical applications, such as drug delivery and tissue
engineering, due to their unique characteristics, such as high water content, tunable
properties, controllable degradation, and their potential responsiveness to extrinsic
signals.3–5 Hydrogels are fabricated by numerous polymerization and crosslinking
strategies to form polymeric networks6 and are generally classified into two categories
based on the nature of their crosslinking, namely physically or chemically crosslinked
hydrogels.7,8 Of these, physically crosslinked hydrogels are assembled through noncovalent crosslinking (e.g., ionic interactions, hydrogen bonding),
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6,9

whereas chemically

crosslinked hydrogels are crosslinked with covalent bonds.10,11 The crosslinks can be
designed to be reversible to enable shear-thinning properties, which can be advantageous
in biomedical applications.12,13
Owing to these unique characteristics, hydrogels can be designed for minimallyinvasive delivery to a tissue site of interest, where accurate localization and monitoring of
the hydrogel are of great importance.

3,14,15

Additionally, the in vivo degradation of

hydrogels can play an important role in achieving desired therapeutic outcomes.16 Thus,
the ability to image hydrogels is useful to confirm that they have been successfully
administered to the target site and in the correct quantity, as well as to monitor the
hydrogel erosion over time, which is in contrast to the traditional sacrifice of animals at
each timepoint to monitor residual hydrogel in vivo.17,18 To directly image hydrogels in vivo,
they can be rendered imageable with various medical imaging modalities by using
intrinsically imageable polymers during hydrogel formation or by functionalizing hydrogels
with contrast-generating materials through physical loading or chemical grafting. 19,20
To date, multiple imaging modalities have been used to detect and monitor
hydrogels in tissues, with each of them having their own advantages and limitations (Table
7.1).

21–26

For example, CT is one of the most widely used clinical imaging modalities,

where computerized X-ray imaging is used to produce three-dimensional, anatomic
images with high spatial and temporal resolution.27 To distinguish hydrogels from the
surrounding soft tissues in CT, heavy element-based X-ray contrast agents, such as
iodinated molecules or gold nanoparticles (AuNP), are incorporated into the hydrogel to
impart radiopacity.28 While other X-ray based imaging modalities such as conventional
radiography, spectral photon-counting computed tomography (SPCCT), mammography,
and fluoroscopy would offer similar benefits to utilizing radiopaque hydrogels, there have
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only been a few studies reporting the use of these modalities for hydrogel imaging as
compared to more commonly used CT. 29–31

Table 7.1 Characteristics of imaging modalities used for hydrogel imaging. Note
that while the poor soft tissue contrast of CT is typically viewed as a disadvantage
for imaging, in the context of hydrogel imaging it may be an advantage, since it
allows the hydrogel to be clearly distinguished from background soft tissue. On the
other hand, the excellent soft tissue contrast of MRI can render identification of the
hydrogel challenging due to a confounding endogenous signal.
Imaging
Advantages
Limitations
Source Contrast agents
modality
§
CT

Optical
imaging

Photoacoustic

Ultrasound

§

Radiation

§

Poor soft tissue
contrast

§

Anatomic imaging

§

Low cost

§

Common artifacts

§

High spatial
resolution

§

High cost

§

Low sensitivity

§

Soft tissue contrast

§

Long scan times

§

High sensitivity

§

High cost

§

Quantitative

§

§

Metabolic activity

High radiation
exposure

§

High sensitivity

§

§

Multichannel
imaging

Complex relationship
between signal and
probe concentration

MRI

Nuclear
imaging

High spatial
resolution

§

Poor tissue
penetration

§

Not available in the
clinic

§

Non-invasive

§

High penetration
depth

§

Limited field of view

§

Widely available

§

Common artifacts

§

Low cost

§

Low resolution

§

Portability

§

Operator dependent

X-rays

Iodinated small
molecules, barium sulfate
suspension, gold
nanoparticles

Radiowaves

Gadolinium chelates, iron
oxide nanoparticles,
exchangeable protons

Gamma-rays

Radioisotopes
(e.g., 18F, 124I)

Light

Quantum dots,
fluorescence dyes

Light/sound

Quantum dots, gold
nanoparticles,
semiconducting polymers

Sound wave

Microbubbles

As another example of an imaging modality, MRI uses a large magnetic field and
radiowaves to perform anatomical imaging of soft tissues.32 It is a noninvasive and
nondestructive diagnostic tool with good potential for monitoring tissue implants.33,34
Similar to CT, MRI uses contrast agents (e.g., gadolinium) to enhance internal structures.
35

Hydrogels can either be functionalized with contrast agents so that they can be

distinguished from adjacent tissues with conventional MRI, or can produce an endogenous
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signal in the absence of exogenous contrast agents with techniques such as chemical
exchange saturation transfer (CEST) MRI. 36,37
In contrast to CT and MRI, fluorescence imaging relies on the absorption and
scattering properties of tissues or biomaterial components.38,39 Its high sensitivity,
resolution and high throughput render this technique popular for in vivo imaging,40
however, its low tissue penetration (<1 cm) limits its utility. Probes that absorb in the nearinfrared (NIR) region (i.e., 650-900 nm) are often used for in vivo imaging as most tissues
have relatively low NIR absorbance. Thus, non-invasive in vivo tracking of hydrogel
distribution and degradation can be achieved by labeling with fluorescent probes (e.g.,
fluorophores, fluorescent dyes, quantum dots, upconversion nanoparticles).41 In addition
to these techniques, other imaging modalities such as nuclear imaging, ultrasound, and
photoacoustic imaging can also be used to visualize the in vivo distribution and
degradation of hydrogels, although these modalities remain relatively underexplored for
these applications. A summary of imageable hydrogel formulations, hydrogel crosslinking
method, imaging functionalization, and modality can be found in Table 7.2.

Table 7.2 Representative hydrogel formulations and modifications for imaging.
Polymer

Crosslinking
Method

Imaging
Functionalization

Imaging
Modality

Reference

Intrinsically Imageable Hydrogels
Alginate/liposomes
HA-SH/gelatin-SH
Peptide conjugate
(glutamic acid
+phenylalanine)
HA

Ionic crosslinking
(Ca2+)
Michael addition
(PEG-diacrylate)
Amphiphilic peptide
self-assembly
Michael addition
(divinyl sulfone)
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N/A*

CEST MRI

N/A

CEST MRI

N/A

CEST MRI

N/A

CEST MRI

Han et al.
(2020) 42
Zhu et al.
(2019) 36
Lock et al.
(2017) 43
Shazeeb et al.
(2018) 37

Hydroxyethyl
methacrylate-modified
HA (HeMA-HA)

Radical
polymerization

N/A

CEST MRI

Polyacrylamide

Radical
polymerization

N/A

Fluorescence

Multiarm PEG acrylates

Michael addition

N/A

Fluorescence

Bovine serum albumin
(BSA)/ Human serum
albumin (HAS)

Enzymatic
(Glutaraldehyde)

NA

Fluorescence

Dorsey et al.
(2015) 44
Xu et al.
(2019) 45
Tsou et al.
(2018) 46
Ma et al. (2016)
47

Physical Loading of Contrast Agents
Gelatin-tyramine

Lee et al.
(2018) 48

Enzymatic

Gold nanoparticles

CT

Radical
polymerization

Gold nanoparticles

CT

Alginate

Ionic crosslinking

Gold nanoparticles

CT

Keshavarz et
al. (2018)50

Gelatin methacrylamide
(GelMA)

Radical
polymerization

Gold nanoparticles

CT

Celikkin et al.
(2019) 51

Poly (bis (4carboxyphenoxy)
phosphazene) disodium
(PCPP)

Ionic crosslinking

Gold nanoparticles

CT

Bouché et al.
(2020)41

Gelatin-tetrazine/gelatinnorbornene

Dynamic covalent
(Diels-Alder)

Iopidamol and tantalum
oxide particles

CT

Hong et al.
(2016) 21

Alginate

Ionic crosslinking

Platinum nanoparticles

CT

Wang et al.
(2016) 52

Polyacrylonitrile (PAN)

Radical
polymerization

Barium sulfate
suspensions

CT

Zhang et al.
(2018) 53
Coutu et al.
(2012) 54

PNAGA-PAAm
copolymer
N-acryloyl glycinamide

Hydrogen bonding

Wu et al. (2018)
49

Chitosan

Ionic crosslinking

Iodinated contrast agents

Fluoroscopy

AMPEG550

Hydrophobic
association

M-ferrite nanoparticles

MRI

DTPA-Gd (III)

MRI

DOTA-Gd(III)

MRI

Bakker et al.
(2018) 34

Chitosan-DTPA

Schiff base
(PEG-dialdehyde)

Kim et al.
(2012) 19
Liu et al. (2016)
22

Polyethylene glycol
(PEG)

Hydrogen bonding

Chitosan

Hydrogen bonding

Ferumoxytol

MRI

Chen et al.
(2020) 55

Dehydrodipeptides

Peptide selfassembly

Iron oxide nanoparticles

MRI

Carvalho et al.
(2019) 56

N-methacryloyl chitosan

Radical
polymerization

Carbon nanodots

Fluorescence

Wang et al.
(2017) 57

RADA16-I peptide

Peptide selfassembly

Indocyanine green (ICG)

Fluorescence

Fmoc-diphenylalanine

Peptide selfassembly

CdTe and CdSe quantum
dots

Fluorescence
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Jin et al. (2017)
58

Kim et al.
(2010) 59

GelMA

Radical
polymerization

NaYF4:Yb,Er@PAA
upconversion
nanoparticles

Fluorescence

Dong et al.
(2017) 60

Gelatin

Hydrogen bonding

NaLuF4:Er3+, Yb3+
@graphene oxide (NGO)
nanoparticles

Fluorescence

Li et al. (2019)61

Silk fibrin

Peptide selfassembly

NaLuF4:Er3+, Yb3+
@graphene oxide (NGO)
nanoparticles

Fluorescence

Ferrous/ferricyanide ions

Photoacoustic

Cheng et al.
(2017) 63

Ultrasound

Leng et al.
(2015) 24

Fluorescence/

Jin et al. (2019)

Dibenzaldehydeterminated telechelic
PEG (DF-PEG)/chitosan

Dynamic covalent
(Schiff base)

Silk fibrin

Peptide selfassembly

SonoVueTM microbubbles

Polypeptide PC10

Peptide selfassembly

Ag2S quantum dots

PEG diacrylate (PEGDA)

Radical
polymerization

Zn ferrite magnetic
nanoparticles (MNPs) and
ICG

He et al. (2018)
62

photoacoustic

26

Fluorescence/

Wu et al. (2017)

MRI/Ultrasound

64

Chemical Grafting of Contrast Agents
Polyvinyl
alcohol (PVA)

Radical
polymerization

2,3,5Triiodobenzaldehyde

CT

Ashrafi et al.
(2017)15

HA-carbazate

Michael addition

F19

MRI

Yang et al.
(2014) 65

HA-Aldehyde

Dynamic Covalent

HA-Hydrazide

(Schiff Base)

Gadolinium complex

MRI

BermejoVelasco et al.
(2018) 66

Chitosan/HA

Ionic crosslinking

GdDOTA nanoparticles

MRI

Courant et al.
(2012) 67

Cellulose nanocrystal/silk
fibroin

Peptide selfassembly

Iron oxide nanoparticles

MRI

Chen et al.
(2018) 68

Near IR-gelatin

Fluorescence

Park et al.
(2019) 23

Bodipy-aldehyde

Fluorescence

Belali et al.
(2017) 69

HA-tyramine

Enzymatic

Gelatin

(Tyraminadase)

Chitosan

Dynamic Covalent
(Schiff Base)

PEG-bonded
polyacrylamide (PAM)

Radical
polymerization

Glucose-responsive
fluorescent monomer

Fluorescence

Heo et al.
(2011) 70

PCL-PEG-PPOR-PEGPCL

Hydrophobic
associations

Protoporphyrin

Fluorescence

Dong et al.
(2016) 71

SPECT/CT

Patrick et al.
(2020) 72

SPECT/CT

Oyen et al.
(2017)73

SPECT/CT

Lauren et al.
(2014) 74

SPECT/CT

Op’t Veld et.al
(2019)75

Ba2+
Alginate

In3+

Ionic crosslinking

Zr4+
Amphipathic hexapeptide
H-FEFQFKNH2

Amphipathic
peptide (beta
sheet)

Carboxymethyl-cellulose

Hydrogen bonding

Polyisocyanopeptide
(PIC)

Peptide selfassembly

DOTA-In3+

99m

Tc

Indium-111 (111In)
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Ionic crosslinking

Chitosan

131

-I

(TPP)
Amphiphilic block
copolymers

PLGA-PEG-PLGA

Rohdamine B and
CoFe2O4 nanoparticles

Scintigraphy
Fluorescence/
MRI/Ultrasound

Kim et al.
(2014) 25
Chen et al.
(2020) 76

Building from these examples and with a specific focus of imaging hydrogels
injected into the myocardium, we sought to develop an approach that is simple and could
be used across a wide range of hydrogels. Herein, we selected iohexol, a clinically used
contrast agent, that could be directly encapsulated into hydrogels during gelation to
introduce radiopacity. We first evaluated the influence of iohexol concentration on key
characteristics of radiopacity, injectability, and mechanical strength when encapsulated in
a hyaluronic acid (HA)-based hydrogel. We then investigated the in vivo radiopacity and
that hybrid SPECT/CT imaging with encapsulated iohexol and used this to verify the
intramyocardial delivery of the hydrogels to the targeted area of injury. Further, we
investigated the retention of these radiopaque hydrogels in a clinically relevant porcine
model of MI.
After establishing that encapsulation of iohexol can be used to confirm the delivery
of hydrogels with SPECT/CT to the heart, we expanded this imaging approach to evaluate
injectable hydrogel therapies in the heart through bulking mechanisms. Specifically, we
were motivated by recent studies suggesting that the intramyocardial delivery of injectable
hydrogels within the MI area may have therapeutic benefits via mechanical bulking in both
small and large animal models, including with significant reduction of LV diastolic and
systolic volumes.
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We hypothesized that intramyocardial delivery of our radiopaque

injectable hydrogels within the MI region would be therapeutically beneficial to increase
the wall thickness in the MI region, leading to lower regional wall stress and reduced infarct
LV wall thinning, infarct expansion, LV dilation, and adverse remodeling. Using a novel
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cineCT-derived myocardial strain framework, we evaluated early hemodynamic,
mechanical, and structural effects in our porcine MI model after hydrogel injection.
7.2. METHODS
7.2.1 MATERIALS
Hyaluronic acid (HA, MW = 400 kDa, 74 kDa) was purchased from LifeCore
(Chaska, MN). OmnipaqueTM Iohexol was purchased from GE Healthcare (Chicago, IL).
All other reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise
specified.
7.2.2 POLYMER SYNTHESIS
HA-hydrazide (HA-HYD) and HA-aldehyde (HA-ALD) were synthesized as
previously described
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(Figure 7.1A). To synthesize HA-HYD, HA (74 kDa) and adipic

acid dihydrazide were dissolved in dH2O. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) and hydroxybenzotriazole (HOBt) were dissolved in a DMSO/dH2O mixture and
added dropwise to the HA solution. The solution pH was adjusted to 6.8 every 30 minutes
for 4 hours, followed by reaction for 24 hours. The solution was dialyzed against dH2O for
3 days, after which products were precipitated in cold acetone and dialyzed again for a
week. Products were lyophilized and stored under nitrogen at -20°C for use. HA-HYD was
characterized via 1H NMR (Bruker) by integrating the the butyl linker (8H, 2.1-2.5 ppm,
1.5-1.8 ppm) relative to the methyl of HA (3 H, 2 ppm) and was found to have a hydrazide
modification of approximately 30% of disaccharide repeat units.
To synthesize HA-ALD, HA (400 kDa) and sodium periodate were dissolved in
dH2O. The reaction was stirred for 2 hours in the dark and subsequently quenched in
ethylene glycol. The solution was then dialyzed for 5 days against dH2O and lyophilized.
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HA-ALD was stored under nitrogen at -20°C until use. HA-ALD could not be quantified by
1

H NMR because aldehydes revert to diols in D2O. To quantify aldehyde modification, HA-

ALD was dissolved at 2 wt% and subsequently reacted with tert-butyl carbazate in dH2O
overnight as previously described.80 The next day, reactants were mixed with 2,4,6trinitrobenzenesulfonic acid for 1 hour. Samples were then reacted with 0.5 N hydrochloric
acid and the absorbance was measured at 340 nm on a microplate reader (Tecan) and
compared to tert-butyl carbazate standards. Using this method, HA-ALD was found to
have a 20% modification of disaccharide repeats.
7.2.3 IOHEXOL ENCAPSULATION AND HYDROGEL FORMATION
HA-HYD and HA-ALD were mixed with equal masses of HA-HYD and HA-ALD to
form hydrogels at a final concentration of 4 wt%. To load into syringes, dissolved polymers
were manually mixed into 1 mL BD syringe barrels and subsequently centrifuged to
remove air bubbles.81 For iohexol encapsulation experiments, HA-HYD and HA-ALD
macromers were dissolved in iohexol (350 mg/mL, 100 mg/mL, 35 mg/mL, 3.5 mg/mL)
solutions in PBS and assembled into syringes (Figure 7.1B). Of note, 350 mg/mL is the
concentration of iohexol that is often used in clinical applications.
7.2.4 HYDROGEL CHARACTERIZATION
Rheological measurements were performed using an AR2000 stress-controlled
rheometer (TA Instruments) fitted with a 20 mm diameter cone and plate geometry, 59
min 42 s cone angle, and 27 μm gap. Rheological properties were examined by time
sweeps (1.0 Hz; 1% strain). For shear recovery experiments, shear-thinning was
performed at 250% strain with recovery at 0.5% strain, each at 20 Hz. To measure
extrusion forces, following hydrogel loading into syringes, syringes were loaded into an
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Instron mechanical testing machine using a 50 N load cell under tensile extension mode
with flow rate of 2 mL/hour to assess required forces.
To assess radiopacity, hydrogels with increasing concentrations of iohexol were
injected into micro-centrifuge tubes and scanned using a clinical hybrid SPECT/CT system
(Discovery 570 NMCT, GE Healthcare) with a slice thickness of 0.625 mm at various
energies (80, 100, 120, 140 keV, 250 mA) before and after the addition of 700 uL PBS.
The hydrogels samples were scanned every day for 4 days while changing the PBS daily.
CT data from both systems was reconstructed and, using custom algorithms (MATLAB,
MathWorks, Natick, MA), radiopacity was assessed in the hydrogel and diffusion into the
PBS portions as CT intensity in Hounsfield units (HU).
7.2.5 PORCINE MODEL OF MI, HYDROGEL INJECTIONS, AND IN VIVO IMAGING
This study was approved by the institutional animal care and use committee
(IACUC) at Yale University School of Medicine. The studies were performed in agreement
with the position of the American Heart Association on research animal use and in
accordance with the National Institutes of Health Guidelines for Care and Use of
Laboratory Animals. Male Yorkshire pigs (n=3, 42-45 kg) were administered amiodarone
for 3 days pre-operatively (200 mg po) to reduce risk of arrhythmias. A transdermal
fentanyl patch was placed 12 hr prior to surgery and maintained for 3 days post-operatively
for pre-operative and post-operative analgesia. The animals were sedated (diazepam: 10
mg/kg po, ketamine/xylazine: 20/5 mg/kg IM respectively), intubated, and maintained on
1-2% isoflurane delivered in an oxygen/nitrous oxide mixture (40/60%). Arterial blood
pressure was monitored by a fluid filled pressure system throughout the procedure by
placement of an arterial sheath in the right femoral artery. Central lines were placed
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percutaneously for delivery of fluids (NaCl 10 ml/kg/hr), therapeutic drugs (amiodarone 1
mg/ml/min) and imaging agents as described below.
A small left lateral thoracotomy was performed and the pericardium opened to
visualize the basal and mid-anterolateral wall of the LV. MI was induced by permanent
occlusion of either obtuse marginal branches of the left circumflex artery or diagonals of
the left anterior descending artery, dependent on the coronary anatomy of each individual
animal. Approximately 15-20 min following occlusion, the animals were injected with
99mTc-tetrofosmin (10-20 mCi) to delineate and assess the in vivo ischemic risk area.
The iodinated hydrogel was delivered via direct epicardial intramyocardial injections (9 x
100 ul per injection, 27G tuberculin syringes) in a pre-defined 3x3 grid pattern across the
MI and peri-MI region using a custom delivery jig. Following injection of the hydrogel, the
grid was removed, chest closed and air removed from the chest cavity via a chest tube.
SPECT imaging was performed on a hybrid SPECT/CT scanner (Discovery 570
NMCT, GE Healthcare) over 15 min to the defined 99mTc-tetrofosmin perfusion defect.
This was followed by a non-contrast CT for attenuation correction, anatomic colocalization, and visualization of the hydrogel injections. An in vivo contrast cineCT was
acquired following SPECT/CT imaging after intravenous injection of 25-35 ml of iodinated
contrast (Omnipaque 350, Novaplus) via a power injection (Medrad) at a rate of 3 ml/min
followed by a 30 ml infusion of saline. The contrast CT was acquired at 120 kV, 450 mA
during a simulated breath hold (short duration disconnection of ventilator) to reduce
respiratory motion. The
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Tc-tetrofosmin and contrast CT image were fused to

demonstrate placement of the hydrogel within the MI perfusion defect.
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Animals were maintained on amiodarone (200 mg po) along with antibiotics
(Baytril, 500 mg po) and Carprofen (2-4 mg/kg IM or po) for additional analgesic pain
management for the 3-day post-operative period. At 3 days, animals were anaesthetized
and intubated as previously described for repeat in vivo hybrid 99mTc-tetrofosmin SPECT
imaging and repeat non-contrast and contrast CT imaging. After completion of the in vivo
imaging, animals were euthanized and the hearts were rapidly excised and filled with a
dental impression material (alginate type II, regular set, Henry Schein) to preserve heart
shape. The excised hearts were then placed back in the hybrid SPECT/CT imaging
system for high resolution ex vivo imaging.
7.2.6 CONTRAST X-RAY CINECT IMAGING
In vivo contrast cineCT images were acquired on 64-slice CT scanner (Discovery,
NMCT 570c, GE Healthcare) following the intravenous injection of 25-35 ml of iodinated
contrast (iohexal 350, Novaplus) via a power injector (Medrad) at a rate of 3 ml/min
followed by 30 ml saline flush. The CT images were acquired at 120 kV, 350 mA, with a
0.625 mm slice thickness at end-expiration achieved by disconnecting the ventilator for a
short duration (15-20 secs). Contrast CT images were acquired prior to MI, and 3 and 7
days post-MI. These ECG-gated contrast CT were acquired retrospectively and
reconstructed over the entire cardiac cycle in 10% phases using filtered back projection
with a voxel size of 0.488x0.488x0.625 mm3.
7.2.7 SPECT AND CT IMAGE PROCESSING
In vivo and ex vivo CT DICOM volumes were imported into ImageJ for formatting.
Images were cropped to be centered on the LV cavity within a region of 120x120x120 mm.
SPECT DICOM volumes were imported into ImageJ and the stack histogram was
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normalized using a 1% target saturation level. SPECT and CT images were then
converted to 8-bit grayscale, saved as TIFF stacks, and imported into Matlab.
Using a custom Matlab program, normalized SPECT maps were resampled to the
same resolution as the in vivo CT images they were acquired after and manually registered
to those CT images. Ex vivo images were processed using a custom ImageJ macro, which
inverted the grayscale images so that the myocardium was the brightest feature and then
used successively larger 3D median filters of size 2x2x2, 3x3x3, and 4x4x4 pixels to
smooth the background signal of the tank and reduce radial CT lighting artifacts. In vivo
and ex vivo CT and SPECT images were then resampled to the LV axis using the following
protocol. A custom Matlab program was used to trace the endocardial boundaries of the
LV at 2 different regions: 1) below the basal valve plane and just above the first papillary
muscle and 2) 10 mm above the endocardial tip of the apex. These boundaries were then
extracted and fit to 2 ellipses to obtain the ellipse centroids. The centers of both ellipses
were then used to define the LV axis, and the volume was resampled to be centered on
the LV axis in XY, with the LV axis corresponding to the Z axis with a new isotropic
resolution of 0.5x0.5x0.5 mm/pixel. Volumes were then manually rotated so that within the
midcavity view the right ventricle (RV) was oriented to the left and the X-axis bisected the
mid-septum. SPECT images were transformed using the same transformation as their
corresponding CT image.
To automate the segmentation of the LV from in vivo CT images, we trained a deep
neural network U-Net model to segment contrast CCT images of porcine hearts using LV
masking data generated by 2 different experienced cardiac imagers. Training data was
constructed by centering and resampling to the cardiac axis 567 CCT volumes of 20
porcine hearts at various imaging times and contractile states between ED and ES with a
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voxel resolution of 1x1x1 mm/voxel. Manual masking of the LV myocardium was
conducted every 3 mm along the cardiac axis from the basal valve plane to the apex using
the clinical program SegmentCT (Medviso, Sweden), and manual masks were then
interpolated to the full image resolution of 1x1x1 mm. The trained AI model was an
adapted version of the U-Net, a convolutional neural network (CNN) that adds successive
upsampling steps to the max-pooling steps typical of a CNN, allowing for high resolution
outputs. The constructor for the network architecture was provided through the Project
MONAI package, a PyTorch-based framework designed to enhance deep learning
workflows for medical image analysis. To prepare the training data, images were first
regularized such that voxels with intensities in the 25 to 75 percentile range were scaled
to values from -0.5 to 0.5, respectively. Patches of size 96x96x64 voxels were randomly
sampled from the training set with a bias towards patches centered around foreground
voxels. The dataset was then augmented by randomly rotating patches by 90-degree
increments. The model calculated the sum of the Dice loss and cross-entropy loss, and
this loss function was optimized by the Adam optimizer with a learning rate of 0.001. The
model was trained for 3000 iterations on a NVIDIA GTX 1080 Ti GPU with 11 GB of VRAM.
To remove artifacts, the foreground voxels not in the largest connected component were
discarded. After training, the model was used to predict new segmentation masks with a
high degree of accuracy compared masks provided by trained cardiologists.
7.2.8 HIGH RESOLUTION DISPLACEMENT TRACKING AND STRAIN ANALYSIS
Down sampled NIfTI images (1x1x1 mm) of the resampled CT volumes were
exported corresponding to ED, ES, and an intermediate phase in vivo and 10 and 60
mmHg at peak cavity expansion ex vivo (generally 60-65% through the inflation cycle).
NIfTI volumes were processed with nonlinear registration using the program
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BioImageSuite (CP Spacing:4, Iterations:10, Resolution:1.25, Affine), to calculate the
displacement fields between corresponding images. Displacements were calculated
between 10 and 60 mmHg ex vivo. In vivo, displacements were calculated between ED
and an intermediate phase to ES and between the intermediate phase and ES. The
cumulative displacement field between ED and ES was then exported using these two
fields. Incremental registration was used in vivo because it improved the accuracy of the
tracking due to the large deformation and shape change between ED and ES.
Displacement fields were imported into Matlab for strain analysis.
A custom Matlab program was used to mask displacement calculations to the LV.
For ex vivo displacements, an intensity threshold was used to remove parts of the
displacement field corresponding to the background, and a conical cutout was manually
sized to remove displacements corresponding to the RV just beyond the septum. For in
vivo displacements, LV masks generated by the U-Net AI at ED were used to remove
displacements corresponding to nearby tissues from the displacement field of the LV.
Once displacement fields were properly segmented to the LV, the X, Y, and Z,
displacement fields were smoothed by a 3D, symmetric gaussian filter of size 5x5x5 (σ=3)
with a tolerance of 50% for missing values to avoid over smoothing LV volume edges.
Displacements were then converted to radial (UR), circumferential (UC), and long axis
(UZ) displacements, and the displacement gradients at each calculation point (1x1x1 mm)
were calculated by fitting each displacement component to local trilinear polynomials over
the neighborhood of 11x13x11. 3D Lagrangian strains were calculated from the cylindrical
deformation gradient at each point as follows:
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ERR is radial strain, ECC is circumferential strain, EZZ is LV long-axis strain, ERC is radialcircumferential shear, ERZ is radial-axial shear, and ECZ is circumferential-axial shear. We
also measured ENmax maximum principal strain and ESmax maximum shear strain to obtain
strain measures independent of coordinate system as follows: 1) the eigenvalues of the
Lagrangian strain tensor were found at each calculation point, 2) ENmax was calculated as
the largest eigenvalue and ENmin as the smallest eigenvalue 3) ESmax was calculated as
(ENmax - ENmin)/2.
Cardiac strains were computed for regions based on the American Heart
Association (AHA) 17-segment model and also divided into normal, peri-infarct border
zone, infarct, and area at risk (border + infarct) zones as determined by threshold masking
with registered SPECT images. The true apex was excluded from the analyses. SPECT
intensity values below a threshold of 50% of maximum were classified as within the MI
region. SPECT values between 50-60% max intensity defined the border region. All other
regions were classified as normal regions. The AHA 17 segments were also assigned a
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% viability score by averaging the SPECT threshold results (0-infarct, 0.5-border, 1healthy) for all points within each region. Regional strain were expressed as mean ±
standard deviation of the mean.
7.2.9 HEMODYNAMICS
ECG, LV pressure (mmHg), and aortic pressure (mmHg) signals were acquired
continuously using LabChart and were exported as a series of 5 heartbeats sampled every
millisecond at selected time points corresponding with: baseline CT angiography, ~60 min
post-MI at the time of SPECT and CT imaging with and without contrast, and 90 min posttreatment (Hydrogel or Control) during final in vivo SPECT/CT imaging. Sampling started
just before the QRS complex and covered 5 full heartbeats up to the peak LV pressure of
the sixth beat. This data was exported to a custom Excel analysis spreadsheet (Figure 3)
that was used to analyze the 3 signals and their smoothed first and second derivatives to
identify the timing of: start of the QRS complex (T1, the inflection point of the maximum of
second derivative of ECG signal); aortic valve opening (T2, first cross-point post-QRS of
the aortic and LV pressures); aortic valve closing (T3, the inflection point of maximum
second derivative of aortic pressure post aortic valve opening defined by the dichrotic
notch); mitral valve opening (T4, the zero-point crossing of the first derivative of LV
pressure after the dichrotic notch). These times were then used to calculate critical time
intervals of the cardiac cycle: isovolumetric contraction time (IVCT, T2 - T1), ejection time
(ET, T3 - T2), isovolumetric relaxation time (IVRT, T4 – T3), and LV filling time (FT, T1 of
next heartbeat - T4). The Tei Index time constant (IVCT+IVRT)/ET was also calculated,
which is normalized for heart rate. The area below the LV pressure curve covering ET
(mmHg-sec), also known as stroke work or systolic pressure time index (SPTI) a measure
of systolic demand, and the area between the aortic and LV pressures covering IVRT, FT,
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and IVCT (mmHg-sec), also known as diastolic pressure-time integral (DPTI) a measure
of diastolic supply, were also calculated. These were used to calculate the supply/demand
ratio (S/D ratio) as DPTI/SPTI. Peak LV pressure, LV end diastolic pressure (EDP), and
heart rate (HR) were assessed along with LV pressures sampled at 10 evenly spaced
points over each heartbeat starting from ED for generation of CT derived pressure-volume
loops as detailed below. All measures were then averaged over the 5 beats at each time
point of interest (baseline, 60 min post-MI, and 90 min post randomization to treatment).
7.2.10 STATISTICAL ANALYSIS
For hydrogel characterization experiments, all statistics were performed in Graphpad
Prism 7. All data are reported as means ± standard deviation (SD) and performed in
triplicate unless otherwise indicated. Comparisons between two groups were performed
by Students t-test with two-tailed criteria and significance determined at p < 0.05 with * or
** indicating p < 0.05 or 0.01, respectively. For comparison between multiple groups,
significance was determined by one-way ANOVA with post hoc testing.
For in vivo studies, statistical analyses were performed using the MATLAB
statistics and machine learning toolbox (version R2015a). We analyzed for: 1) changes in
strain between baseline day 1, post-MI day 3, post-MI day 7, and post-Gel day 7 (in vivo
time points); 2) regional differences in in vivo and ex vivo strain magnitude between the
infarct, border, and healthy regions; 3) changes in strain within the infarct, border, and
healthy regions between time points; 4) correlations between percent of healthy tissue
and average strain in the 17 segments; and 5) changes in ejection fraction and
hemodynamics between different time points.
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Differences between the standard spatial regions and between normal, border,
infarct, and area of risk regions were compared using a 2-way repeated measures ANOVA
with a Sidak multiple comparison test (Matlab: ranova, fitrm). Repeated measures models
were grouped such that measures from the same heart, but different locations were
considered repeated within-subjects measures, whereas observations from different
hearts were considered independent measures. In vivo changes between the time points
Baseline Day 1, Post-MI Day 3, Post-MI Day 7, and Post-Gel Day 7 were tested for
significance using a student T-test (Matlab: ttest). Changes in adjacent regions were
compared using a 2-way repeated measures ANOVA (Matlab: ranova, fitrm). Pairwise
comparisons within groups, mean differences, and 95% confidence intervals were
obtained afterward from the fitrm model with the Matlab function multcompare, which
adjusts p-values for multiple comparisons. P-values were considered significant if the pvalue was less than 0.05 (**) and borderline significant if the p-value was less than 0.1 (*).
A linear model (Matlab: fitlm, anovan) was used in each heart to test for correlation
between the percent of each region that was healthy and the average strain in the region.
7.3. RESULTS
7.3.1. POLYMER SYNTHESIS AND RADIOPAQUE HYDROGEL FORMATION
HA was modified with hydrazides via amidation between adipic acid dihydrazide
and carboxyl groups of HA or with aldehydes through oxidation with sodium periodate
(Figure 7.1A). Synthesis of HA-HYD led to ~30% modification of disaccharide repeat units
with hydrazides and synthesis of HA-ALD led to ~20% modification of disaccharide repeat
units with aldehydes. HA-HYD and HA-ALD components were dissolved at 4 wt% in
iohexol solution in PBS with varying concentrations and formed into hydrogels by mixing
the two dissolved macromers to form hydrazone bonds as crosslinks (Figure 7.1B).
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Figure 7.1. Hydrogel formulation for encapsulation of iohexol. A) Modification of hyaluronic
acid (HA) with either hydrazides (HA-HYD) or aldehydes (HA-ALD). B) Incorporation of iohexol
confers radiopacity to hydrogels formed from the mixing of HA-ALD and HA-HYD and the hydrogel
properties allow shear-thinning for direct injection into the myocardium.

7.3.2. MECHANICAL PROPERTIES AND INJECTABILITY OF RADIOPAQUE
HYDROGELS
Hydrogels were shear-thinning and self-healing due to the dynamic nature of the
hydrazone crosslinks. Using shear oscillatory rheometry, we observed that increasing the
shear rate led to decreased material viscosity, demonstrating shear-thinning of the
hydrogels and easy ejection from a 27G syringe (Figure 7.2A). After formation of
hydrogels, they could be cut and placed together for self-healing of broken hydrazone
bonds (Figure 7.2B). To further assess self-healing, strain cycling on shear-oscillatory
rheometry was used to evaluate the hydrogels at low strain (0.5%) and in response to
high, deforming strain (500%). Here, all formulations tested demonstrated a rapid decline
in G’ upon application of high strain and a rapid recovery upon cessation of the strain,
indicating that the hydrogels are injectable (Figure 7.2C).
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Figure 7.2. Shear-thinning and self-healing properties allow injectability. A) Shear-thinning of
hydrogels on shear oscillatory rheometry, demonstrating decreasing viscosity with increasing
shear-rates (Inset: ejection of hydrogel through 27G x 1/2” syringe). B) Self-healing of dyed
hydrogel discs placed together and allowed to heal for 10 minutes in air after cutting; manual
stretching of healed hydrogel discs after 10 minutes demonstrates self-healing behavior. C)
Application of cyclic low (0.5%) and high (500%) strains on shear-oscillatory rheometry
demonstrating a rapid decrease in modulus in response to high strain and rapid recovery upon
cessation of shear, applicable over multiple cycles of loading.

Using shear oscillatory rheometry (Figure 7.3A), the kinetics of hydrogel (4 wt%
HA-HYD and HA-ALD) formation and final hydrogel properties were monitored at four
iohexol concentrations (3.5, 35, 100, 350 mg/mL) and controls without iohexol (0 mg/mL).
The gelation profiles for 100 mg/ml iohexol and the control without iohexol exhibited similar
kinetics, indicating that encapsulation of iohexol did not alter gelation time. Gelation
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(measured as cross of storage (G’) and loss (G’’) moduli) occurred within minutes and a
plateau modulus was reached within ~30 minutes. Increasing the iohexol concentration
did not significantly change the final storage (G’) and loss (G’’) moduli of hydrogels up to
concentration of 100 mg/mL of iohexol; however, encapsulation of 350 mg/mL iohexol led
to a significant decrease in the storage modulus and increase in the loss modulus
compared to the control without iohexol.

Figure 7.3. Encapsulation of iohexol up to 100 mg/mL does not affect mechanical properties.
A) (left) Representative profiles of the gelation (storage modulus: G’, loss modulus: G’’) behavior
of HA-HYD and HA-ALD hydrogels either without (0 mg/mL) or with (100 mg/mL) iohexol; (right)
quantification of G’ and G’’ across various iohexol concentrations (*p<0.001 compared to hydrogels
without iohexol). B) (left) Representative ejection force profiles of hydrogels either without (0
mg/mL) or with (100 mg/mL) iohexol; (right) quantification of ejection forces across various iohexol
concentrations (*p<0.001 compared to hydrogels without iohexol).

To understand the effect of iohexol encapsulation on the injection force, we
measured force profiles of hydrogels with increasing concentrations of iohexol (0, 3.5, 35,
100, 350 mg/mL) extruded through ½ mL tuberculin syringes with 27G needles at a
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constant extrusion rate. Stable force profiles were observed and increasing the iohexol
concentration increased the force needed for extrusion significantly compared to controls
without iohexol (Figure 7.3B). However, up to 100 mg/mL, the extrusion forces were
below or similar to those previously measured for clinically available dermal fillers.82
7.3.3. ASSESSMENT OF RADIOPACITY OF HYDROGELS ACROSS VARIED
IOHEXOL CONCENTRATIONS AND TIME
Hydrogels with increasing concentrations of iohexol were injected into microcentrifuge tubes and scanned using a clinical hybrid SPECT/CT system (Discovery 570
NMCT, GE Healthcare) at different energy levels (80, 100, 120, 140 keV, 250 mA). At 80
keV, the CT enhancement was directly related to the iohexol concentration within the
hydrogel (Figure 7.4A). Hydrogels with iohexol concentration of 35 mg/mL and above
were distinguishable by clinical CT. The use of lower voltages resulted in higher CT
attenuation (Figure 7.4B), as the x-ray output energy spectrum at these low voltages was
closer to the iodine k-edge of 33 keV.83 Thus, the use of 80 keV resulted in the strongest
contrast enhancement per iodine concentration. Given the unchanged mechanical
properties with iohexol incorporation and the most favorable characteristics for
visualization, we selected the 100 mg/mL iohexol concentration for the in vivo chronic
imaging studies.
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Figure 7.4. Radiopacity of hydrogels can be monitored across different CT intensities and
over time. A) CT images of hydrogels with various iohexol concentrations in the presence and
absence of PBS acquired on a clinical CT scanner using standard acquisition parameters (80 keV,
250 mA). Hydrogels with iohexol concentrations above 35 mg/mL were visible. B) CT intensity
profiles (expressed as Hounsfield Units (HU)) across a hydrogel with 100 mg/mL iohexol and PBS
(shown from bottom of tube on left through the PBS above the hydrogel on the right) over the
range of CT energy levels used clinically. C) CT images (acquired at 80 keV, 250 mA) and
associated quantitative intensities (HU, mean ± SD) for a hydrogel containing 100 mg/mL iohexol
in a tube with PBS above the hydrogel imaged daily over four days. PBS was changed daily (inset:
visualization of tube over time). (*p<0.05 for CT intensity between the hydrogel and PBS)
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In order to define the potential of serial CT imaging to track hydrogel retention in
vivo, we added PBS on top of the hydrogels and quantified the contrast signal over 4 days.
Serial CT imaging of the gel and PBS at 80 keV demonstrated that the iohexol diffused
quickly out of the hydrogels into the overlying PBS within two to three days (Figure 7.5C).
While the iodinated hydrogel was indistinguishable from the PBS by eye at 4 days,
quantification of the CT intensity showed that the CT intensity between the hydrogel and
PBS remained statistically significant through day 4.
7.3.4. PORCINE IMAGING STUDIES
Hydrogels containing 100 mg/mL iohexol were injected into the middle of the
myocardium in a 3x3 grid via epicardial injections (9 injections total) in a porcine MI model
(Figure 7.5). This was to distribute the hydrogel throughout the MI region. The injection
sites could be easily visualized by contrast CT angiogram (Figure 7.6A). Threedimensional reconstruction of the in vivo contrast CT angiogram demonstrated the pockets
of hydrogel formed in the myocardial wall (Figure 7.6B).

Further, hybrid
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Tc-

tetrofosomin SPECT/CT imaging confirmed initial delivery of the hydrogel within the MI
perfusion defect (Figure 7.6C).
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Figure 7.5. Intramyocardial injection of radiopaque hydrogels. A) For hydrogel delivery, a
flexible plastic patch (1-2 mm thick) with 9 poles (each 7 mm tall) distributed in a 3x3 grid 1 cm
apart was placed on the surface of heart over the infarct area. B) Insulin syringes loaded with
hydrogel were passed through the poles on the patch in order to reproducibly deliver the hydrogel
into the middle of the myocardial wall in the infarct area (MI) in a 3x3 array (white arrow). LV
indicates left ventricle; RV, right ventricle.

Figure 7.6. Radiopaque hydrogels can be guided into the area of perfusion defect via hybrid
SPECT/CT imaging. A) In vivo contrast CT long axis 2D image (120 keV, 450 mA) acquired on
the day of delivery, demonstrating the placement of the hydrogel in the anterior-lateral wall of the
LV. B) 3D rendering of the in vivo contrast CT angiogram in which multiple hydrogel injections can
be clearly visualized over contrast in LV cavity. C) In vivo 99mTc-Tetrofosmin hybrid SPECT/CT
image. The perfusion defect can be visualized on the antero-lateral wall (blue-green) versus the
normal perfusion area (yellow-orange) and the hydrogel can be clearly visualized (yellow arrow) in
the hypo-perfused region.

Despite hydrogel visualization up to day 4 during in vitro characterization studies
and clear radiopacity of the hydrogels in vivo immediately post-delivery (Figure 7.7A), the
hydrogel was not visible at 3 days post-delivery with CT imaging (Figure 7.7B). High
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resolution ex vivo SPECT/CT imaging could also not visually detect the hydrogel except
for discrete hypoenhancement of the hydrogels discernable on the ex vivo high-resolution
CT scan of the heart (Figure 7.8A). These hypoenhanced regions matched the ex vivo
visualization of the hydrogels (Figure 7.8B), confirming the presence of hydrogel pockets
in the myocardium at day 3 and suggesting that the contrast agent diffused out of the
hydrogel on days 2 and 3.

Figure 7.7. Radiopaque hydrogels are visible in vivo immediately after delivery. Serial in vivo
CT imaging demonstrating radiopacity of hydrogel (A) immediately following intramyocardial
delivery (yellow arrows) and (B) 3 days post-delivery.

Figure 7.8. Radiopaque hydrogels are only visible via ex vivo CT four days after delivery.
(A) High resolution ex vivo CT image of the heart following casting of the ventricle cavities with
alginate to maintain the heart shape. A hypo-enhanced area can be visualized (yellow arrow) that
corresponds to the hydrogel visualized on (B) a corresponding ex vivo slice of the left ventricle
within the infarct area (red arrow).
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7.3.5 EVALUATION OF IN VIVO STRAIN AND FUNCTIONAL OUTCOMES POST-MI
AND AFTER THERAPEUTIC HYDROGEL DELIVERY
Now that we have developed an approach to image hydrogel placement into the
myocardium, we looked towards evaluating the therapeutic impact of hydrogel injection
using strain analysis and hemodynamic measures (i.e., ejection fraction) as primary
outcomes in a porcine model of MI. Thirteen Yorkshire pigs underwent surgical occlusions
of obtuse marginal branch of the left circumflex coronary artery. Myocardial perfusion
defect sizes were determined from reconstructed 99mTc-tetrofosmin SPECT images using
commercial software (4DM, INVIA). Segments with

99m

Tc-tetrofosmin activity <50% the

intensity of normal segments were classified as infarcted segments (infarct) and all other
segments were classified as unaffected (non-infarcted) (4DM software, INVIA) (Figure
7.9). After assessment of area at risk, hydrogel group (n=8) underwent intramyocardial
delivery of radiopaque hydrogel in the MI region. The control group (n=5) were evaluated
over the same time period without hydrogel injection.
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Figure 7.9. Confirmation of hydrogel delivery within the perfusion defect. In panel A through
F a short axis view of a representative animal from the hydrogel and control group is shown. A and
B represents the baseline state, followed by the post-MI state (C and D), and following hydrogel
delivery (E and F). On the right, SPECT images 1 hour post permanent occlusion of the obtuse
marginal (OM) branch of the left circumflex coronary artery in the same animal. In panel G, Short
axis, horizontal and vertical long axis view of the attenuation corrected 99mTc-Tetrofosmin SPECT
images showing the perfusion defect in the anterolateral wall; H) AHA 17 segment presentation of
the left ventricle showing the perfusion defect mainly located in segments 6, 12 and 1, showing the
perfusion defect located within the left circumflex territory. Segments with 99mTc-tetrofosmin activity
<50% the intensity of normal segments were classified as infarcted segments (MI) and all other
segments were classified as unaffected (remote).

Strain analysis was conducted at baseline, after MI induction and post-hydrogel
injection. The novel cineCT platform developed for in vivo measurement of 3D high
resolution Lagrangian strains in the left ventricle is described elsewhere.84 Figure 7.10
demonstrates a representative segmentCT strain analysis with AHA 17-segment view.
Reconstructed CTA volumes were imported into semi-automated commercial software
(SegmentCT , Medviso, Sweden) to track the epicardial and endocardial surfaces within
these images over the cardiac cycle, allowing calculation of the strain in three different
orientations (longitudinal, radial and circumferential) from the 2D images. Peak systolic
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radial (Err) and circumferential (Ecc) strains were computed for 16 standard LV regions
(Figure 7.10).

A

C

B

Figure 7.10. SegmentCT Strain Analysis in 17 segments: A) epi- and endo-cardium borders
defined at ED and B) tracking of epi- and endo-cardial borders to determine radial (Err) and
circumferential (Ecc) strain, and D) Peak Ecc summary in the AHA 17-segment view.

After hydrogel injection, both absolute and normalized radial (Err: +53.3%, ENrr :
+52.7%, p<0.05) and circumferential strain (Ecc :+50.7%, ENcc :+44.1%, p<0.05) in the
infarct region significantly increased. In remote non-infarcted regions, normalized radial
(ENrr : -7.6%) and circumferential (ENcc :-5.6%) strain decreased back toward baseline
levels, representing a reduction in the remote compensatory response. In the Control
group, normalized strain continued to decline within the infarct region by -10.6% for ENrr
and -25.5% for ENcc with no change in remote non-infarcted regions. Strain changes were
compared between the Hydrogel and Control groups using a two-way ANOVA (Figure
7.11), and the improvements to ENrr and ENcc within the infarct region and reduced
compensation in ENrr within non-infarcted regions were found the be significantly different
than the Control group (p < 0.05).
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Strain Measures Over Time
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Figure 7.11. Changes in strain measured from CT at Baseline, Post-MI, and Post-Gel (or
Control) in the Hydrogel (n=8) and Control (n=5) groups: A) ENrr in the infarct region, B) ENrr in the
noninfarcted region, C) ENcc in the infarct region, D) ENcc in the noninfarcted region. From left to
right: (1) strain measures over time, (2) changes Post-MI hour 1 compared to Baseline (decreased
strain in infarct region and increased, compensatory strain in noninfarcted regions), (3) changes
after Hydrogel/Control compared to Post-MI (increased strain in infarct region and decreased
compensating strain in noninfarcted regions in Hydrogels, further decrease in strain within the
infarct region and in Controls). Statistical tests: student’s t-test of sequential changes (*) and
ANOVA (—) comparing changes in the Hydrogel and Control groups. Significance Levels: *** = p
< 0.01, ** = p < 0.05, * = p < 0.1. Whiskers on the line plots show the standard error of the mean.
Boxplots indicate median changes and 25% and 75% quantiles, with whiskers showing the full
range of the data.
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Beyond strains, we sought to evaluate the influence of the injectable HA-hydrogels
on functional outcomes of the heart in our porcine model of MI after intramyocardial
injection as compared to control. Figure 7.12 illustrates representative LV pressure
volume curves for 2 pigs (1 Hydrogel and 1 Control) at baseline, post-MI, and posthydrogel or control. From these data the following pressure-volume measures were
A

analyzed for changes from baseline, post-MI, and post-treatment: end diastolic Volume
(EDV), stroke volume (SV), LV ejection fraction (EF), and pressure-volume loop area
(PVA).
Control

Control

B

A

Gel

Control

Control

Figure 7.12.
B Illustrative Pressure-Volume loops in A) the control group at Baseline, Post-MI
early (1 hr), and Post-MI late (2 hr, Control) and B) the hydrogel group at Baseline, Post-MI, and
Post-Gel.

After hydrogel delivery, cardiac function seemed to stabilize with only small
Gel

changes in EDV (-2.2 mL), SV (-0.2%), EF (+2.9%), and PVA (+4.1%) from post-MI
measurements. Three out of eight hearts exhibited substantial improvements in EF and
SV after treatment and two of those also exhibited large improvements in PVA (Figure
7.13). In the Control group however, cardiac function continued to decline significantly on
average from post-MI measurements in 4 out of 5 hearts and stabilized in only one. On
average, EDV decreased further by -9.8 mL, SV by -33.8%, EF by -25.1%, and PVA by 32.4% (p < 0.1) in the Control group. These LV pressure-volume changes were compared
between the Hydrogel and Control groups using a two-way ANOVA (Figure 7.13), and the
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decrease in EF and SV (p < 0.01) and PVA (p < 0.05) were found to be significantly larger
in the Control group.
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Figure 7.13. LV Pressure-Volume changes between Baseline, Post-MI, and Post-Gel (or
Control) in the Hydrogel (n=8) and Control (n=5) groups: A) end diastolic volume (EDV), B) ejection
fraction (EF), C) stroke volume (SV), D) pressure-volume curve area (PVA). From left to right: (1)
pressure-volume measures over time, (2) changes Post-MI hour 1 compared to Baseline (declining
EDV, EF, SV, and PVA), (3) changes after Hydrogel/Control compared to Post-MI (continued
decline in EDV, EF, SV, PVA in Controls, no further decline in Hydrogels). Statistical tests: student’s
t-test of sequential changes (*) and ANOVA (—) comparing changes in the Hydrogel and Control
groups. Significance Levels: *** = p < 0.01, ** = p < 0.05, * = p < 0.1. Whiskers on the line plots
show the standard error of the mean. Boxplots indicate median changes and 25% and 75%
quantiles, with whiskers showing the full range of the data.
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LV wall thickness at ED was calculated for the same 16 segments used for CTA
strain analysis (Figure 7.14). In the Hydrogel group, the LV thickness increased post-MI
by 0.60 mm in the infarct region (p<0.1) and 0.36 mm in the remote non-infarcted region
(p<0.05). Changes were similar in magnitude within the Control group post-MI. There were
no significant changes in LV thickness in the Control group after this time. However, LV
ED wall thickness increased significantly (p<0.01) in the infarct region by 0.83 mm
following intramyocardial hydrogel injection in the Hydrogel group. Changes in LV ED
thickness were compared between the Hydrogel and Control groups using a two-way
ANOVA. In the infarct region, changes in LV thickness increased by 1.15 mm (p<0.1)
compared to control changes.
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Figure 7.14. Changes in ED myocardial thickness within the infarct region measured from CT
at Baseline, Post-MI, and Post-Gel (or Control) in the Hydrogel (n=8) and Control (n=5) groups.
From left to right: (1) ED myocardial thickness measures over time, (2) changes Post-MI hour 1
compared to Baseline (thickening in infarct region), (3) changes after Hydrogel/Control compared
to Post-MI (further thickening in infarct region in Hydrogels). Statistical tests: student’s t-test of
sequential changes (*) and ANOVA (—) comparing changes in the Hydrogel and Control groups.
Significance Levels: *** = p < 0.01, ** = p < 0.05, * = p < 0.1. Whiskers on the line plots show the
standard error of the mean. Boxplots indicate median changes and 25% and 75% quantiles, with
whiskers showing the full range of the data.

7.4. DISCUSSION
There has been tremendous growth in the area of injectable hydrogels for treating
MI.85,86 Experimental studies have demonstrated that limiting MI expansion with the
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introduction of hydrogels can significantly attenuate post-MI remodeling14 with finite
element analyses implicating decreased myocardial fiber stresses on these positive
outcomes.14 Further, the delivery of therapeutic drugs and cells can be improved with
hydrogels that help to localize the therapy to a specific region for efficacy and to reduce
off-target adverse effects.87,88 However, the efficacy of these therapies depends on the
distribution, volume, retention, and mechanical properties of the material over time.
Therefore, the development of techniques to track hydrogel placement are critical to
advance these therapies. Evaluation of the location, volume and pattern of hydrogel
delivery as related to changes in material properties, function, and local molecular events
will help to advance this field.
Herein, we introduced radiopacity through encapsulation of the iodinated contrast
agent iohexol. We employed hydrazide-aldehyde chemistry to synthesize hyaluronic acid
hydrogels with important shear-thinning and self-healing properties, adapted from
previously established chemistries that have allowed such hydrogels to be used in various
biomedical applications.79,89 We demonstrated that encapsulation of 100 mg/mL iohexol
enabled hydrogel visualization, without compromising material properties of the hydrogel.
Above 100 mg/mL, iohexol molecules likely interfere with hydrazine crosslink formation
resulting in increased extrusion forces and changes in material mechanics. Importantly, at
100 mg/mL iohexol, the forces were comparable to that of clinically available injectable
materials.82
We completed in vivo studies using 100 mg/mL iohexol concentration in a chronic
porcine model of MI following permanent coronary occlusion. We were able to visualize
the iodinated hydrogel within the perfusion defect using hybrid SPECT/CT imaging with
99m

Tc-tetrofosmin a standard clinically SPECT myocardial perfusion agent. Although the
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hydrogel was clearly visible on the day of intramyocardial delivery, at 3 days post-delivery,
the hydrogels were no longer readily visible on in vivo imaging, suggesting that much of
the encapsulated iohexol had already diffused into the surrounding tissue.
Compared to methods of direct conjugation of iodinated moieties onto polymers
that assemble into hydrogels, encapsulation increased the amount of signal that could be
included in the hydrogel without significantly affecting the material properties. However,
encapsulated iohexol diffused out of hydrogels on day 2 and day 3, limiting the use of this
approach for non-invasive in vivo hydrogel tracking over time. Furthermore, since the
iohexol diffusion did not couple to hydrogel erosion, this approach may not be used to
track hydrogel degradation in vivo.
The iodine content by weight in the radiopaque hydrogels reached 30%, and the
loading was high enough to produce visible CT attenuation in vivo. These contrast agents
are rapidly cleared by the kidney when administered intravenously, and generally manifest
toxicity in patients with impaired renal function and when administered in large doses.83
For standard non-invasive or invasive cardiac imaging procedures patients may receive
100 to 300 mL of low molarity contrast agents that contain 350 mg/mL iodine.90 Given that
our approach involves injection of 900 µl of hydrogels containing 100 mg/mL iodine that is
released over days, we expect the local and systemic toxicity to be negligible.
Encapsulation of iohexol combined with a multimodality image-guided approach
may help to define the critical anatomical location for optimization of delivery and volume
of hydrogel administration. The successful introduction of radiopacity to hydrogel
motivated follow-up studies to first create a novel experimental platform to assess changes
in the active and passive deformation of the LV myocardium within infarct, border and
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remote normal regions using contrast cineCT imaging of normal porcine hearts and heart
before and after creation of an anterolateral MI and following the intramyocardial delivery
of our radiopaque hydrogel.

99m

Tc-tetrofosmin SPECT imaging was used to assess the

ischemic risk area to confirm the area for injection.
After validation of the radiopaque hydrogel, we employed an acute porcine model
of permanent coronary artery occlusion resulting in MI to study the hemodynamic,
biomechanical and functional changes in the LV in the early post-MI period and following
the intramyocardial delivery of our iodine encapsulated theranostic hydrogel. Serial
multimodality imaging approach including ECG-gated hybrid SPECT/CT and cineCT
imaging was used to define the area at risk post-MI, track hydrogel delivery, and obtain
high-resolution images of LV regional and global indices of cardiac function after MI and
hydrogel delivery. We demonstrated that intramyocardial delivery of a hydrogel within the
infarct region early post-MI stabilizes and/or restores LV function and geometry as evident
by improved radial strains in the area at risk, reduced compensatory changes in remote
regions, and stabilization or improvement of LVEDP, LVEF and PVA. To our knowledge,
this is the first study to show favorable changes of hemodynamics and function following
acute intramyocardial hydrogel delivery with a multimodality imaging approach in a large
animal model of acute MI.
In summary, we demonstrated that a multimodality imaging approach to guide and
track intramyocardial delivery of hydrogel in the infarct region early post-MI stabilizes
and/or restores cardiac function by increasing contractile radial strains in the area at risk
and decreased compensatory changes of the adjacent and remote tissues. While these
therapies were delivered through a surgical approach, development of advanced catheter-
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based delivery technologies may facilitate clinical translation which may have potential
clinical applications by reduction of adverse outcomes.
Future studies will focus on investigating the real time structural (3D morphology
and volume) and functional status (drug release) of these hydrogel systems coincident
with changes in the tissue in response to hydrogel therapies. This work will lay the
foundation for minimally invasive image-guided delivery of hydrogels for treatment of
patients after MI. The ability to deliver a hydrogel through a catheter under multimodality
image guidance will enable numerous hydrogel formulations with different therapeutic
contents to be investigated, helping to advance clinically relevant biomaterials therapies.
7.5 CONCLUSION
In summary, we have used the encapsulation of iohexol to impart radiopacity to
hydrogels to allow visualization early after injection. The radiopaque hydrogel is easily
injectable through a 27G needle and can be administered through image-guided delivery.
Although the iohexol diffuses from the hydrogel to limit long-term imaging, visualization of
the hydrogel placement, particularly in combination with other imaging techniques, is an
important advancement in the development of cardiac hydrogel therapies.
Using our novel radiopaque hydrogel, we then demonstrated the ability of contrast
cineCT to track infarct expansion and early post-infarction remodeling and were able to
correlate these changes with regional variation in active and passive strain using in vivo
and ex vivo imaging. After acute intramyocardial hydrogel delivery to the infarct area,
diastolic function appeared to either stabilize and/or improve, LVEDP decreased slightly,
while EDV, stroke volume, ejection fraction, and P-V loop area did not change appreciably
in 5 animals (stabilized function) and improved in 3 animals. The changes in these global
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indices were associated with normalization of radial and circumferential strain, which
increased within the infarct region and was reduced within remote compensatory regions.
These changes contrasted with controls in which all functional metrics continued to
decline. The beneficial effects of acute hydrogel delivery within the infarct region were
associated with increases in ED infarct thickness or bulking. However, the long-term
benefits of this acute intramyocardial hydrogel delivery post-MI requires further evaluation.
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CHAPTER 8
CONCLUSIONS, LIMITATIONS, FUTURE DIRECTIONS

8.1 OVERVIEW
This dissertation describes the optimization of scaled-up bone marrow
mesenchymal stromal cell (MSC)-derived extracellular vesicle (EV) biomanufacturing
conditions to generate doses required for large animal studies, and the use of injectable,
hyaluronic acid (HA) hydrogels for the improved retention of MSC-EVs in small and large
animal models of myocardial infarction (MI). The use of injectable hydrogels for biomedical
applications was described in Chapter 3 as an overview of design requirements for shearthinning, self-healing chemistries. Chapter 4 describes the optimum biomanufacturing
conditions to scale-up MSC-EV production and characterizes the size, distribution,
morphology, and contents of isolated EVs. In Chapter 5, the optimized and scaled-up
MSC-EVs were investigated in vitro for cellular responses and then encapsulated in an
injectable hydrogel and assessed for improvements in functional outcomes in a porcine
model of MI. In Chapter 6, a secondary network was added to the injectable hydrogel to
prolong the delivery of MSC-EVs, whose release, biodistribution, and therapeutic efficacy
were assessed in a rat model of MI. Chapter 7 discusses the design and development of
radiopaque injectable hydrogels for image-guided delivery towards future minimallyinvasive hydrogel delivery approaches for cardiac repair. The rest of this chapter will
describe the major conclusions of each of these studies, as well as the limitations of the
studies and potential future directions for further exploration.
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8.2 SPECIFIC AIM 1: INVESTIGATE THE SCALE-UP OF PORCINE MSC-DERIVED
EVS WITH DYNAMIC CULTURE CONDITIONS, AND ASSESS EV CONTENT AND IN
VITRO THERAPEUTIC POTENTIAL BASED ON ISOLATION METHOD.
8.2.1. CONCLUSIONS
In this aim, we investigated the optimum biomanufacturing conditions to generate
large MSC-EV doses required for large animal studies. Using four different biological
porcine bone marrow donors and three different cell culture methods, we demonstrated
that dynamic bioreactor culture conditions via microcarriers in a spinner flask created the
highest yield of MSC-EVs for scale-up with minimum batch-to-batch variability. Using
mass spectroscopy proteomics and RNA-sequencing, we assessed the content of MSCEVs and showed that dynamic culture conditions generated MSC-EVs with more proangiogenic, immonumodulatory, and anti-apoptotic factors.
8.2.2. LIMITATIONS AND FUTURE DIRECTIONS
In this aim, we sought to create an EV biomanufacturing platform with high purity
and reproducibility for large doses of MSC-EVs. While we successfully identified
microcarriers in a spinner flask as a scalable platform to generate large doses in a broad
and generalizable manner, we also found that selection of cell source/biological donor is
also important. In this aim, we used porcine bone marrow-derived MSCs that were isolated
in-house: however, to create a fully generalizable method, immortalized MSC lines need
to be fully characterized and utilized to create an off-the-shelf product with no donor
variability for future studies.
Another limitation of this study is the use of fetal bovine serum (FBS) in the cell
culture media during the expansion of MSCs. While FBS was not used during the EV
237

collection period, there might be residual xenobiotic content in the final product, creating
a significant concern for manufacturing Good Manufacturing Practice (GMP) product. This
limitation is largely due to lack of validated, widely available and cost-effective chemically
defined cell culture media. There are recent studies focusing on the use of human platelet
lysate (hPL) instead of FBS1; however, hPL has its own set of GMP concerns due to
heterogeneity of blood samples, extraction protocols and preparation strategies.
Additionally, the ultracentifugation (UC) method was a significant bottleneck in this
study. Differential UC, while scalable, is a labor-intensive process and is limited by the
volumes that can be accommodated by the rotors used. Currently, the largest rotor
available for UC can accommodate for up to 360 mL of conditioned medium—for a large
animal dose (1e12 particles), we found that at least two cycles of UC need to be done. As
size exclusion chromatography (SEC) and tangential flow filtration (TFF) become more
scalable and available, these methods should be used to achieve a more pure population
of small EVs.2 Lastly, further basic studies are required to identify the bioactive contents
(miRNA, proteins, lipids) of MSC-EVs.

8.3 SPECIFIC AIM 2: INVESTIGATE THE IN VIVO THERAPEUTIC POTENTIAL OF
MSC-EVS, INCLUDING IN A CLINICALLY RELEVANT PORCINE MODEL OF MI.
8.3.1. CONCLUSIONS
Building on Aim 1, Aim 2 uses the optimized MSC-EV biomanufacturing platform
to assess the therapeutic potential of MSC-EVs in vitro for their efficacy on tubule
formation and cardiac spheroid contraction and when delivered from injectable hydrogels
in a porcine model of MI. MSC-EVs were successfully encapsulated in our previously
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developed HA-based shear-thinning, self-healing hydrogel based on Guest-Host (GH)
interactions and injected intramyocardially to achieve local and sustained delivery in the
infarct zone. We hypothesized that MSC-EVs improve outcomes (i.e., ejection fraction and
infarct size) and that sustained delivery from hydrogels enhances this therapeutic efficacy
at the terminal timepoint of 8 weeks. While the CMR segmentation analysis and addition
of more animals to improve sample size are ongoing, we envision that the findings of this
Aim will validate the use of hydrogels and EV therapies to prevent the pathological
remodeling of the heart after MI. MSC-EVs are promising therapeutic agents for clinical
translation as they are acellular, non-immunogenic, non-tumorigenic, and nonarrhythmogenic.
8.3.2. LIMITATIONS AND FUTURE DIRECTIONS
Further in vitro and pre-clinical studies should be conducted to investigate whether
any of these bioactive components alone or in combination can recapitulate the
therapeutic efficacy of MSC-EVs. A synthetic, bottom-up approach to create fully
functional EVs with precisely controlled lipid, protein and RNA contents could allow rapid
manufacturing of efficacious, synthetic EV-based therapies.3
One of the main limitations of this study is the limited sample size inherent to the
use of large animal models. In addition, while the size of the infarct (median of 12% infarct
area) was small compared to that of small animal models, this is in line with infarct sizes
reported in the literature for large animal studies.4 In accordance with our studies, an
approximately 10% mortality rate was expected from this model,5 making larger infarcts
logistically impossible with acute infarct sizes >30% of LV volume that result in the loss of
the majority of the subjects within 48 hours of the acute MI.4 Furthermore, future studies
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should focus on dose-escalation experiments in large animals to determine the optimum
timing, dose or mode of injection for MSC-EVs.
Another limitation of this study is the mode of delivery. While the
ischemia/reperfusion was achieved via minimally invasive balloon occlusion, the
intramyocardial injection of the MSC-EVs via hydrogels required a left lateral thoracotomy.
While injectable hydrogels offer minimally-invasive delivery, catheter compatibility
presents a critical hurdle for clinical translation. Towards minimally-invasive hydrogel
delivery, others have explored transendocardial injections via a MyoStar catheter6 guided
by NOGA cardiac mapping system (Biologics Delivery Systems, Cordis Corporation,
Hialeah, Florida) and pericardial delivery through custom dual lumen delivery catheters.
7,8

However, these systems are not widely accessible and established for other material

platforms. We envision that our hydrogel system can be delivered percutaneously in future
studies using a subxiphoid window via a long needle or a catheter.

8.4 SPECIFIC AIM 3: INVESTIGATE EXTENDED DELIVERY OF MSC-DERIVED EVS
AND

ASSESS

THEIR

RELEASE,

BIODISTRIBUTION,

AND

THERAPEUTIC

POTENTIAL IN VIVO IN A RAT MODEL OF MI.
8.4.1. CONCLUSIONS
This Aim builds on the injectable Guest-Host hydrogel system in Aim 2 and adds
a secondary network comprised of gelatin crosslinked by microbial transglutaminase
(mTGase) to understand the therapeutic benefit of extending the release and
biodistribution of MSC-EVs to further time points. We first showed that GH hydrogels were
retained in healthy rat hearts for 7 days, while Interpenetrating Network Hydrogels (IPN)
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were retained for up to 14 days in vivo. Harnessing the stability and versatility of metabolic
labeling established by our lab and others,9 we then successfully adapted this biorthogonal
labeling strategy to reliably label and track EVs, and showed that MSC-EVs released from
IPN hydrogels were retained in rat hearts for up to 14 days. Finally, we used MSC-EVs
released from both GH and IPN hydrogels to understand the therapeutic efficacy of MSCEVs in a rat model of MI. The EV functionalization method developed here can easily be
used to incorporate active target ligands, small molecules or to conjugate EVs to other
materials, enabling the development of multifunctional EVs for therapies.
8.4.2. LIMITATIONS AND FUTURE DIRECTIONS
Our results highlight the power of metabolic labeling for reliable tracking of release
and biodistribution of MSC-EVs in vivo. However, one of the main limitations of the
biodistribution study is that we used in vivo imaging system (IVIS) to quantify radiant
efficiency across the myocardium and other organs after they have been explanted.
Ideally, we would have tracked the biodistribution of labeled MSC-EVs in the same animal
over time. However, due to non-specificity of the imaging system, we were only able to
track the release of labeled EVs at different timepoints across different animals. In order
to minimize variability in this study, we staggered our surgery times so that we harvested
all organs from animals on the same day to image together.
Future studies should focus on using this metabolic labeling strategy to understand
the release and biodistribution of EVs in large animal studies. Conjugation of a iodinated
contrast agent or radiolabel can be a powerful way to track EV release and distribution
over time in vivo via CT or SPECT imaging modalities.
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8.5 SPECIFIC AIM 4: DESIGN A RADIOPAQUE INJECTABLE HYDROGEL SYSTEM
TO EVALUATE HYDROGEL LOCALIZATION, RETENTION, AND DEGRADATION
TOWARDS THERAPEUTIC DELIVERY TO THE HEART.
8.5.1. CONCLUSIONS
In this aim, we successfully introduced radiopacity to injectable hydrogels through
encapsulation of the iodinated contrast agent iohexol. We employed hydrazide-aldehyde
chemistry to synthesize HA hydrogels with important shear-thinning and self-healing
properties, adapted from previously established chemistries that have allowed such
hydrogels to be used in various biomedical applications.10,11 We demonstrated that
encapsulation

of

100

mg/mL

iohexol

enabled

hydrogel

visualization,

without

compromising material properties of the hydrogel and successfully visualized the iodinated
hydrogel injected to the myocardium in a porcine model of MI using hybrid SPECT/CT
imaging. Then using a multimodality imaging and strain analysis platform with ECG-gated
hybrid SPECT/cineCT, we were able to define the area of perfusion defect and area at
risk post-MI, inject the hydrogels intramyocardially, obtain high-resolution images of LV
regional and global indices of cardiac function after MI and hydrogel delivery. We
demonstrated that intramyocardial delivery of a hydrogel within the infarct region early
post-MI stabilizes and/or restores LV function and geometry as evident by improved radial
strains in the area at risk, reduced compensatory changes in remote regions, and
stabilization or improvement of LVEDP, LVEF and PVA.
8.5.2. LIMITATIONS AND FUTURE DIRECTIONS
The main limitation of this study is the rapid diffusion of iohexol out of the
hydrogels. Although this material formulation can be used to guide hydrogel delivery and
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confirm the location of hydrogel post-delivery, the hydrogels were no longer readily visible
on in vivo imaging by day 3, suggesting that much of the encapsulated iohexol had already
diffused into the surrounding tissue. Therefore, this system cannot be used to track the
degradation of the hydrogel over time. Future studies should focus on contrast agent
coupling methods whereby hydrogel erosion can be correlated to signal attenuation.
This study developed a minimally invasive hydrogel imaging system and
demonstrated that radiopaque hydrogels can be delivered in an image-guided manner.
However, the injected hydrogels were administered via lateral thoracotomy. Our ongoing
studies focus on the administration of hydrogels minimally invasively, relying solely on
image-guidance through long needles or catheters. The ability to deliver a hydrogel
through a catheter under multimodality image guidance will enable numerous hydrogel
formulations with different therapeutic contents to be investigated, helping to advance
clinically relevant biomaterials therapies

8.6 GENERAL CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS
The broad conclusions of this dissertation pertain to the combinatorial and
synergistic potential of biomaterials and MSC-EVs for myocardial infarction. Herein, we
demonstrated that MSC-EV production can be rapidly scaled up reproducibly using
dynamic cell culture conditions in a bioreactor (i.e., microcarriers in a spinner flask).
Biomaterials, and in particular injectable hydrogels, play a major role in the local and
sustained delivery of EVs. Thus, the concomitant use of the two technologies together will
enable their translation and eventual human use.
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Limitations in general include problems with delivery method and timing, as
described in the aims of this thesis. Additionally, standardized in vitro potency assays and
in vivo dose escalation studies are required for clinical translation of MSC-EVs. Using the
labeling strategies described in this thesis, these MSC-EVs can be functionalized with
other proteins, small molecules, targeting ligands or biomaterials to create advanced
targeted delivery systems. Other questions remain for effective clinical translation
regarding the source of EVs as autograft or allograft or whether they should be derived
from cell culture via immortalized cell lines. While immortalized cell lines can allow highly
reproducible off-the-shelf strategies, autograft or allograft derived MSCs may offer higher
therapeutic efficacy.
Despite these challenges, the future of both biomaterials and MSC-EV strategies
is enormous, especially at their interface. To this date, no FDA-approved EV-based
treatments exist; however, some clinical trials are completed and many are underway.
Future studies focusing on fundamental EV biology and their mechanisms of action can
unlock a huge therapeutic potential within the field of drug delivery. As MSC-EV based
therapies and biomaterials evolve, we anticipate that the work featured in this thesis can
help guide the development of more effective therapeutics for the heart, as well as toward
widespread biomedical applications where injectable therapies are useful.
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